7-1-2021

DEVELOPMENTAL ORIGINS OF METABOLIC DISEASES

Daniel J. Hoffman
Department of Nutritional Sciences

Theresa L. Powell
University of Colorado Anschutz Medical Campus

Emily S. Barrett
Rutgers Environmental and Occupational Health Sciences Institute

Daniel B. Hardy
Western University, daniel.hardy@schulich.uwo.ca

american physiological society
PHYSIOLOGICAL REVIEWS
REVIEW ARTICLE

DEVELOPMENTAL ORIGINS OF METABOLIC DISEASES



AUTHORS

Daniel J. Hoffman, Theresa L. Powell, Emily S. Barrett, Daniel B. Hardy

CORRESPONDENCE

dhoffman@sebs.rutgers.edu

KEY WORDS

developmental origins; environmental toxins; metabolic diseases; obesity; placenta

CLINICAL HIGHLIGHTS

1. David Barker, MD, was a pioneer in the area of the Developmental Origins of Adult Health and Disease whose seminal epidemiological studies in the UK linked an adverse in utero environment to postnatal metabolic diseases.
2. Poor growth in utero or during early childhood has also been shown to result in adapted metabolism and altered body composition that may increase the risk for chronic diseases in adulthood.
3. Numerous epidemiological and animal studies have further elucidated Barker's early work and explain how placental-induced IUGR manifests in dysglycemia, dyslipidemia, fatty liver disease, and adverse cardiovascular outcomes.
4. As the interface between the mother and her developing infant, the placenta is actively responding to a wide variety of maternal signals and changing its function according to the ability of the mother to support fetal growth and development.
5. Metabolism disrupting chemicals are ubiquitous in the modern environment, and exposure (in utero or postnatally) may compound the impacts of an adverse in utero environment and promote metabolic disease.

HOFFMAN ET AL., 2021, *Physiol Rev* 101: 739–795
December 3, 2020; Copyright © 2021 the American Physiological Society
https://doi.org/10.1152/physrev.00002.2020

american physiological society
PHYSIOLOGICAL REVIEWS
Physiol Rev 101: 739–795, 2021
First published December 3, 2020; doi:10.1152/physrev.00002.2020
REVIEW ARTICLE

DEVELOPMENTAL ORIGINS OF METABOLIC DISEASES

Daniel J. Hoffman,[1] Theresa L. Powell,[2] Emily S. Barrett[3], and Daniel B. Hardy[4]

[1]Department of Nutritional Sciences, Program in International Nutrition, and Center for Childhood Nutrition Research, New Jersey Institute for Food, Nutrition, and Health, Rutgers, the State University of New Jersey, New Brunswick, New Jersey; [2]Department of Pediatrics and Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; [3]Department of Biostatistics and Epidemiology, School of Public Health and Division of Exposure Science and Epidemiology, Rutgers Environmental and Occupational Health Sciences Institute, Rutgers, the State University of New Jersey, New Brunswick, New Jersey; and [4]Department of Obstetrics and Gynecology and Department of Physiology and Pharmacology, The Children's Health Research Institute and the Lawson Health Research Institute, The University of Western Ontario, London, Ontario, Canada

Abstract

Almost 2 billion adults in the world are overweight, and more than half of them are classified as obese, while nearly one-third of children globally experience poor growth and development. Given the vast amount of knowledge that has been gleaned from decades of research on growth and development, a number of questions remain as to why the world is now in the midst of a global epidemic of obesity accompanied by the "double burden of malnutrition," where overweight coexists with underweight and micronutrient deficiencies. This challenge to the human condition can be attributed to nutritional and environmental exposures during pregnancy that may program a fetus to have a higher risk of chronic diseases in adulthood. To explore this concept, frequently called the developmental origins of health and disease (DOHaD), this review considers a host of factors and physiological mechanisms that drive a fetus or child toward a higher risk of obesity, fatty liver disease, hypertension, and/or type 2 diabetes (T2D). To that end, this review explores the epidemiology of DOHaD with discussions focused on adaptations to human energetics, placental development, dysmetabolism, and key environmental exposures that act to promote chronic diseases in adulthood. These areas are complementary and additive in understanding how providing the best conditions for optimal growth can create the best possible conditions for lifelong health. Moreover, understanding both physiological as well as epigenetic and molecular mechanisms for DOHaD is vital to most fully address the global issues of obesity and other chronic diseases.

developmental origins; environmental toxins; metabolic diseases; obesity; placenta

CLINICAL HIGHLIGHTS

1. David Barker, MD, was a pioneer in the area of the Developmental Origins of Adult Health and Disease whose seminal epidemiological studies in the UK linked an adverse in utero environment to postnatal metabolic diseases.
2. Poor growth in utero or during early childhood has also been shown to result in adapted metabolism and altered body composition that may increase the risk for chronic diseases in adulthood.
3. Numerous epidemiological and animal studies have further elucidated Barker's early work and explain how placental-induced IUGR manifests in dysglycemia, dyslipidemia, fatty liver disease, and adverse cardiovascular outcomes.
4. As the interface between the mother and her developing infant, the placenta is actively responding to a wide variety of maternal signals and changing its function according to the ability of the mother to support fetal growth and development.
5. Metabolism disrupting chemicals are ubiquitous in the modern environment, and exposure (in utero or postnatally) may compound the impacts of an adverse in utero environment and promote metabolic disease.

1. EPIDEMIOLOGY OF THE DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE

1.1. Introduction

For perhaps the first time in modern history, the height of US Americans appears to have reached a plateau (1), while a generation of children in Japan may not grow taller than their parents. A recent study in *Scientific Reports* described a trend in Japan in which pregnant women are gaining less weight than recommended, a phenomenon that is accompanied by an increased prevalence of low-birth-weight babies and a mean adult height that has been decreasing by a few millimeters a

year since the mid-1990s (2). Although some may suggest that this is nothing more than a natural variation in body size, a "fetal programming" perspective predicts that Japan may witness a concomitant increase in the incidence of nutrition-related chronic diseases in coming years. The reasoning for such an assertion rests with the evidence available from research on the long-term influence of nutrition and growth during gestation on adult health, broadly known as the "developmental origins of health and disease" or DOHaD.

The historical origins of DOHaD date back to research on mortality rates in England and Wales in which David Barker and colleagues (3) reported that men were dying from diseases normally associated with wealth but in regions of relative poverty with a high prevalence of low birth weight. From available ecological data on infant mortality rates and deaths from diseases in England, there was a high correlation (0.79–0.83) between infant mortality from 1921 to 1925 and deaths from heart disease, bronchitis, and stomach cancer from 1968 to 1978 and a low correlation (0.46–0.54) with lung cancer and stroke, with some variations in degree of correlation by sex and age. However, the authors were extremely cautious in their conclusions and cited a number of similar studies that found consistent trends but did not rule out confounding factors that could not be included at the time because of either lack of data or statistical methods that were unable to control for confounding variables. Still, since that publication in 1986, there are now over 1,000 scientific papers on the topic "developmental origins of health and disease."

To best illustrate how windows of opportunity exist to either promote health or increase the risk of disease, it is essential to consider those factors that support human growth and development even well in advance of conception. Given that the intrauterine period is one of tremendous cellular growth and differentiation, a brief review of how maternal diet influences fetal growth is provided. *Preconception and Early Life Influences on Growth* complements a more in-depth discussion of current research of placental influences on fetal growth and offspring health presented in subsequent sections of this article. As well, understanding the confluence of dietary and environmental factors as they interact to support fetal growth is essential to developing a broad appreciation of the multitude of factors related to "fetal programming" as depicted in **FIGURE 1**.



FIGURE 1. Schematic of potential preconception and maternal/placental health factors that can influence birth size and the impact on health in childhood that can influence adult health in the long term with underlying environmental disruptors that contribute to the developmental origins of metabolic diseases.

1.2. *Preconception and Early Life Influences on Growth*

An increasing number of studies have shown that paternal and maternal body composition and diet influence not only the first generation of offspring (4–6) but the second generation as well (7). Moreover, some studies are now reporting not only phenotypic differences in children exposed to poor maternal or early childhood diet but also epigenetic differences that provide mechanistic hypotheses (8). The intrauterine period of growth is extremely important for lifelong health, as growth and development of fetal tissues and organ systems occur at a very rapid pace. Any perturbation to this process, through either nutritional insufficiency or exposure to endocrine disruptors or toxicants (discussed in detail in IN UTERO ENVIRONMENTAL CHEMICALS AND METABOLIC DISEASES), not only interrupts or delays the growth process but may be manifested as metabolic abnormalities that challenge adult health. Indeed, altered growth patterns, such as slow or rapid growth, are now considered to be a primary predictor of body composition and health. However, it is helpful to provide a brief overview of major factors that affect both intrauterine and postnatal growth before discussing the intricacies of DOHaD. More important, within this section, but more so in subsequent sections, specific physiological mechanisms that underlie epidemiological or clinical studies are reviewed in great detail to fully explore how perturbations to normal growth and development increase the risk of chronic diseases later in life.

1.2.1. Maternal diet and nutritional status.

The influence of maternal diet and nutritional status on fetal growth and health of the offspring is well documented in other reviews (9, 10), but it is important to consider that a host of other factors also influence fetal growth, such as maternal smoking, which explains 52% of the variance in birth weight and 37% of the variance in birth length (11). With respect to maternal diet, a number of studies have been conducted to investigate the relationship between maternal diet and birth weight. For example, one study of maternal factors used path analysis to determine the interactions between maternal dietary patterns and maternal cytokines on birth weight and determined that a maternal diet composed primarily of tubers and eggs is associated with low birth weight, mediated by high maternal adiponectin concentrations (12). A study from Brazil reported that a dietary pattern defined as "highly processed," based on maternal dietary records showing a greater intake of refined grains, high-fat foods, and low fiber, increased the risk of delivering a small-for-gestational age (SGA, birth weight below the 10th percentile of a reference) baby (13). Likewise in a study of 1,040 women in the United States, poor maternal dietary quality, based on a low score of the Healthy Eating Index (HEI), as well as a high-fat diet were associated with increased neonatal adiposity but not lean body mass (LBM) (14, 15). In Nepal, maternal supplementation with folic acid, iron, and zinc resulted in children having lower fat mass (FM) compared with children born to control mothers (16). As well, a higher maternal intake of n–3 and n–6 fatty acids was associated with greater adiposity assessed by skinfold measures at the age of 3 yr (17). With regard to maternal body composition, a small cohort study from Brazil reported that maternal FM was predictive of birth weight and fetal growth, independent of diet (18). Thus, improving maternal health and ensuring a minimum level of food security and dietary diversity to all mothers must be a priority for health professionals throughout the world. In short, improving maternal nutrition is among the best means to prevent acute and chronic diseases of their children.

Although dietary intake is difficult to assess in free-living people, a great deal of knowledge can be gleaned from randomized controlled trials in which women receive a nutritional supplement or a placebo. Such studies are the best approach to determine how a nutrient or combination of nutrients can influence fetal growth and offspring health, independent of potential confounding factors. For example, offspring of women who used multivitamins during pregnancy had a slower rate of FM accretion compared with offspring of control women (19). Regarding bone density, increased maternal intake of calcium-rich food and higher folate status are associated with greater offspring bone mineral content (BMC) and bone mineral density (20). It has also been found that higher first-trimester vitamin B_{12} status is associated with greater BMC, adjusted for total bone area (21). Finally, maternal β-carotene concentrations were associated with greater offspring BMC at 2 wk postnatal (22). Potential mechanisms for these observations include epigenetic modifications that may promote adiposity, as it has been reported that hypermethylation of the umbilical cord tissue retinoic acid X receptor, a key regulator of adipocyte proliferation, was associated with increased offspring FM at 9 yr of age (23). However, there is an overall lack of consistent and robust data on the influence of maternal micronutrient intake on body composition in childhood. It is important to note that one would not expect to detect significant differences between groups <1 yr of age given that development of adipose tissue is highest during the first postnatal year, with a second period of rapid adipose tissue deposition in the prepubertal period (9–14 yr) (24).

1.2.2. Maternal obesity and offspring health.

Given the increased global prevalence of obesity (25), the impact of maternal obesity on fetal development and offspring health has gained tremendous attention over the past 20–30 yr. Although this topic has been explored previously (26), it merits a brief discussion given that the mechanisms related to placental influences on fetal health as well as maternal physiology and later offspring health are discussed below in this review. A recent meta-analysis of a large number of birth cohorts found that a higher maternal prepregnancy body mass index [BMI, weight (kg)/height $(m)^2$] increased the risk of the offspring being overweight (6). Specifically, a child born to a woman with a prepregnancy BMI $>$ 25 was 1.7 times more likely to be overweight in early childhood and twice as likely to be overweight in late childhood. The authors also reported that greater gestational weight gain increased the risk of childhood overweight, independent of prepregnancy BMI. Although BMI is only a clinical indicator of excess adiposity, a study of 24,289 offspring from the Nurses' Health Study II found that children born to women who were obese had higher percent body fat, systolic blood pressure, and fasting glucose at ages 9–14 yr compared with offspring of normal-weight women, despite having similar birth weight and despite statistical adjustment for lifestyle factors that may promote obesity (27). Yet the precise mechanisms underlying these associations are poorly understood given the multitude of factors that influence not only fetal development but adult health, given the diverse environmental changes that occur after birth and well into adulthood.

A number of studies of both humans and rodents do provide insight into potential physiological mechanisms that explain how maternal obesity may promote poor health outcomes for offspring later in life. For example, one study found that offspring telomere length decreased as maternal BMI increased even after adjusting for maternal education, maternal and paternal age, and birth weight (28). Higher maternal BMI was also negatively associated with cord blood and placental telomere length, suggesting that a higher maternal BMI may influence cellular functions of the placenta well before any negative health outcomes are manifested in the offspring (discussed in greater detail in ROLE OF THE PLACENTA IN FETAL GROWTH AND METABOLIC DISEASES). In a study of obese female mice, not only were the offspring more hyperinsulinemic compared with control pups, but they also presented with increased hepatic lipid content, increased concentrations of peroxisome proliferator-activated receptor (PPAR)γ, and lower concentrations of triglyceride lipase (29). It was suggested that these findings could be attributed to altered mitochondrial function as evidenced by uncoupling of the cytochrome system and increased hepatic oxidative stress as a result of insulin resistance and subsequent effects on the regulation of hepatic lipid metabolism. The results of this study are consistent with another study of rats in which pups born to obese mothers had similar lipid profiles and insulin resistance (30). When the authors studied differential gene expression with RNA-sequencing analyses, it was determined that 1,365 genes in the male offspring and 70 genes in the female offspring were expressed differently from control offspring and that most of the altered genes were essential for insulin signaling and lipid metabolism. Finally, one study of note focused on the long-term effects of maternal obesity in baboons, where female baboons were fed a high-fat, high-fructose diet before conception (31). It was found that offspring of the high-fat baboons, compared with control offspring, had higher hepatic lipid accumulation and downregulation of genes associated with the tricarboxylic acid (TCA) cycle and oxidative phosphorylation pathways. More explicit mechanisms beyond those discussed focused on epigenetic changes that may be attributed to maternal obesity and are discussed in subsequent sections below.

1.2.3. Breastfeeding and complementary feeding.

From the moment of birth, the newborn is dependent on others for providing energy and nutrients, and breastfeeding is the best method for ensuring healthy growth and development (32). However, $<$12 mo of exclusive breastfeeding is associated with $>$800,000 deaths in children under 5 yr of age (33). Still, in many low-income countries, fewer than 50% of newborns are breastfed and only 41% are exclusively breastfed in the first 6 mo (34). Among breastfed babies, the metabolically active lean tissue mass almost doubles and the primary source of energy provided is still from breast milk, but after 6 mo of age, energy from breast milk gradually becomes insufficient to meet the increased energy needs of the infant. Therefore, the difference between energy delivered and energy required to maintain homeostasis and growth must be met by solid foods, known as complementary foods. Any delay in the delivery of complementary foods or providing less than optimal nutrition slows or halts growth, as energy and nutrient needs are unmet during this period of rapid growth. The introduction of optimal complementary foods beginning at 6 mo of age is important, along with ensuring that such foods are age appropriate, safely prepared, and of good quality to prevent deficiencies or other food-borne illnesses that can interrupt healthy growth. Regardless, it is estimated that $<$25% of children under the age of 2 yr in low- and middle-income countries receive foods from the

recommended food sources (i.e., dairy, fruits and vegetables, and protein sources) and almost 30% of children under 1 yr of age do not receive any complementary foods, a major and serious threat to their growth and future health (35).

1.2.4. Intestinal disruptions and microbiome.

The delivery of nutrients to any animal occurs through absorption in the intestines. Changes to cellular structure, mucosal composition, or bacterial population of the intestines threaten this process and can result in growth deficits. Enteropathogenic bacteria that cause diarrhea are known to change the cytoskeletal arrangement of enterocytes, essentially breaking down the normal intestinal barriers, limiting complete absorption of nutrients (34). In fact, the number of episodes of diarrhea is positively associated with postnatal growth retardation (36), and the more often a child suffered diarrhea before age 2 yr, the more likely he/she is to experience growth retardation. The implications of these findings are great given that intestinal infections and enteropathy are highly prevalent and caused by a myriad of factors that are not nutritional in nature but have a direct impact on nutritional status, regardless of the diet consumed. Along with the impact on nutritional status is the ongoing issue of how infections affect the microbial milieu of the intestines, namely the microbiome (37).

The microbiome has gained a lot of attention in the past decade, particularly as new research has shown that specific profiles of the microbiome predict childhood obesity and body composition (38, 39). One study from Madagascar found that stunted children [height for age *z* score (HAZ) less than −2.00] presented with intestinal bacterial overgrowth composed of bacteria that are more consistent with the oropharyngeal cavity (40). The authors concluded that the conditions that precipitated growth retardation were accompanied by a "decompartmentalization" of the gastrointestinal microbiome in which the normal intestinal milieu is replaced by oropharyngeal bacteria from the stomach to the colon. Furthermore, undernourished children have a poorly developed gut microbiota (41), which is important for growth given that bacterial β-fructofuranosidases cleave β(2,1) bonds differentially in sucrose, fructooligosaccharides, and inulin (44). Moreover, gut microbiota assist in the digestion of nonresistant starch (45) and are capable of producing amino acids (46) and some B vitamins (47, 48), suggesting that the microbial profile plays an important role in healthy growth and may prevent growth faltering.

Several studies have now investigated the relationship between the microbiome and growth retardation. One of the most elegant studies to date was conducted in Bangladesh, in which a healthy microbial profile was established as a reference (49). It was found that children with subacute malnutrition presented with an "immature" microbiome relative to the reference and that this profile became more consistent with the reference after treatment with either a standard therapeutic diet (Plumpy'Nut) or khichuri-halwa, a local therapeutic diet composed of rice, lentils, green leafy vegetables, and oil. This work is complemented by a clinical study in which bacteria from undernourished children was transplanted to germ-free mice and the immature microbiota from the undernourished children resulted in impaired growth of the otherwise healthy mice that were fed a standard diet (50). Taking this research even further, a randomized, double-blind protocol was used to compare standard therapy with various microbiota-directed complementary food (MDCF) prototypes in Bangladeshi children with moderate malnutrition (51). The MDCF group had increased concentrations of insulin-like growth factor binding protein (IGFBP)-3 and decreased concentrations of growth differentiation factor 15, growth and bone formation promoter and agonist, respectively, similar to what was observed in healthy children. Thus, diet and the microbiome not only are critical for supporting healthy growth but appear to interact at a highly refined level to promote growth when conditions are favorable.

Part of the mechanism behind how the microbiome promotes or impedes growth may be through the role of various bacterial phyla on proper functioning of metabolic pathways. For example, the Bacteroidetes phylum is richer in genomes central to biosynthesis of biotin, folate, riboflavin, and de novo niacin synthesis compared with Firmicutes. In addition, almost all Bacteroidetes species are able to synthesize pantothenic acid, coenzyme A (CoA), and thiamine monophosphate, essential nutrients for the tricarboxylic acid (TCA) cycle and for metabolism of fatty acids, as CoA is essential to activate fatty acids (as acyl-CoA) for β-oxidation. Importantly, these B vitamins are necessary for energy metabolism and are required for proper functioning of the metabolic pathways for glucose metabolism and β-oxidation. Moreover, biotin is a cofactor for converting propionyl CoA to methylmalonyl CoA, which enters the TCA cycle as succinyl CoA and allows some amino acids (e.g., isoleucine and methionine) to enter the TCA cycle. The final step of the process requires vitamin B_{12} and folate, which are essential for the pathway to continue to produce ATP and without which the metabolic capacity of the cells is compromised.

Within the context of DOHaD, a number of areas of opportunity exist in which perturbations to maternal health, through either nutritional deficiencies or excesses, may have a significant impact on fetal growth and development. To further illustrate such effects, a review of famine

studies and birth cohorts along with clinical studies of poor childhood growth is presented below.

1.3. Cohort Studies of Development Origins of Metabolic Diseases

Although DOHaD is a relatively broad field, there are a number of population studies that have demonstrated an increased risk of obesity and other chronic diseases in children born after in utero nutritional insults. Moreover, analyses of data from famines and historical cohort studies have provided some of the most consistent and compelling data on this topic. More recently, clinical studies of adults and children who experience nutrient or energy restriction during gestation and early life are now providing exciting new data on physiological adaptations following growth retardation. The studies reviewed below draw from a diversity of cohorts, including survivors of famines and recent experiences of migrating refugees. The precise physiological modifications or adaptations that can explain or support these epidemiological or clinical studies are further explored in subsequent sections on placental, molecular, and environmental mechanisms of DOHaD.

1.3.1. Famine studies.

Famines throughout the world have occurred for a variety of reasons (e.g., civil strife, war, political instability, climate change), and a number have been studied retrospectively to understand the influence of famine on in utero and postnatal growth and subsequent adult health as presented in a number of books and reviews (52, 53). For brevity, this review focuses on just two of the most well-studied famines. One of the first cohort studies of in utero famine exposure and adult health is the Dutch Hunger Winter study of adults who were born before, during, and after the Nazi-imposed famine of 1945–46, during which time pregnant women consumed between 750 and 1,000 calories per day (54). Using birth records, investigators identified adults who were exposed to the famine during specific periods of gestation and categorized them according to early, middle, or late gestation. Health outcomes among these famine-exposed individuals have been extensively compared to outcomes among adults born before the famine or conceived after the famine. Those adults (mean age of 29 yr) who were exposed to maternal starvation in late gestation had lower glucose tolerance compared with those exposed early in gestation or never exposed to the famine (54). In addition, adults who were exposed to the famine during any 10-wk period of gestation had an increased risk for hypertension compared with unexposed adults (55). Likewise, poor growth due to undernutrition or micronutrient deficiencies has been found to increase the risk of obesity (56, 57), and men from the Dutch famine cohort who were exposed to famine during the first two trimesters of gestation had a higher risk of obesity compared with men exposed during late gestation and early infancy (58).

A second well-characterized famine cohort comprises adults who were born during the Chinese "Great Famine" of 1959–1961 (52), a famine that lasted far longer than the Dutch famine and affected millions of adults and children. Adults at 56 yr of age who were exposed to the Chinese famine in utero were 1.5 times more likely to develop T2D compared with unexposed adults (59). Similar to the Dutch Hunger Winter study, adults exposed to the Chinese famine in utero had a fourfold greater risk of hypertension compared with unexposed adults at age 32 yr (60). As well, women who were exposed to the Chinese famine in utero were more likely to be obese compared with women born after the famine (61). To address how famine exposure in utero interacts with broad dietary changes, adult survivors of the Chinese famine were included in a clinical study of T2D and dietary intake and analyzed by famine exposure and diet (62). Adults who had been exposed to severely affected famine areas in utero were more likely to have hyperglycemia compared with nonexposed adults, yet those adults who had been exposed to severe famine in utero and consumed a "Western" diet were almost eight times more likely to have hyperglycemia compared with the nonexposed adults. This study may be among the first that clearly showed not only how in utero nutrient deprivation has long-term metabolic consequence but that such perturbations are exacerbated by environmental changes, such as shifts from a traditional to a Western diet, and is a clear demonstration of how the prenatal and postnatal environment may interact and impact the risk of chronic diseases.

1.3.2. Historical cohort studies.

Perhaps one of the best-studied birth cohorts of healthy children is the Hertfordshire cohort, in which >1,000 babies were included in a program that recorded birth weight and early feeding practices beginning in the 1920s (63). From this cohort, close to 265 studies have been conducted, with hundreds of papers published on topics ranging from obesity to insulin resistance to hypertension. Early studies of the Hertfordshire cohort found that term infants with a low birth weight were twice as likely to develop T2D and coronary heart disease compared with those with normal birth weight (63–65). Similar results have been published in birth cohorts from South Africa, Finland, the United States, and Brazil among others (61, 66–69). Certain inherent challenges

exist in human cohort studies that make comparisons between them difficult and often limit consensus, such as whether or not gestational age was recorded, lack of explicit data on maternal diet or weight gain, limited access to accurate measures of body composition or infant diet, and so forth. Nonetheless, many studies have provided generally consistent results, and these studies are reviewed separately, with a discussion on the collective conclusion to follow.

To determine how socio-environmental factors influence growth, an innovative study was developed in South Africa before the fall of apartheid: the Birth to 20 (Bt20) cohort studied 3,200 infants in Soweto, Johannesburg, South Africa (67). With serial measures of body composition, postnatal growth patterns differentiated between birth size and/or growth as a risk factor for later outcomes, such as obesity. One of the most important papers published from this study found that rapid growth in infancy was associated with adolescent obesity (70). Likewise, prepubertal rapid weight gain increased the risk of adult adiposity and early menarche, a known risk factor for metabolic disorders and cancer (71, 72). Yet a cohort study in the United States found that children who experienced intrauterine growth retardation had a greater waist circumference and insulin resistance compared with children born with normal birth weight, independent of changes in BMI *z* score (BMIZ, defined as BMI relative to age according to WHO standards) from birth to age 10 yr (73). Similar results were reported for a separate study, in which children with greater childhood weight gain had greater FM, independent of birth weight, compared with children with a slower rate of weight gain (73). In short, these studies emphasized that research needs to extend beyond simple measures of fetal growth (i.e., size at birth) and childhood body size. Investigators also need to begin to explore the interactions between intrauterine growth and environmental exposures that may influence both pre- and postnatal growth, as the life course approach to both epidemiology and biology is more informative from both practical and scientific perspectives.

Exactly how postnatal growth influences nutritional status was the focus of the Project Viva study, in which a gain in BMIZ was associated with increased adiposity, independent of birth size (68). Moreover, a rapid increase in BMIZ from 6 mo to 1 yr was associated with greater insulin resistance in midchildhood (7–11 yr of age), independent of birth weight (68). As well, increased BMIZ in the first 6 mo was associated with higher systolic blood pressure in childhood (68). Thus, accelerated rate of growth, as measured by temporal changes in BMIZ, is associated with negative health outcomes later in life. This point is highlighted in a recent study of Mexican children who grew slowly, regardless of their birth size or current height, and were more likely to have greater adiposity compared with children who grew rapidly (74). Increased adiposity, although not a disease in and of itself, is associated with greater disease risk, and children who were born small with subsequent rapid growth had a greater risk for insulin resistance compared with children born larger or with a moderate rate of postnatal growth (75). Moreover, childhood obesity is a major contributor to adult obesity and poor health, suggesting that increased adiposity in childhood may increase the risk for adult obesity and chronic diseases. Clearly, nutrition during gestation has a profound and long-term impact on body size and body fat distribution and may limit the development of metabolically active tissue, contributing to metabolic disorders. Yet, as a number of different methods to assess body composition were used in the studies discussed above, along with different statistical analyses, an important point for future studies is to normalize methods to make all data comparable in terms of interpretations and comparisons of conclusions.

1.3.3. Conflicts and refugees and DOHaD.

Although global migration, in particular the migration of refugees from various conflicts and civil strife, is quite high and has gained tremendous media attention, little research on the health of such migrants has been reported. However, international migration could be a major concern to host countries, as welcoming thousands of refugees who have experienced continued nutritional and emotional challenges and are then introduced to a completely different nutritional and social environment may allow for elements of DOHaD to be expressed and result in an increased incidence of nutrition-related chronic diseases among refugee immigrants.

The issue of immigrant and refugee health becomes even more relevant to DOHaD when studies of refugee children are reviewed, given that refugees tend to experience more negative environments before emigrating compared with nonrefugee immigrants. For example, refugee immigrant children were almost five times as likely to be stunted compared with nonrefugee immigrant children (76), suggesting that refugees experience chronic undernutrition or exposure to unhealthy environments before their migration to more developed countries. These findings are consistent with another study in which 30% of refugee children were found to be growth retarded (77). One study of Sudanese refugee children reported that 30% of the children had low BMC and elevated cholesterol, triglycerides, and insulin resistance (78). The precise causes of these conditions are difficult to determine given the multitude of psychosocial and nutritional stressors faced by refugees, but given that

almost 40% experience past and current food insecurity, dietary intake and quality are most likely important factors to consider. The height for age of the children improved during a 5-yr follow-up period, and there was a significant increase in the BMIZ as well, but not to the point of being overweight or obese. The issue of obesity is a general concern and highlights why cases of refugee migration may contribute to the prevalence of chronic diseases. In a case-control study in the United States, 512 refugee children from a number of countries were compared to 1,175 low-income US children receiving services at the same health centers (79). The refugee group had a significantly higher increase in BMIZ compared to the "control" group over a 1-yr period, and the increase was even greater for children under 2 yr of age. Moreover, refugee children who were classified as stunted had a significant increase in BMIZ, while the control children experienced a decrease during the same time period. Finally, refugee children grew from the 47th percentile of BMI, adjusted for age and sex, to the 63rd percentile, and the prevalence of obesity more than doubled in a 3-yr period. These data are important, but they must be considered with the utmost caution, as migration is a politically and socially sensitive issue. Discussing such research within the context of DOHaD is highly relevant, as understanding how nutritional and environmental insults influence lifelong health is important not just from a scientific perspective but also from the perspective of conducting research to improve the human condition, which applies to all humans, not just those who live in developed and stable countries and societies. However, there is a risk that discussion of these issues in light of recent political changes in the world may be used as an argument against migration and the hosting of refugees. Regardless, the more attention that can be devoted to understanding the health of all people may open the door for broader discussions on how to end the causes of mass migration and promote improved health and nutrition programs in situations where civil strife and unrest necessitate the migration of people.

1.3.4. Clinical studies of growth retardation and growth patterns.

Although famine studies and retrospective studies provide valuable data, more explicit information on potential mechanisms can be better gleaned from clinical studies of poor growth and biological outcomes. For example, children born small have an increased risk for obesity that is part of a U-shaped relationship between birth weight and BMI such that adults born weighing $<$2,500 g or $>$3,500 g are more likely to be classified as obese compared with those born weighing 3,000 g (80). In a study of 18,000 Swedish women, those born small or large ($<$2,500 g or $\geq$4,000 g) had a higher BMI in adulthood than women born with a "normal" weight (81). A major limitation to these studies is the use of BMI to assess obesity, as BMI is a tool for screening individuals for obesity, not a proxy for body fatness. Clinical studies that assess body composition and body fat distribution are often more helpful in elucidating the effect of early nutrition on adult body composition. It is also well recognized that birth size reflects only one dimension of growth and the postnatal period may play an equal, if not greater, role in overall growth and adult health such that the rate of growth, assessed as change in BMIZ or rate of weight gain, is predictive of adult BMI or body composition (82).

There has been considerable interest surrounding the relationship between severe growth retardation and the long-term impact on health. It was previously reported that adults who were classified as stunted (HAZ less than $-$2.00) are more likely to be obese compared with nonstunted peers (83). Senegalese girls who were stunted in early childhood (6–18 mo of age) had greater subcutaneous fat on the trunk and arms compared with nonstunted girls (84). Guatemalan adults who were stunted in childhood have greater central fat compared with adults who were never stunted (85), similar to stunted children in Brazil who gained more truncal fat compared with nonstunted children from the same shantytowns (86). In contrast, in the Bt20 cohort adolescents who were stunted at age 2 yr did not have a higher BMI compared with those who had never been stunted (87). It is important to note that the children in the Bt20 cohort were not classified as stunted at the time BMI was measured and many of the children could have experienced catch-up growth in the 10+ yr of follow-up. As well, a study in Bolivia found that stunted children were more likely to have a lower BMIZ and body fatness compared with nonstunted peers (88). However, no difference between height for age and FM was reported from a cohort study in Brazil (89). There are a number of reasons for what appear to be divergent results, including sample size, socio-economic environment, dietary intake, and methods to assess adiposity. The lack of consensus between various studies highlights the need to incorporate advanced imaging and statistical methods in new cohort studies and to standardize methodologies so that results between studies are comparable and available for pooled data sets that will expand the ability to address fundamental questions regarding early-life nutrition and adult health.

1.4. Physiological Adaptations following Growth Retardation

Although epidemiological studies provide solid evidence for associations and often explain how various factors



FIGURE 2. Potential social, environmental, or physical exposure that promote poor growth in utero or childhood and associated physiological responses or adaptions (with references) that ultimately contribute to the developmental origins of metabolic diseases. CPT-A, carnitine palmitoyltransferase 1A; RFTN1, Raftlin, lipid raft linker 1; FAS, fatty acid aynthase; KLF13, Kruppel-like factor 13; UCP, uncoupling protein; PPAR, peroxisome proliferator-activated receptor.

influence biological outcomes, there is always the need for corroborating evidence that provides a clear biological mechanism. The literature reviewed below is focused primarily on human and some rodent and nonhuman primate data as shown in **FIGURE 2**, which depicts the relationship between specific exposures and physiological outcomes, but more explicit mechanisms are gleaned in subsequent discussions of basic experimental data below in this review (see ROLE OF THE PLACENTA IN FETAL GROWTH AND METABOLIC DISEASES and ADVERSE IN UTERO ENVIRONMENT AND METABOLIC DISEASE).

1.4.1. Epigenetics and in utero famine exposure.

Recently, with the advent of new techniques to study epigenetic modifications, a number of investigators have retrospectively studied the epigenetics of in utero famine exposure. For adults from the Dutch famine, prenatal malnutrition-associated differentiated methylated regions (P-DMR) were analyzed according to timing of gestational exposure to the famine (91). Differential methylation patterns existed in six P-DMRs that were associated with genes that influence growth and metabolic functions, such as insulin signaling (INSR), pancreatic beta cell functioning (SMAD7), as well as lipid (CPT-1A) and cholesterol (KLF13) metabolism. More important, the methylation patterns identified had positive correlations with the phenotypic outcomes associated with each gene, suggesting that early exposure to nutrient restriction may influence epigenetic control of metabolic processes later in life. Consistent with the results from the Dutch famine, adults who experienced gestational exposure to famine in Bangladesh and were underweight as adults were more likely to be hyperglycemic compared with unexposed adults (8). Moreover, those same men who had been exposed to famine in utero and remained underweight as adults showed differences in methylation patterns, primarily hypomethylation, in 6 of 16 metastable epialleles (ME) compared with men who were exposed to the famine postnatally or were never exposed (8). To further illustrate these results, a study was conducted in the Gambia during seasonal changes in food availability (dry vs. rainy seasons corresponds to nutrient-limited vs. nutrient-rich seasons), where access to total energy and methyl-donor nutrients, such as folate and the B vitamins, is severely restricted (100). Analyses of peripheral blood lymphocytes showed that there was significant hypermethylation of six ME in infants who were conceived during the rainy season compared with those conceived during the dry season. Perhaps more profound is the fact that maternal periconception biomarkers for methyl-donor nutrients significantly predicted methylation patterns of the offspring. Indeed, epigenetic analyses from the Chinese famine study yielded similar results, such that adults who were exposed to the more severe famine in utero had significantly higher total cholesterol and low-density lipoprotein concentrations compared with adults who were never exposed to the famine, independent of age and sex (90). Similar to the epigenetic studies of the Dutch famine, adults exposed to the severe famine had increased methylation of the CpG1 site of the IGF2 gene compared with those exposed to moderate or no famine.

1.4.2. Dysfunctional energy expenditure.

In terms of energy expenditure, an early study of growth and metabolism compared the resting metabolic rate (RMR) between growth-retarded (HAZ less than −1.50) and control children in Guatemala and found no differences in RMR, even when controlling for lean body mass

(LBM), the most metabolically active tissue (101). A study in Brazil also found no differences in RMR between growth-retarded children and control children, controlling for LBM (102). Yet others have reported a lower rate of energy expenditure in growth-retarded children compared with normal-height children, but these studies compared RMR per unit body weight and did not use linear regression analyses, the accepted statistical method for adjusting for body weight or LBM between groups (103–105). Again, the divergence in results is most likely due to the use of statistical methods that control for the mass of metabolically active tissue; using ratios can often result in statistically significant differences where no actual difference exists. This is apparent when one considers that studies in which metabolic differences were reported used ratios of energy metabolism per unit body weight of LBM rather than multiple linear regression analysis. It is now accepted that multiple linear regression analysis is the more appropriate statistical approach for studying such parameters (106), given that the mathematical use of ratios requires the two variables to have a linear relationship that includes passing through the 0 intercept, which LBM and energy expenditure do not, thus necessitating the use of advanced statistical methods over more simple tests.

1.4.3 Adaptations in substrate metabolism.

Although studies of energy expenditure provide important information about metabolism, more intricate aspects of basal metabolism, specifically the metabolism of macronutrients, can better inform potential mechanisms related to metabolic adaptations following linear growth restriction (**FIGURE 3**). Perhaps the first study of metabolic adaptations and childhood growth retardation was conducted in a cohort of children in Brazil in which growth-retarded children had lower rates of fat oxidation compared with normal-height children from the same shantytowns of São Paulo (92). Similar results have been published from distinct genetic, ethnic, and geographical cohorts including adult men from the Hertfordshire Cohort in the United Kingdom (93), a study of seminomadic adults from the Buryat communities in Siberia who experienced growth retardation after the collapse of the Soviet Union (95), and a study of North Korean children who were either stunted or short for age (94). All three studies consistently found that study participants who were shorter than their peers had a significantly lower rate of fat oxidation. Potential mechanisms to explain these results are considered exploratory, as it is difficult to conduct invasive biological measures of metabolism because of ethical constraints on studying poor growth in vulnerable populations. Nonetheless, it is important to reiterate that outcomes of various studies of body composition or energy metabolism may be attributed to differences in study design, statistical analyses, or the socio-economic environment in which the study was conducted.

There are also a number of studies of nonhuman animals that address the question of metabolic adaptations resulting from energy and/or nutrient restriction during



FIGURE 3. Illustration of physiological mechanisms to support association between poor growth in childhood and metabolic adaptations that promote chronic diseases in adulthood. AMPK, AMP-activated protein kinase.

gestation or early childhood. For example, a study of pigs born with low (L) or normal (N) birth weight received an ad libitum diet after birth and then were fed an energy restriction (R) diet after weaning (96). Not only did the L pigs have significantly lower fat oxidation compared with the N pigs, but the rate of fat oxidation was ~50% lower in the LR pigs compared with the NR pigs. Biochemical explanations for these findings may be found in a study of protein-restricted pigs that were subsequently fed a 14% protein diet and were found to have increased intramuscular fat content as well as increased expression of lipogenic genes (e.g., FAS, PPARγ, and FABP4) compared with pigs fed a 20% protein diet (107). Interestingly, the pigs on the low-protein diet had a lower expression of lipolytic genes compared with pigs fed the control diet. In addition, studies of sheep demonstrated that energy restriction alters substrate metabolism in a tissue-specific manner that favors carbohydrate metabolism (108). Finally, a study in rodents found that vitamin A supplements in early life resulted in a reduced expression of key adipogenic markers (PPARγ and lipoprotein lipase) and increased adiposity when rats were fed a high-fat diet compared with control rats on the same diet (97). More important, the gain in FM was independent of body weight, which is suggestive of adipocyte hyperplasia.

To further illustrate the influence of energy restriction on energy metabolism and body composition, mice exposed to intermittent fasting (IF) three times a week had lower fat metabolism compared with the ad libitum (AL) group, regardless of whether they were fed a high-fat or normal diet (109). The IF mice had lower gonadal and inguinal fat pad weights and increased energy expenditure compared with the AL mice. Furthermore, the IF mice had increased UCP-1 mRNA concentrations in both fat depots, suggesting that fasting stimulated an increase in the uncoupling of energy expenditure in these depots and could explain the increase in total energy expenditure as a response to intermittent energy restriction. This "browning" of white adipose tissue may reflect the modified characteristics of the fat depot, as it resembled brown fat that is more energetic and associated with higher energy expenditure. Yet, given that this adaptation occurred after a period of refeeding, it is difficult to determine whether the changes in UCP-1 mRNA concentrations were a response to energy restriction or refeeding. Nonetheless, a parallel study was conducted in which thyroid hormone metabolism in skeletal muscle was measured in rats that were semistarved and refed to promote "catch-up" fat (110). After refeeding, the refed animals had depressed protein synthesis in skeletal muscles and a lower rate of 3,5,3′-triiodothyronine (T_3) synthesis. It was concluded that severe energy restriction essentially limits energy availability for protein synthesis and drives available nutrients toward fat deposition rather than energy utilization.

It is important to emphasize that specific metabolic adaptations that elicit endocrine or molecular responses to preserve body fatness generally will not be manifested without concomitant "environmental" changes, such as increased exposure to processed or refined foods for humans or refeeding protocols for nonhuman studies. In one such study of pigs, those who were energy restricted and then refed on an ad libitum diet experienced compensatory growth and deposited more fat in the subcutaneous depot than the control group (99). The refed pigs also had differential expression of 86 genes that are associated with key regulatory and signaling pathways associated with homeostasis and energy metabolism. Specifically, the refed pigs appeared to downregulate genes associated with the AMP-activated protein kinase (AMPK) pathway. For example, the control pigs, compared with the refed pigs, presented with an upregulation of genes that regulate carbohydrate metabolism, including genes that promote translocation of glucose transporters and stimulate glycolysis. These molecular adaptations are consistent with the phenotypic findings that refed pigs gained more back fat and had greater intramuscular fat compared with control pigs. Thus, despite differences in species and study protocols, energy or protein restriction during key periods of growth appears to elicit metabolic adaptations similar to what is reported in human studies of growth retardation, shedding light on potential mechanisms that explain why poor growth is associated with metabolic diseases in adulthood.

1.4.4. Summary.

The studies presented thus far have ranged from historical studies of famines to clinical studies of growth-retarded humans to molecular analyses of pig and rodent experiments. A consistent pattern emerges from these studies, simply that energy or nutrient restriction during key periods of growth is followed by specific adaptations in hormonal or biochemical processes that favor fat deposition, especially when paired with postnatal environmental changes, such as exposure to adequate, energy-rich foods. However, it is important to discuss a caveat to interpreting these studies en masse, as the scientific philosopher Karl Popper noted that regardless of the number of positive observations made, one cannot ignore the potential that a negative outcome may be found in the future (111). In that vein, it is important and necessary to acknowledge that many of the studies presented come from a range of animal species that may have acutely different physiological systems that could respond to various perturbations in subtly different manners. Likewise, studying health outcomes of older humans following a nutritional insult many decades earlier may not be able to

account for any of the multitude of environmental factors (e.g., exercise, smoking, exposure to environmental toxins, stress) to which laboratory animals are not exposed. Finally, the science of life course analysis is becoming more prominent in the human biology arena, and it is important to recognize that the timing of various insults, either in utero or during infancy or childhood, relative to measures of metabolism or disease development may contribute to disparate results among studies. Thus, these limitations are not trivial; nor are they insurmountable, provided a proper perspective is taken when comparing a large cross section of research.

Nonetheless, the results presented thus far do lend credence to the hypothesis that poor growth results in a number of physiological adaptations that may promote chronic diseases under favorable environmental conditions. This is consistently observed in clinical and animal models of fetal growth restriction whereby the enriched postnatal environment adversely affects the function of the liver, adipose, pancreas, and heart. However, before these postnatal outcomes manifest, the adverse in utero environment is first sensed and unfortunately impacted by the placenta. ROLE OF THE PLACENTA IN FETAL GROWTH AND METABOLIC DISEASES provides strong evidence that the maternal-fetal interface recognizes and attempts to adapt to the maternal insult but, however, ultimately contributes to the impaired fetal development that results. The role of the placenta in normal and abnormal fetal growth is reviewed, including oxygen and nutrient transport along with endocrine function.

2. ROLE OF THE PLACENTA IN FETAL GROWTH AND METABOLIC DISEASES

As noted above, Barker and others first established the importance of adequate intrauterine growth for lifelong health (3). Indeed, numerous epidemiological studies across the globe have since described the adverse conditions confronting human populations that contribute to poor growth in utero and during early childhood (52, 64, 73, 112). The role of the placenta in determining the fetal growth trajectory is supported by human studies of poor placental functional capacity associated with growth failure in utero as well as activation of placental nutrient delivery in cases where fetal overgrowth is observed. In this section, we present evidence for a critical role of the placenta to both respond to maternal conditions and modulate fetal growth by changing the delivery of nutrients needed to sustain growth. These short-term adaptations might be beneficial short term for fetal survival but ultimately can contribute to poor neonatal outcomes and an increased risk of noncommunicable diseases later in life.

2.1. Placental Function and Fetal Growth

In humans, as in all eutherian mammals, pregnancy results from internal fertilization and development of the embryo and fetus. Carefully orchestrated changes in maternal physiology and a well-functioning placenta are required to provide gas exchange, supply macro- and micronutrients, and remove waste products. In addition, the placenta is a versatile endocrine organ secreting hormones that promote the maternal metabolic and cardiovascular adaptations to pregnancy, including the development of maternal insulin resistance and the increase in uteroplacental blood flow across gestation. Given the broad discussion above of epidemiological and clinical studies of maternal diet or body composition and birth outcomes, it is important to present potential mechanisms that may reside in placental development and physiology that may impart disease risk for infants born intrauterine growth restricted (IUGR, birth weights in the lowest 3–5% centiles of a reference).

It is clear that alterations in placental development and/or function adversely impact fetal development that results in the birth of an infant classified as SGA or IUGR. However, at the opposite end of the spectrum is fetal overgrowth, resulting in the delivery of a baby classified as large for gestational age (LGA, birth weight above the 90% percentile) or macrosomia when a baby is born weighing >4,000 g at any gestational age. As discussed above, being born small or large relative to a healthy standard increases the risk of developing obesity and other metabolic disorders (63, 64, 67, 68, 101, 113). As changes in placental function are believed to directly contribute to abnormal fetal growth and body composition, the placenta plays a critical role in the developmental programming of metabolic disease (114). Thus, a better understanding of molecular mechanisms regulating placental function, including maternal and fetal signals (115), may inform us on the underpinnings of the intrauterine origins of metabolic disease and lead to the development of novel intervention strategies.

2.1.1. Placental development and function.

The placenta originates from the earliest cellular differentiation in the embryonic blastocyst and comprises several trophoblast cell lineages. The inner cell mass develops into the fetus, and the extraembryonic cells differentiate into the trophectoderm that becomes the mature placenta and fetal membranes (116). Robust development of the fetal (umbilical) and maternal (uteroplacental) vascular beds is critical for optimal delivery of nutrients and gas exchange. Ultimately, human placental development brings these two circulations into close approximation, separated by only two cell layers, a transporting



FIGURE 4. Placental anatomy and transporter localization in the syncytiotrophoblast: amino acid (AA) transport across the syncytiotrophoblast (ST) to the fetal capillary endothelial cell; glucose transport; and lipid transport. BM, basal plasma membrane; FATP, fatty acid transporting protein; GLUT, glucose transporter; MVM, microvillous plasma membrane; SNAT2, sodium-dependent amino acid transporter isoform 2; LAT1, leucine transporter isoform 1; TG, triglyceride; LPL, lipoprotein lipase; FABP, fatty acid binding protein; NEFA, non-esterified fatty acid.

epithelium called the syncytiotrophoblast and the fetal capillary endothelium. The syncytiotrophoblast, illustrated in **FIGURE 4**, is a polarized syncytial epithelium that serves as both the primary barrier and the key transporting cell between maternal and fetal blood supplies. Importantly, the composition of nutrients in fetal blood is distinct from the mother throughout gestation; therefore, the placenta does not simply function as a semipermeable filter. Mechanisms for solute transfer across the placenta include passive and facilitated diffusion, active transport, and endocytosis. Macronutrient transport across this barrier is accomplished through specialized transporting proteins, channels, or exchangers in the plasma membranes of the syncytiotrophoblast (117, 118). Placental transport function is modulated in response to the ability of the mother to provide nutrients as well as in response to fetal demand signals (119). Thus, placental capacity for delivering nutrients changes in response to maternal signaling and directly impacts the fetal growth trajectory, making it a primary cause for pathological fetal growth (120).

2.1.2. Placental blood flow in normal, IUGR, and LGA pregnancies.

Optimal fetal growth is dependent on adequate blood flow on both sides of the placental barrier and is facilitated by placental gas exchange to allow for transfer of oxygen to the fetus and removal of carbon dioxide from the fetal compartment (121, 122). Maternal blood flow to the placenta increases when uterine immune cells and extravillous trophoblast cells transform the spiral arteries in the uterine endometrium and radial arteries in the myometrium, converting tightly coiled vessels to large, unresponsive conduits that open into the placental intervillous space (123). This transformation decreases the resistance in the uteroplacental circulation starting at ~20 wk of gestation (124) and allows for 25–30% of maternal cardiac output to perfuse the placenta by late pregnancy (125). The redirection of maternal blood to the placental circulation is supported by an expansion of the maternal blood volume beginning in early pregnancy (126). Failure to remodel maternal vessels results in ischemia, oxidative stress, low nitrous oxide production, and release of antiangiogenic soluble factors such as fms-like tyrosine kinase 1 (sFLT-1) and Endoglin (sENG) (127). Proangiogenic factors like placental growth hormone (pGH) and vascular endothelial growth factor A (VEGFA) are antagonized by these factors (128), leading to reduced invasion of the trophoblast and maternal endothelial dysfunction. The net effect is a failure of uteroplacental blood flow to increase, which is believed to underlie pregnancy complications such as preeclampsia and IUGR (129, 130).

Increasing uteroplacental blood flow across gestation is paralleled by increased feto-placental blood flow, regulated by vascular tone and angiogenesis (130). Poor placental angiogenesis has been observed

in IUGR pregnancies, but the mechanisms regulating this process are complex and not completely understood. Placental vasculature lacks innervation and autonomic control, making humoral factors of key importance in determining blood flow (131). In fact, impaired fetal vascular development has been linked to alterations in prostaglandin E_2 reactivity (132) and endothelin-1 levels (133) and an imbalance in branching and nonbranching angiogenesis resulting in longer unbranched capillary loops in the villous vascular tree (134). A number of angiogenic (VEGFA, pGH, fibroblast growth factor, angiopoietins 1 and 2), as well as antiangiogenic (sENG, sFLT-1) factors have been implicated in feto-placental vascular development. Data on the role of these factors are not consistent between various animal models of IUGR or in human IUGR (135). Doppler ultrasound measures of reduced umbilical artery blood flow are indicative of poor feto-placental perfusion and restricted fetal growth, but these measures lack adequate specificity to be used clinically to predict long-term outcomes (124, 136). Recently, a large clinical study combined Doppler ultrasound measures with known biomarkers for angiogenesis, inflammation, and pregnancy disorders but did not find significant improvement in prediction of poor intrauterine growth (137). Inadequate angiogenesis in the placenta has also been suggested to reflect poor vascular development in fetal organs such as lung, heart, and pancreas (138–140). Therefore, markers of poor placental angiogenesis may provide predictive biomarkers for postnatal complications such as bronchopulmonary dysplasia and cardiovascular and metabolic disease due to poorly developed blood supply in these critical organs (141–144).

2.1.3. Placental nutrient transfer in normal, IUGR, and LGA pregnancies.

In terms of fetal nutrition and growth, the placenta plays a critical role in the transfer of nutrients, such as glucose and key micronutrients, to promote and sustain fetal growth and development. Energy required for fetal growth comes from glucose, the primary substrate for fetal energy metabolism, which is transferred across the placental barrier by facilitated diffusion (118), and fetal glucose levels remain lower than those of the mother and fluctuate with maternal glycemic status. Glucose transporters are embedded in the plasma membranes of the syncytiotrophoblast and facilitate the movement of glucose down its concentration gradient (145). Several non-insulin-dependent glucose transporters (GLUTs) are expressed in the human placenta, including GLUT isoforms 1, 3, 9, and 12 (146). The apical or microvillous plasma membrane (MVM) of the syncytiotrophoblast has highly abundant GLUT1 transporter expression, allowing for rapid uptake of glucose from maternal blood in the intravillous space (145). The placenta metabolizes ~30% of the glucose taken up from the uteroplacental circulation (147), and glucose transporters in the fetal-facing basal plasma membrane (BM) allow glucose to flow down its concentration gradient to the fetal capillary. The BM is believed to be the rate-limiting step for glucose transfer because of the lower expression of GLUT proteins and much smaller surface area compared with the MVM (145), suggesting that any alterations in the BM may result in poor fetal growth.

In IUGR, inadequate placental glucose transfer due to a reduced placental surface area may contribute to slow growth rates, but no significant changes in GLUT1 expression in MVM or BM have been reported in these pregnancies (145, 148). In pregnancies complicated by obesity, where fetal growth is more likely to be accelerated, expression of GLUT1 in BM is correlated with birth weight (149), and several GLUT isoforms (1, 4, and 9) were recently reported to be positively correlated with fetal growth in pregnancies complicated by gestational diabetes (GDM) (150). It was recently reported that insulin-responsive GLUT4 is found in the human placental BM and that changes in expression occur with activation of the insulin receptor on the MVM. These data suggest control of glucose delivery through high postprandial maternal insulin to increase delivery when glucose is abundant (151). Once in the fetal circulation, glucose stimulates the fetal pancreas to release insulin, a strong promoter of fetal growth (152). In pregnancies complicated by maternal hyperglycemia such as those of obese and diabetic mothers, increased placental flux of glucose to the fetus likely contributes to accelerated fetal growth (153).

With regard to micronutrients, the impact of maternal diet on offspring body composition is discussed above in this review and is most likely dependent on placental delivery of micronutrients. For example, adequate Ca^{2+} is essential for fetal bone mineralization, and adequate fetal Ca^{2+} is ensured when Ca^{2+} levels are higher than those of the mother, facilitated by Ca^{2+}-ATPase localized in the BM to transport Ca^{2+} against its gradient (154). The importance of this process is demonstrated by the observation that growth-restricted fetuses have relatively "normal" bone length and density compared with other compartments of body composition (154). Ca^{2+}-ATPase expression and activity are higher in the BM of IUGR placentas, suggesting a compensatory mechanism to support bone development in the fetuses who are slowing somatic growth of lean mass and FM (155). This mechanism is particularly relevant to stunting in early childhood as well, since placental Ca^{2+} transfer may influence linear growth in utero, and would be of critical interest to better understand the life course effects of placental physiology.

Fetal growth requires rapid and sustained protein synthesis; thus lean tissue accretion during fetal growth requires adequate protein synthesis and amino acids are higher in fetal circulation compared with the mother because of two key secondary active transport systems in the syncytiotrophoblast that are dependent on the cellular Na^+ gradient generated by Na^+-K^+-ATPase. System A is an amino acid transporter in the MVM responsible for uptake of nonessential amino acids against their concentration gradient energized by the inwardly directed Na^+ gradient (156). This uptake creates high intracellular concentrations of amino acids, which then diffuse across the BM, mediated by efflux transporters and exchangers, to enter the fetal blood (157). System L exchanges the high intracellular levels of nonessential amino acids for essential amino acids, such as leucine, in the maternal circulation (158). Such coordinated transporter functions allow for a net accumulation of both essential and nonessential amino acids in the fetal compartment to support protein synthesis and growth. In fact, reduced placental amino acid transport capacity is a consistent feature of IUGR pregnancies (159–167). Conversely, increased amino acid transport capacity has been reported in placentas from pregnancies with LGA babies of both obese and diabetic mothers, but this has not been consistently reported in all studies (117, 150, 168–176).

Lipids are essential for neural development and hormone synthesis, and maternal circulating lipids increase across gestation to provide fatty acids (177) that serve as an energy source as well as structural building blocks for the fetus and are precursors for important signaling lipids (178). However, the mechanisms for lipid transfer across the placental barrier are not fully understood. Lipoprotein receptors in the MVM allow complex maternal lipids to bind to the syncytiotrophoblast (179), where lipases on the MVM surface release nonesterified fatty acids to be taken up by the placenta (180). Fatty acid transporting proteins (FATPs) and CD36 fatty acid translocase are localized to both plasma membranes in placenta (181). Lipase activity was found to be lower in pregnancies complicated by IUGR and higher in diabetic pregnancies delivering LGA infants (182). Moreover, in pregnancies complicated by IUGR, an upregulation of fatty acid transporters was found in the MVM (183), suggesting a compensatory mechanism for delivering much-needed lipids to the slow-growing fetus. A novel lipid transporter for phospholipids, Major Facilitator Superfamily Domain (MFSD2a), was recenly reported to be present in the human placenta. Expression of MFSD2a, a transporter with a strong affinity for lysophosphatidylcholine species that contain docosahexaenoic acid (DHA), correlated with the percentage of DHA in the umbilical circulation of women with GDM (184). A strong association between MFSD2a expression and umbilical cord lysophosphatidylcholine-DHA suggests a role for this transporter in supplying n–3 long-chain polyunsaturated fatty acids to the fetus (185).

2.1.4. Placental hormones in normal, IUGR, and LGA pregnancies.

Endocrine regulation of fetal growth is tightly regulated by the placenta, as the syncytiotrophoblast secretes hormones that coordinate maternal adaptations to pregnancy that support the growth of the developing fetus and prepare the mother for lactation. Changes in placental endocrine functions may contribute to adverse fetal development and contribute to the programming of metabolic disorders in the offspring, yet underlying mechanisms are not completely understood. Examples of key hormones secreted by the placenta that have distinct roles in normal and impaired maternal-fetal physiology are listed in **TABLE 1**, and their roles in normal and abnormal fetal development along with potential links to postnatal metabolic disease are discussed below.

Specifically, human chorionic gonadotropin (hCG) is produced primarily by syncytiotrophoblasts and has a structure similar to luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Key hCG functions include autocrine/paracrine stimulation of placental growth and differentiation, maintaining progesterone production by the corpus luteum until the placenta takes over as the main site for progesterone synthesis, proangiogenic effects in the uterine and placental vasculature, promotion of trophoblast invasion, and suppression of the maternal immune system to prevent rejection of the conceptus (189, 190). In early pregnancy, hCG does not predict the development of pregnancy complications with the sensitivity required for a clinically useful biomarker (191). This may, in part, be due to imprecise conception dating and rapid changes in hCG levels in early pregnancy and partly explains why hCG has not been found to predict developmental programming of metabolic disease.

Likewise, human placental lactogen (hPL), or human chorionic somatomammotropin, is produced mainly by the syncytiotrophoblast and is structurally very similar to growth hormone (GH). Increases in circulating hPL reflect changes in placental mass (189, 192). hPL binds to GH and prolactin receptors and modulates maternal lipid and carbohydrate metabolism during pregnancy. Specifically, hPL activates maternal adipose tissue lipolysis, contributing to a pronounced increase in maternal circulating lipids during pregnancy (189). Moreover, hPL increases maternal pancreatic mass and insulin secretion, contributing to maternal postprandial hyperinsulinemia to compensate for insulin resistance in pregnancy

Table 1. ***Placental hormone functions, changes with pregnancy pathology and associations with DOHaD***

Hormone	Function	IUGR*	Obesity/Diabetes*	DOHaD	References
Human chorionic gonadotropin (hCG)	• Stimulates trophoblast invasion and growth • Proangiogenic • Immunosuppression			Indirect associations	67, 186
Placental lactogen (hPL)	• Increases maternal lipolysis and glycolysis • Stimulates maternal pancreatic β cell expansion	Decreased	Increased	Indirect associations	163
Placental growth hormone (pGH)	• Decreases maternal insulin sensitivity • Stimulates IGF release • Promotes growth	Decreased	Increased	Hypertension Insulin resistance	187
Insulin-like growth factor (IGF)	• Stimulates placental nutrient transport and hormone release	Decreased	Lower IGFBP	Hypertension Insulin resistance	85, 188
Progesterone	• Enhances implantation • Uterine quiescence	Increased	Decreased	Indirect associations	187
Estrogen	• Stimulates blood flow • Angiogenesis • Increased nutrient delivery	Decreased	Increased	Insulin resistance	183
Leptin	• Decreased apoptosis • Increased invasion • Immunosuppression	Decreased	Increased	Appetite regulation Hypertension	67

IGFBP, IGF binding protein; IUGR, intrauterine growth restriction. *Relative changes in hormone levels are in comparison to healthy pregnancies with appropriate growth for gestational age fetus.

and maintain euglycemia (193). hPL is also secreted into the fetal circulation but, however, at much lower concentrations than in the maternal circulation, where it has been proposed to stimulate the growth of several tissues (194, 195). Placental hPL production is therefore highly relevant to fetal growth because of the metabolic impact on the mother and growth stimulation in the fetus, but few studies clearly link hPL directly to pathological fetal growth or long-term health risk in the offspring (196).

In addition, human placental growth hormone (pGH) is structurally highly related to hPL and prolactin and supports fetal growth by promoting maternal gluconeogenesis and lipolysis (192) to increase maternal circulating nutrients for placental uptake and transfer to the fetus (197). This variant of pituitary growth hormone, which is normally secreted in a pulsatile manner, is produced constitutively by the syncytiotrophoblast from 15–20 wk of gestation through parturition, replacing maternal pituitary growth hormone for the second half of gestation (192, 198). The physiological roles of pGH are similar to pituitary growth hormone, such as stimulating insulin-like growth factor 1 (IGF-1) and modulating maternal metabolism, including insulin resistance (189). Reports of association between pGH levels and pregnancy complications are varied, but reduced fetal growth has been associated with low maternal pGH levels (196, 199) and LGA infants of obese and GDM mothers are associated with increased pGH in the maternal circulation (200, 201). Notably, pGH expression has been linked with adult height, suggesting that intrauterine growth as well as adult longitudinal growth are determined by placental hormones and intrauterine exposure (202). This provides a strong link between placental hormone synthesis and offspring growth restriction or stunting when the mother has poor access to nutrition during pregnancy.

At the same time, insulin-like growth factors (IGFs) are critically important for growth and differentiation during development. IGF-1 promotes maternal tissue growth, trophoblast invasion, and placental blood flow as well as linear growth in the postnatal period (203). IGF-1 is regulated by pGH during pregnancy (204), which in turn is highly responsive to maternal nutrient status. IGF-2 levels are higher than IGF-1 in both maternal and fetal circulations (205). Nutrient transporter activity and expression as well as placental hormone production are regulated by IGF-2 (206). These signaling interactions create a strong link between maternal nutritional status,

pGH/IGF, and fetal growth, as evidenced by placental IGF-2 expression being positively correlated with birth weight (207). Bioactivity of IGF is also regulated by multiple IGF binding proteins (IGFBPs). In fetal life, IGFBP-1 represents the most important binding protein, and the affinity of IGFBP-1 to bind IGF-1 is modulated by phosphorylation, enhancing the affinity for IGF-1 binding (42), providing an additional level of control in this critical growth-regulating network. IUGR is associated with lower IGF-1 and -2 in the umbilical cord (208) and hyperphosphorylation of IGFBP-1 in both the fetal (43) and the maternal (209) circulations. On the other hand, GDM is associated with lower levels of IGFBP-1 and -7, which likely results in increased IGF bioactivity in these pregnancies (210).

Finally, placental estrogens are also key steroids that influence fetal development and impact postnatal metabolic disease. Estrogens are produced in the syncytiotrophoblast, and the predominant precursor, DHEA-S, is synthesized by the fetal adrenal cortex and delivered to the placenta, where it is converted to estrogen by CYP19A1 (aromatase) and released preferentially to the mother (211). Functions of estrogen in pregnancy are diverse, including stimulation of uteroplacental blood flow, endometrial growth, placental angiogenesis, and nutrient uptake (211). Placental estrogens act on the maternal liver to increase very low-density lipoprotein (VLDL) production, supporting the increase in circulating triglycerides in the second half of pregnancy (189). Moreover, both high and low intrauterine estrogen exposure have been associated with adult insulin resistance (212, 213).

2.1.5. Placental exosomes in normal, IUGR, and LGA pregnancies.

Fetal growth is also regulated by placental signaling other than the endocrine systems discussed above. In particular, increased circulating extracellular vesicles (EVs) with surface trophoblast markers suggest that the placenta is communicating with the mother through EV signaling (214). The vesicle cargo is diverse, including proteins, lipids, and nucleic acids, which can be taken up by target cells in the maternal vasculature or immune cells to modulate maternal physiology and facilitate adaptation to pregnancy (215). One role of placental EVs is thought to be immune tolerance to prevent fetal rejection (216), but other functions, such as spiral artery remodeling, trophoblast invasion, and modulating cytokine release, have also been attributed to EVs and a subgroup of placental EVs called exosomes. Exosomes from the placenta have been proposed to play a role in pregnancy complications, including GDM and preeclampsia (215, 217), through modulation of specific exosome content that has been shown to be affected by the local placenta microenvironment (216). The ability to modulate exosome content allows the placenta to send divergent signals to the mother in pregnancies complicated by low uteroplacental blood flow or maternal metabolic disease or in conditions of increased oxidative stress (215). A specific role for exosomes to modify metabolic processes in the mother across gestation has been proposed, but additional cause-and-effect experiments are needed. Nonetheless, whether placental EVs are released to the fetal circulation to modulate organ development or as a programming mechanism is less clear and remains an area of active research (218).

2.2. *The Placenta as a Nutrient Sensor and Fetal Development*

A major role of the placenta involves regulating blood flow, nutrient transport, and endocrine signaling for proper fetal development, and more recently the placenta has been suggested to function as a nutrient sensor (119) and is regulated in response to an array of maternal signals that aid in determining nutrient transfer to the developing fetus. Moreover, the association between the activity of placental nutrient transporters and fetal growth, birth weight, and adiposity suggests a mechanistic link between placental nutrient transport capacity, fetal growth rates, and maternal body composition (114). A better understanding of how placental transport functions are regulated may provide novel therapeutic avenues to prevent or alleviate abnormal fetal growth and therefore long-term fetal programming of metabolic disease. For example, if maternal nutrient status or uteroplacental blood flow is low, this is "sensed" by the syncytiotrophoblast, which responds by slowing its own growth and downregulating the expression and/or activity of nutrient transporters, thereby slowing fetal growth. By adjusting fetal nutrient delivery to match the ability of the mother to provide substrates for growth, the placenta functions as the arbiter of intrauterine growth. This premise is further supported by higher IGF-1 levels, mechanistic target of rapamycin (mTOR) activation, and increased amino acid and fatty acid transporter expression in placentas of GDM and obese mothers (172, 176, 181, 219), in whom fetal overgrowth is more common. Conversely, IUGR pregnancies are known to be associated with lower levels of growth factors, smaller placentas, and reduced mTOR and amino acid transport capacity including in animal models of protein or calorie restriction during gestation that mimic poor maternal nutrition or famine (220–223). Given the complex nature of how the placenta regulates nutrient delivery to the fetus, a thorough discussion of potential pathways is necessary.



FIGURE 5. Placental mechanistic target of rapamycin (mTOR) is responsive to a wide variety of upstream inputs including macronutrient availability, oxygen, energy status, and hormonal growth signals and in turn regulates placental growth and nutrient transporter function, which leads to changes in fetal growth rate, body composition, and developmental programming. hCG, human chorionic gonadotropin; hPL, human placental lactogen; IGF, insulin-like growth factor; pGH, placental growth hormone.

The mTOR signaling pathway responds to multiple metabolic signals and regulates key placental functions. This signaling pathway has been proposed as a central component of a placental nutrient sensor (224). Specifically, as shown in **FIGURE 5**, mTOR regulates placental growth and nutrient transporters and is responsive to a wide variety of upstream inputs including macronutrient availability, oxygen, energy status, and hormonal growth signals (225). In the human placenta, these signals originate predominantly in the mother and inform the syncytiotrophoblast about her nutritional and health status. There are two mTOR complexes (mTORC1 and mTORC2) that respond to nutrient signals by modulating downstream kinase activities, which in turn control fundamental cellular processes such as protein synthesis, cytoskeleton activity, and proliferation (226). In fact, reducing mTORC1 or mTORC2 by siRNA silencing in cultured primary human trophoblast (PHT) cells resulted in a significant reduction (−50%) in amino acid transport activity due to loss of amino acid transporter localization in the MVM (227). Conversely, siRNA targeting to reduce deptor expression in PHTs, the endogenous mTOR inhibitor, caused a dramatic increase in both expression and activity of amino acid transporters (228).

Emerging evidence also suggests a strong link between placental mTOR signaling, cellular lipid metabolism, and amino acid transporter activity. In cultured PHT cells, incubation with different fatty acid species differentially modulates mTOR activity and amino acid uptake. Treating PHT cells with oleic acid (OA) activated mTOR and stimulated amino acid uptake through System A (229). Conversely, treatment with docosahexaenoic acid (DHA) inhibited mTOR and lowered System A activity (230), suggesting that pregnancies associated with maternal hyperlipidemia (e.g., obesity and GDM), which have higher levels of OA in circulation, may be contributing to activation of placental mTOR, resulting in greater amino acid delivery, and potentially contribute to the development of LGA infants more commonly found in these mothers (231). Likewise, the increasing lipid levels in the maternal circulation across gestation, especially species like OA, would stimulate nutrient delivery to the fetus by coordinating fatty acid and amino acid transport, likely contributing to the higher birth weights in these pregnancies.

Interestingly, women with adequate DHA in their diet may provide a necessary counterbalance to the stimulation by OA, confirming studies that a well-balanced diet with foods containing ω–3 long-chain polyunsaturated fatty acids is more likely to result in healthy birth weight because of the interactions of nutrient levels and placental function.

Extending this discussion of maternal diet and fetal growth, it is well documented that low maternal folate status is associated with reduced fetal growth and birth defects (232, 233), and a potential mechanism for these associations is attributed to placental mTOR, as it is responsive to folate availability and functions as a folate sensor (234). Placental mTOR activity may be regulated by maternal dietary folate levels such that folate deficiency inhibits mTOR signaling and System A amino acid transporter activity in PHT cells (235). System A activity was rapidly restored when folate was returned to normal levels in folate-deprived cultured human trophoblast cells (83). AMP-activated protein kinase (AMPK) is highly responsive to cellular energy levels and is a primary mTOR regulator in trophoblast cells (234). Oxidative phosphorylation in mitochondria is an important contributor to cellular energy production, and mTOR has recently been found to regulate mitochondrial biogenesis in the human placenta (236). Oxygen levels also impact mTOR, as seen in decreased placental mTOR with hypoxia-induced growth restriction in rats (237). Likewise, endoplasmic reticulum (ER) stress and autophagy are regulated by mTOR in human placenta and likely contribute to slow placental growth when oxygen or glucose is limiting (237–239).

Although a variety of stimuli activate placental mTOR, the most-studied hormonal effectors in trophoblasts are insulin and IGF-2, which represent positive maternal nutritional signals that activate mTOR and increase nutrient transport to the fetus (197). Amino acid transport is modulated by changing the expression of transporters in the plasma membrane through ubiquitination by the NEDD4-2 ligase that removes the transporter from the membrane and targets it for lysosomal degradation (228). Indeed, placentas of human IUGR pregnancies have lower insulin and IGF-2, reduced mTOR activation, high NEDD4-2 expression, and lower expression and activity of both System A and System L transporters in the MVM (160). A lower transport capacity for amino acids and reduced mTOR activity have also been described in a wide variety of animal models, including IUGR due to decreased uteroplacental blood flow, hyperthermia, or dietary deficiencies (221, 240, 241). On the other hand, accelerated fetal growth due to maternal obesity is characterized by higher insulin and IGF-2, increased placental mTOR activation, and greater nutrient-transporting capacity (228, 242–244). This relationship is particularly evident in women delivering LGA newborns (176, 245). Indeed, coordination between the mother, placenta, and fetus to modulate nutrient allocation confers an evolutionary advantage by reducing fetal nutrient transfer and preserving the mother's health in low-nutrient conditions. However, when nutrients are abundant and blood flow is optimal, the placental mTOR regulatory system has the capacity to increase placental growth, activate nutrient transporters, and accelerate fetal growth. Producing the largest baby the mother can support in this particular pregnancy provides a strong survival advantage, as larger babies have lower infant mortality and morbidity, but the trade-off for accelerated intrauterine growth includes a number of long-term negative health risks (246). In short, these studies provide potential mechanisms for clinical studies describing how maternal diet and body composition influence infant weight and childhood obesity.

In summary, a direct role for placental mTOR signaling in the homeostatic control of fetal growth has recently been proposed (247). In a proof-of-principle experiment, cultured fetal hepatocytes were incubated with conditioned media from trophoblast cells that were deficient in mTOR signaling, and the hepatocytes responded by increasing phosphorylation and secretion of IGFBP-1. Increased IGFBP-1 with greater affinity to bind IGF will result in a decreased bioavailability of IGF and lead to reduced growth of the fetus (247). This novel concept that placental mTOR not only regulates placental growth and function but also communicates directly with the fetal liver to modulate important growth-regulating signals in the fetus is, as of yet, unproven. However, these preliminary reports support the concept that placental mTOR signaling may be an interesting target for efforts to normalize fetal growth in complicated pregnancies and thereby modify the risk for programming of postnatal metabolic disease.

2.3. *Endocrine Regulation of Placental Function*

The relationships between maternal metabolic hormones, placental growth phenotypes, mTOR activation, and nutrient transport changes have been consistently demonstrated in human pregnancies and in a wide variety of animal models of pathological fetal growth including rodents, sheep, and nonhuman primates (**TABLE 2**). The premise that placental function is regulated in response to maternal nutrient status is supported by findings that maternal metabolic hormones modulate placental function. In understanding how hormones mediate interactions at the maternal-fetal interface, they themselves could serve as early biomarkers of fetal growth restriction and postnatal metabolic dysfunction. This is best exemplified by insulin signaling in the

Table 2. ***Changes in maternal insulin, placental mTOR, and amino acid transport in human and animal models of pregnancy pathologies for restricted and accelerated fetal growth***

Pregnancy Condition	Maternal Insulin/IGF*	Placental mTOR Activity*	Placental Amino Acid Transport*	References
Human IUGR	Low	Decreased	Decreased	232, 248
Low-protein diet in rat with IUGR	Low	Decreased	Decreased	249
Nutrient restriction in baboon with IUGR	Low	Decreased	Decreased	221
Human GDM with fetal overgrowth	High	Increased	Increased	172, 246
Human obesity (with fetal overgrowth)	High	Increased	Increased	219
High-fat diet mouse with fetal overgrowth	High	Increased	Increased	242

GDM, gestational diabetes; IUGR, intrauterine growth restriction; mTOR, mechanistic target of rapamycin. *Relative changes in each parameter are compared to healthy pregnancy with normal fetal growth trajectory.

placenta, where activation of the insulin receptor in the placenta promotes proliferation mediated by the activation of two distinct signaling pathways: ERK signaling and activation of mTOR through AKT signaling (250). Insulin and IGF stimulation of mTOR has been demonstrated by phosphorylation of well-established mTOR targets, including S6K/RS6 and 4EBP1, in cultured PHTs (227). High maternal insulin and/or IGF, observed in pregnancies complicated by obesity and/or GDM, are more likely to result in larger placentas and greater nutrient transport expression (251, 252). Conversely, pregnancies complicated by IUGR are characterized by lower maternal circulating insulin/IGF, smaller placentas, and reduced placental amino acid transport capacity (117).

Furthermore, placental hormones, such as pGH and hPL, also contribute to the placental adaptive responses to changes in maternal nutritional and metabolic status. Mothers who fail to gain adequate weight in pregnancy have lower pGH levels, reduced IGF-1, smaller placentas, and low birth weight (253). Reduced pGH secretion prevents further depletion of maternal nutrient reserves and preserves resources to support lactation capacity. Conversely, high levels of hPL in pregnancies exhibiting fetal overgrowth contribute to further expand maternal beta cell mass and insulin production, which maintain maternal fasting normoglycemia despite peripheral insulin resistance and promote nutrient allocation for fetal growth (199).

Glucocorticoids are critically important during development to provide a necessary stimulus for maturation of tissues at the expense of growth (254) and have specific roles in regulating placental function (255) including reduced glucose and amino acid transport (255) and reduced placental lactogen release (256). Increased maternal glucocorticoids occur with maternal stress or poor maternal nutrition and result in decreased placental size in all species studied (257). High maternal glucocorticoids result in a decreased expression and/or activity of several nutrient transporters including GLUT and System A (258, 259). A reduced surface area for transfer and decreased transporter activity will limit nutrient transfer and slow fetal growth in pregnancies with high glucocorticoid levels (260). Placental blood flow may also be negatively impacted by stress, as glucocorticoids reduce *vegf* gene expression and reduce placental vessel size (261). Finally, sexual dimorphism has been reported in the placental response to glucocorticoids, with males being more sensitive and having greater inflammatory and vascular responses (262), potentially contributing to sexual dimorphism in programming events.

Finally, maternal circulating levels of adiponectin, secreted from maternal adipose tissue, are inversely correlated with maternal BMI or FM (263). The action of adiponectin in peripheral tissues, such as muscle, is to increase insulin sensitivity, and the loss of this sensitizing agent with increasing adiposity promotes insulin resistance associated with obesity (264). Contrary to muscle, adiponectin inhibits insulin signaling in the placenta through the activation of PPARα, a transcription factor that increases ceramide synthase expression, resulting in increased intracellular ceramide and inhibition of IRS-1 (265). High adiponectin in lean mothers inhibits insulin-stimulated placental nutrient uptake and results in greater allocation of resources to the mother. The opposite occurs in obese women who have high insulin levels and low adiponectin, both of which promote nutrient transfer to the fetus (266). In fact, there is an inverse correlation between maternal adiponectin and birth weight, suggesting that this is an important maternal resource allocation mechanism to modulate the impact of insulin on placental function and fetal growth

in accordance with maternal nutrient status (172, 267). Supplementation with adiponectin during the final 4 days of pregnancy in high-fat/high-sugar diet-induced obese pregnant mice prevented excess placental nutrient transfer, returned transporter expression to control levels, and prevented fetal overgrowth. Adiponectin supplementation that prevents intrauterine overgrowth in obese dams ameliorates developmental programming of metabolic disease. For example, adult offspring of obese dams who were maintained on normal chow after weaning demonstrated characteristic programming of cardiovascular and metabolic disease including obesity, glucose intolerance, hypertriglyceridemia, liver steatosis, and cardiac diastolic dysfunction. Yet adult offspring of the adiponectin-supplemented obese dams in the third trimester did not present with any of these cardio-metabolic programming events (268, 269). Collectively, these studies suggest that therapeutic strategies directed at placental function to normalize fetal growth without changing the overall phenotype of the mother are sufficient to prevent programming of adult metabolic disease in maternal obesity. Whether or not they can be employed in IUGR pregnancies to ameliorate long-term metabolic disease in postnatal life is the focus of future research studies.

2.4. Placental Epigenetic Regulation in DOHaD

In EPIDEMIOLOGY OF THE DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE, the role of maternal diet in methylation patterns of key metabolic genes was discussed as a potential mechanism linking in utero growth restriction and metabolic diseases in the offspring (8, 100, 202). It is therefore of great relevance that multiple signaling pathways controlling key functions of the human placenta are subjected to epigenetic regulation. Given that epigenetic modifications of DNA in the fetus may contribute to poor metabolic health later in life (270), differential methylation patterns of placental tissue may serve as an early indication of the severity of the programming events in utero.

After methylation erasure in gamete formation and during the blastocyst stage of development, the reestablishment of methylation patterns in the trophectoderm is distinct from the inner cell mass (271). This early phase of development with dramatic changes in methylation is particularly sensitive to environmental and nutritional influences, and given that the placenta is one of the first organs to develop, epigenetic regulation of gene expression likely contributes to trophoblast invasion along with anatomical and functional changes across gestation (272). Although in general trophoblast DNA is mainly hypomethylated, trophoblast DNA also contains a large number of imprinted or monoallelic genes, due to hypermethylation of either the maternal or paternal allele that silences its expression (273). Many of the >100 genes that have been shown to be imprinted in the placenta are involved in the regulation of placental growth and function, including nutrient transport, collectively modulating fetal growth (274). Paternally expressed genes tend to enhance fetal growth potential, whereas maternally expressed genes tend to limit growth, consistent with the conflict hypothesis of imprinted mammalian genes (275, 276). As well, alterations in maternal nutrition and metabolism regulate the expression of both placental and fetal genes by epigenetic mechanisms (277).

The expression of numerous imprinted genes in the human placenta is subjected to regulation across gestation and is associated with fetal growth. Moore and coworkers (278) collected chorionic villous samples (CVS) at 11–13 wk, as well as term villous tissue, to examine the expression of placental imprinted genes and fetal growth across gestation. Paternally expressed IGF-2 and IGF-2 receptor genes in CVS correlated with crown-rump length in early gestation and birth weight at term, but placental expression of these genes at term was not related to size at birth. The expression of maternally imprinted pleckstrin homology-like domain family A (PHLDA) at 12 wk was not associated with early fetal growth, whereas term placenta expression was negatively correlated with birth weight. Likewise, term placental expression of maternal imprinted gene growth factor receptor-bound protein 10 (GRB10) was negatively correlated with head circumference. Expression of the paternally imprinted delta-like 1 homolog (DLK1) was correlated with growth in both early and term gestation (278). Two human growth syndromes exemplify the significance of placental genomic imprinting. It is noteworthy that in the developmental disorder Silver–Russell syndrome, which is characterized by stunted growth and limb or facial asymmetry, 40–60% of cases are due to the imprinted cluster on chromosome 11p15.5 containing the telomeric IGF2/H19 domain, which is controlled by parentally methylated imprinting control region 1 (ICR1). Hypomethylation of ICR1 upstream of IGF2/H19 controls the reciprocal imprinted expression of the paternally expressed growth-promoting IGF2 gene, resulting in lower IGF-2 expression, leading to fetal growth restriction and smaller, underdeveloped chorionic villi in the placenta (279, 280). Conversely, Beckman–Wiedemann syndrome, which exhibits hypermethylation in the imprinting control region of the IGF2 gene, is characterized by fetal overgrowth (281).

To determine associations between placental differential methylation and human intrauterine growth, both genomewide methylation studies and targeted gene

approaches have been conducted. Results of these studies have been inconsistent, perhaps because of small sample size and failure to account for key confounding factors (282). Additionally, polymorphic DNA methylation is a characteristic of imprinted genes in humans and suggests a complex interindividual, tissue-specific variation contributing to a lack of clear methylation/expression concordance in imprinted placental genes. (283). In one study, IUGR was associated with 22 differentially methylated regions (DMRs) in human placenta (284), which were highly predictive of IUGR. However, in a whole genome methylation study no differentially methylated positions were found in placentas of growth-restricted versus normal-size infants (285). Recently, Devaskar and colleagues (286) found >500 differentially methylated genes in CPG islands in placenta from IUGR compared with normally grown and LGA babies. The differentially methylated regions were distinct for each birth weight group studied, suggesting a role for epigenetic regulation of the placenta associated with fetal growth rates. The genes impacted affected critical placental functions such as nutrient transfer, hormone synthesis, and metabolism. Interestingly, the placenta may also contain information about future postnatal disease risk, given that genes associated with cardiometabolic disease were differentially methylated in the placenta in a birth weight-dependent manner (286).

Several factors investigated in the etiology of IUGR have been demonstrated to influence epigenetic regulation of the placenta. For example, maternal health status, such as psychosocial stress, has been associated with differential genomewide placental methylation (287). High levels of maternal stress resulted in divergent methylation patterns in genes coding for metabolic pathways including AKT/PI3K. Moreover, maternal metabolic health, including dyslipidemia, impacts methylation of PPAR genes in placenta and in key organs of the offspring (288). PPARs are key transcription factors that act as central regulators of lipid metabolism, and differential methylation that occurs in utero is believed to contribute to lifelong health risk. Another nutrient-responsive system in the placenta is the OGT or *O*-linked *N*-acetylglucosamine (*O*-GlcNAC) enzyme that catalyzes the addition of *O*-linked *N*-acetylglucosamine to serine and threonine residues in intracellular proteins that regulate placental function due to the loss of regulatory phosphorylation sites. Histone proteins, which are critical for modulating gene expression, are regulated by *O*-GlycNAcylation (289). Placental OGT is differentially expressed in males and females and may represent one of the underlying mechanisms of sex differences in intrauterine programming. In mice, increased stress during pregnancy resulted in a sex-dependent programming of male hypothalamic-pituitary axis, and placenta-specific knockout of the OGT reversed this phenotype (290).

In summary, there are a number of key metabolic and physiological processes that support placental sufficiency and allow healthy fetal growth and development to occur. However, when challenges to placental development or functioning occur, significant effects on the fetus, leading to both acute and chronic adaptations, may be detrimental for postnatal health. Moreover, the placenta does not function independently of maternal physiology and fetal development, and complementary actions imparted by maternal health can add additional insult to a compromised placenta. Therefore, it is clear that a number of processes likely underlie the interactions between the above-discussed relationship between maternal nutritional state (BMI, famine, dietary constraints or excesses, stress, and epigenetics) and birth weight outcomes and long-term health. Although these processes provide a short-term survival advantage to produce a smaller, but viable, fetus, the programming of metabolic disease later in life is a serious long-term consequence.

3. ADVERSE IN UTERO ENVIRONMENT AND METABOLIC DISEASE

As reviewed in EPIDEMIOLOGY OF THE DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE, a large number of epidemiological studies have demonstrated that a number of maternal and paternal factors, such as obesity, exposure to poor nutrition, and famine, are associated with a higher risk of chronic diseases in the offspring. Moreover, as ROLE OF THE PLACENTA IN FETAL GROWTH AND METABOLIC DISEASES nicely illustrates, the impact of these external insults, whether occurring during preconception and/or during gestation, can first be measured upon placental functioning. The placental deficiency (i.e., altered nutrient sensing, nutrition transfer, and/or endocrine function) that ensues ultimately culminates in compromised fetal development. This section provides the latest insights from human and animal studies linking fetal growth restriction with adverse postnatal metabolic outcomes, including dysglycemia, dyslipidemia, fatty liver disease, and cardiovascular dysfunction. Regardless of the prenatal environment leading to placental insufficiency and IUGR, rapid postnatal catch-up growth may exacerbate the incidence and severity of these metabolic deficits.

3.1. Developmental Influences on Dysglycemia

Although over 20 years has passed since David Barker first published the seminal findings that impaired fetal growth is associated with a greater risk of developing diabetes, obesity, and hypertension, we are only now elucidating the underlying mechanisms for these programmed

metabolic deficits (291). Importantly, recent clinical reports such as the EPOCH study have reaffirmed Barker's findings by demonstrating that IUGR children exhibit postnatal catch-up growth leading to higher circulating insulin levels, greater homeostatic model assessment of insulin resistance (HOMA-IR), and lower adiponectin levels in childhood independent of other maternal or childhood factors (292). As T2D is first characterized by early decreases in insulin sensitivity, augmented insulin resistance, and impaired insulin secretion, it is not surprising that all of these characteristics are exhibited early in SGA or IUGR offspring (293). First, IUGR offspring exhibit hypoglycemic hyperinsulinism as early as birth, with a progression of insulin resistance over the first 3 yr of life (294–298). The reduced insulin sensitivity in these offspring can be attributed, in part, to altered skeletal muscle fiber composition that began in utero and is maintained later in life (299). Second, this impaired insulin sensitivity is worsened in SGA offspring with postnatal catch-up growth compared with SGA offspring without catch-up growth or appropriate-for-gestational age (AGA) offspring (300–302). Third, HOMA-IR studies have observed associations between birth weight and β-cell function in later life (295, 303). Although the incidence of IUGR and its corresponding relationship to long-term dysglycemia have remained steadfast over these decades, to date there are no reliable biomarkers for predicting the threat of a poor in utero environment (304). However, advances in metabolomics are beginning to uncover markers such as myoinositol in IUGR newborns, which is linked to glucose intolerance and insulin resistance in adulthood (305, 306), but there is still debate as to whether myoinositol would be a predictive biomarker in utero (306, 307).

To date, although several animal models (i.e., maternal glucocorticoid exposure, protein or caloric restriction, and hypoxemia) exist to model the etiology of fetal growth restriction on the developing pancreas and long-term dysglycemia, we focus our review on the role of maternal uterine ligation in long-term metabolic syndrome (308, 309) first and foremost because placenta-induced IUGR afflicts ~5% of pregnancies and represents the main cause of IUGR in the Western world (308, 310, 311). Second, given that placental insufficiency-induced IUGR leads to decreases in oxygenation and substrate availability for the fetus (312–314), the uterine ligation (or ablation) model serves as an excellent model for examining the impact of idiopathic IUGR on postnatal metabolic disease. In **FIGURE 6** we present an overview of the impact of placental insufficiency on metabolic organs in postnatal life. The permanent ligation of both uterine arteries leads to hypoxia, hypoglycemia, and decreased availability of growth factors (315, 316). Doppler analysis has confirmed that this model mimics the hemodynamic features of the human IUGR fetus particularly in the ductus venosus (317). In rats, uterine ligation leads to development of the metabolic syndrome in the offspring including type 2 diabetes (i.e., reduced β-cell mass), dyslipidemia, and hypertriglyceridemia (318–320). Moreover, several of these metabolic defects are reciprocated into the F_2 generation (321, 322). Elegant studies by Park et al. (323) have demonstrated that uterine-ligated IUGR offspring develop type 2 diabetes because of epigenetic silencing of the critical β-cell transcription factor Pdx-1. Interestingly, the development of glucose intolerance in these IUGR offspring could be ameliorated with the use of Exendin-4 (a GLP analog) in neonatal life to restore Pdx-1 expression and islet vascularity (324, 325). Other long-term IUGR-induced pancreatic defects (e.g., at 6 mo of age) included irregular shape, increased macrophage-induced inflammation, fibrosis, and hemosiderosis, and these effects were enhanced by a high-fat postnatal diet (326). Some of these pancreatic defects can be observed in the second generation, as IUGR female offspring bred to control males led to impaired first-phase insulin signaling in both sexes of the F_2 generation, with sex-specific changes in β pancreatic cell mass (322). Aside from pancreatic defects, the glucose intolerance in these IUGR offspring can also be attributed to defects in insulin target organs including the muscle, adipose, and liver. In the muscle, uterine-ligated IUGR offspring exhibit defects in mitochondrial activity and insulin receptor function in muscle, but this was demonstrated to be dependent upon litter size and sex (327, 328). With respect to adipose, very little is known regarding insulin receptor function in uterine-ligated offspring; however, aged females do exhibit higher lipogenesis due to increased adipose fatty acid synthase and endoplasmic reticulum (ER) stress (329). Interestingly, IUGR liver deficiencies contributing to insulin resistance include altered glucose transporter expression, impairment of fatty acid metabolism, increased glucocorticoid activity, augmented gluconeogenesis, and blunted insulin suppression (318, 319, 330–332). These IUGR offspring also exhibit decreased hepatic and circulating insulin growth factor 1 (Igf-1), which is critical for insulin function, glucose metabolism, and growth (333).

3.2. *In Utero Growth and Dyslipidemia*

Barker's early studies (334) demonstrated that there was a strong correlation between reduced abdominal circumference at birth and elevated total and LDL cholesterol in adulthood. Since that time, elegant studies by Singhal et al. (335) have indicated that catch-up growth in neonatal life, likely due to growth-promoting formula diets, is associated with an exacerbation of the incidence and onset timing of dyslipidemia (e.g., higher LDL-to-HDL ratio) in IUGR infants. Alterations in circulating cholesterol acceptors in the sera of IUGR offspring



FIGURE 6. Summary of the metabolic deficits exhibited in the fetal growth-restricted offspring from dams exposed to uterine artery ligation/ablation. ER, endoplasmic reticulum; EWAT, epididymal adipose tissue; MHC, myosin heavy chain; mTOR, mechanistic target of rapamycin; ROS, reactive oxygen species.

have also been speculated to underlie the reduced cholesterol efflux observed, an indicator of early atherosclerosis long before clinical diagnosis (336). Further evidence that cholesterol homeostasis is impaired early in life is evident from a study of 55 SGA children in which half of them were in the highest quartile for serum total cholesterol of the AGA children at 12 yr of age (337). Interestingly, poor catch-up growth with respect to height, female sex, and early pubertal stage all predicted high cholesterol in these SGA children (337). However, a 2004 systematic review of 79 published studies concluded that impaired fetal growth does not influence long-term blood circulating cholesterol levels to the extent that it would actually increase vascular disease risk (338). It should be noted that within those studies significant heterogeneity was attributed to strong associations observed in several small clinical studies. Another limitation of these studies is the fact

that birth weight was used as the only indication of fetal growth restriction. A study from The Netherlands indicated that greater first-trimester fetal crown-to-rump length is associated with lower total and LDL cholesterol, android-to-gynoid FM ratio, and blood pressure in children aged 5–7 yr (339). However, there were no correlations between first-trimester fetal crown-to-rump length and other cardiovascular outcomes (339). With respect to triglycerides, across several studies fetal growth has been inversely associated with fetal and postnatal circulating triglycerides (248, 340, 341). One exception is the Aboriginal Birth Cohort Study of 11-yr-old children (1987–2001), which identified that circulating triglycerides levels were associated with current child weight but not birth weight (342). Moreover, although blood pressure in that study was inversely proportional to birth weight, this relationship was further strengthened when adjusted for current child weight (342). A recent analysis of Turner syndrome offspring, who are frequently born with low birth weight and undergo greater weight gain in postnatal life, identified strong links between fetal growth and dyslipidemia. In these offspring, there was a significant negative correlation between birth weight and lipid profiles (e.g., cholesterol and triglycerides) along with HOMA-IR (343).

Animal studies utilizing uterine ligation in baboons to mimic placental insufficiency-induced IUGR revealed that female offspring exhibited higher cholesterol, LDL levels, and subcutaneous fat at 8–9 yr (human equivalent of 32–36 yr), whereas male offspring displayed increased pericardial fat deposition (344). High hepatic and circulating serum cholesterol is also observed in uterine-ligated female rat offspring because of decreases in hepatic Cyp7a1, the critical enzyme in cholesterol catabolism (345). Although the mechanism for this was not fully elucidated, others have demonstrated that long-term silencing of *Cyp7a1* in low-birth-weight rat offspring is due to repressive histone modifications that originate in fetal life (346). Aside from changes in cholesterol, male guinea pig IUGR offspring from maternal uterine ligation demonstrate greater epididymal adipose tissue (EWAT), epididymal fat cellular lipid content, and mean epididymal adipocyte diameter by adulthood (347). Similar to what has been observed in the pancreas, IUGR elicits dyslipidemic effects across generations, as F_2 IUGR rats display increased central FM, elevated triglycerides and LDLs, along with higher fatty acids (321). Interestingly, supplementation of the F_1 generation IUGR offspring with essential nutrients (i.e., folic acid, choline, vitamin B_{12}, betaine, L-methionine, L-arginine, and zinc) prevented the dyslipidemia in both sexes of the F_2 generation due to amelioration of IUGR-induced DNA methylation of the promoter of *Igf-1* (321).

3.3. *Intrauterine Growth Restriction and Nonalcoholic Fatty Liver Disease*

Over time, dyslipidemia in the liver can develop into liver fibrosis [i.e., nonalcoholic fatty liver (NAFL)/nonalcoholic fatty liver disease (NAFLD)], and ultimately ~20% of those patients develop end-stage cirrhosis (348). Collectively, liver fibrosis is thought to underlie up to 45% of deaths in the developed world (349, 350). In a multicenter, cross-sectional study, both low- and high-birth-weight children had a greater risk of developing NAFLD (351). An Italian study also found a fourfold higher incidence of pediatric NAFLD in IUGR children, independent of insulin resistance (352). Interestingly, low-birth-weight children had greater odds of developing severe advanced fibrosis, whereas high-birth-weight children were more prone to hepatic steatosis (351). Furthermore, postnatal catch-up growth in the first 6–12 mo of life in SGA prepubertal children was demonstrated to increase the incidence of NAFLD (353), and insulin resistance was significantly correlated to liver steatosis (353).

These observations in humans are nicely replicated in animal models of IUGR. The uterine-ligated guinea pig dam leads to IUGR offspring exhibiting perisinusoidal or periportal fibrosis in the liver accompanied by expression of profibrotic markers including *Tgfb1*, *Mmp2*, and *Smad4* (354). The IUGR-mediated fibrosis may stem early from dyslipidemia, given that uterine ligation leads to an increase in overall and hepatic fat content early in fetal life (355). Moreover, uterine-ligated IUGR mouse pups exhibit higher visceral FM, fasting blood glucose, and leptin concentrations (356). Aside from the dyslipidemia observed, uterine-ligated IUGR offspring also display hepatic insulin resistance at 8 wk, well before any evidence of system insulin resistance from 3 to 6 mo (357). This was due, in part, to suppressed IRS-2 and Akt1 phosphorylation in the liver along with higher expression of the gluconeogenic enzymes PEPCK and G6Pase (357). Similar increases in both hepatic lipids and insulin resistance are also observed in maternal hypoxia-induced IUGR offspring (358). As adipose dysfunction and inflammation are involved in the etiology of NAFLD, it is noteworthy that IUGR rat offspring at 6 mo of age exhibit greater de novo fatty acid synthesis in adipose tissue due to increased acetyl-CoA and fatty acid synthase expression (359). In addition, male IUGR rats at 3 wk of age display high circulating and adipose TNF-α, an early hallmark of NAFLD (360). Moreover, spontaneous IUGR piglets with a postnatal high-fat diet have increased hepatic IL-6 mRNA later in life, suggesting increased local inflammation (98).

Although the contributions of growth restriction followed by a poor postnatal diet need to be better investigated in animal models, one study has demonstrated

that maternal caloric restriction in mouse dams, followed by a postnatal high-fat diet, results in low-birth-weight offspring with an increased incidence of hepatic steatosis coupled with greater infiltration of liver macrophages (361). However, the contributions of IUGR alone on a normal postnatal diet were not examined. Interestingly, these hepatic defects were ameliorated with treatment of tauroursodeoxycholic acid (TUDCA), a known inhibitor of ER stress (361). This suggests that IUGR followed by postnatal high-fat diet may play a role in ER stress-mediated NAFLD, although postnatal catch-up growth of the liver could also be a contributing factor (362). In addition to ER stress, hepatic apoptosis in NAFLD has been attributed to the liver's inability to proceed through autophagy, the process of lysosome-mediated cell degradation (188). This suggests that the intrauterine environment may play an early role in setting the stage of NAFLD in postnatal life, given that IUGR piglets exhibited reduced factors (i.e., mTOR, protein phosphatase 2A) associated with hepatic autophagy (363). This hypothesis is further substantiated by that fact that idiopathic IUGR is associated with greater fatty acid transporters in the placenta (183). Although this review is mainly focused on how placental insufficiency-induced IUGR drives long-term hepatic defects, it is noteworthy that ethanol- or caffeine-induced IUGR in rats also results in offspring with greater incidence of NAFLD (364, 365). Moreover, other complications in pregnancy including maternal obesity or gestational diabetes are also associated with fatty liver disease in postnatal life (366, 367).

3.4. *Intrauterine Growth Restriction and Cardiovascular Disease*

Although the principles of Barker's initial hypothesis were challenged as socio-economic and lifestyle factors were not accounted for in the relationship between fetal growth and the incidence of cardiovascular disease, more recent studies that do statistically adjust for occupation, education, income, and childhood/adult socio-economic status have minimized those concerns (291, 368–371). With respect to birth weight or blood pressure, a number of studies corroborate Barker's findings for both sexes, and across ethnic/racial groups, location, and age (369, 372–374). It has also been reported that for a 1-kg increase in birth weight there is ~2 mmHg lower systolic blood pressure from neonatal life to adulthood (341, 375, 376). However, caution is recommended in interpreting these data, given that such a magnitude of change would never be high enough to fully explain the clinical hypertension observed in Barker's early findings. Clearly, other underlying indexes must also contribute to long-term cardiovascular complications exhibited in these growth-restricted offspring. More recent studies have identified that a higher ratio of apolipoprotein B to apolipoprotein A-I (Apo A1) in fetal plasma, a predictor of atherosclerosis, is elevated in IUGR offspring, uncovering an early link between an adverse fetal environment and cardiac health (377). Elegant Doppler studies have revealed that myocardial performance index (MPI) is elevated in IUGR fetuses with end-diastolic blood flow (EDF) and is further progressed with greater hemodynamic compromise and fetal deterioration even while maintaining cardiac output (378). B-type natriuretic peptide, a well-established predicator of heart failure, was also increased in IUGR fetuses in a severity-dependent manner (378, 379). Doppler studies have further revealed that SGA and IUGR infants exhibit higher blood pressure and carotid intima-media thickness at 3–6 yr of age (380). With respect to the contribution of postnatal catch-up growth, Eriksson and colleagues (381) have demonstrated in a Finnish longitudinal study that rapid weight gain within 1 yr increases the risk of coronary heart disease later in life. However Tzschoppe et al. (382) have shown that an increase in carotid intima-media thickness is demonstrated in IUGR infants at 6 mo irrespective of postnatal catch-up growth and even in the absence of elevated blood pressure. Moreover, IUGR children have more globular hearts and impaired stroke volume, which is compensated by higher heart rates and diastolic changes in infants when the IUGR was early onset (380). In contrast, late-onset IUGR infants displayed higher stroke volume and cardiac output (380). Other studies have linked IUGR outcomes with high aortic intima-media thickness at birth (186, 383, 384). Skilton et al. (385) further demonstrated that the adverse effects of impeded fetal growth on arterial wall thickening could be prevented with dietary ω–3 fatty acid supplementation during the first 5 yr of postnatal life. The first few years of postnatal life may be particularly critical in IUGR offspring, given the stronger associations made between postnatal catch-up growth and long-term blood pressure, irrespective of birth weight (386–388). This is in contrast to maternal obesity-induced cardiac dysfunction in postnatal life (389), where it has been demonstrated in mice born to obese dams that the postweaning diet does not influence the risk of cardiac disease (390).

To date, animal models have shed some light on the underlying mechanisms for the in utero programming of cardiac dysfunction including reduced antioxidants, telomere shortening, mitochondrial dysfunction, reactive oxygen species (ROS) damage, and epigenetic modifications (391). Uterine ligation in guinea pig dams leads to IUGR offspring with increased cardiac fibrosis and aortic wall thickening by adolescence (392). In adulthood, it was further demonstrated in guinea pigs that IUGR has a greater impact on long-term aortic stiffening compared with a postnatal high-fat diet or vehicle controls (393). This is partially explained by the fact that elastin fiber content was

decreased in these IUGR guinea pig fetuses by 14%, followed by a 51% reduction in adulthood (394). Moreover, the central stiffness observed in these IUGR offspring might also result from changes in expression of myosin heavy chain β (β-MHC), a marker of cardiac remodeling (394). β-MHC was also sixfold higher in these IUGR fetuses and threefold higher in IUGR offspring (394).

Although decades of epidemiological and animal studies have further established Barker's observations of an association between a poor in utero environment and long-term metabolic disease, the present review updates its impact on dysglycemia, dyslipidemia, fatty liver disease, and adverse cardiovascular outcomes. Although the animal studies seem to be fairly consistent, there are several examples from clinical studies in which discrepancies exist in predicting a poor postnatal outcome resulting from IUGR. These discrepancies may exist because of differences in the postnatal environment. Clearly, further studies are warranted to address how management of postnatal catch-up growth could ameliorate these metabolic deficits. More importantly, early screening and reliant predictors of IUGR will result in efficacious strategies to reduce the impending threat of impaired fetal growth.

4. IN UTERO ENVIRONMENTAL CHEMICALS AND METABOLIC DISEASES

Thus far, this review has focused on cohort studies of human growth, in utero and early childhood, that may influence the development of metabolic disorders. Clearly, abundant evidence of fetal programming of metabolic function has been presented that identifies key maternal-fetal-placental mechanisms that may put growth-restricted fetuses at increased risk of future disease. In the modern environment, the potential for in utero disruption of metabolic development is further compounded by the thousands of chemicals present in our environments, many of which readily enter the maternal circulation, cross the placenta, and alter fetal hormone production, tissue development, and gene expression. In this section we review epidemiological and experimental evidence on prenatal exposure to environmental chemicals in relation to obesity, glucose, and lipid dysregulation and discuss special considerations and future directions for this emerging field.

4.1. Overview of Environmental Metabolism-Disrupting Chemicals

It has been long known that chemical exposures during pregnancy can have profound and irreversible effects on fetal development. The infamous examples of limb malformations following thalidomide administration and neurotoxic symptoms of Minimata disease resulting from methylmercury exposure provide incontrovertible evidence of fetal vulnerability to environmental exposures (395, 396). More recently, it has become clear that in utero chemical exposures may impact health and disease risk in more subtle ways as well. Indeed, a wide range of environmental chemical exposures can alter the intricately coordinated developmental processes underlying fertilization, cellular differentiation, organogenesis, and fetal development. Developing organisms are at even greater risk given the lack of mechanisms (e.g., detoxifying enzymes, DNA repair mechanisms, blood-brain barrier) that may offer greater protection from chemical exposures in mature individuals (397).

In contrast to the examples of overt toxicity described above, more often, environmental exposures have subtle developmental impacts. One timely example is the role of environmental exposures in the modern epidemic of obesity and metabolic diseases, first proposed in 2002 by Baillie-Hamilton (398) after observing the parallel temporal rises in environmental pollutants and obesity. In the nearly two decades since then, considerable research has examined the "obesogenic" effects of a wide range of environmental chemicals in vitro, as well as in animal models and humans (399). Informed by growing evidence that obesity cannot be fully explained by an imbalance between caloric intake and expenditure, Blumberg and Grün's (399) obesogen hypothesis proposed that environmental chemicals could promote obesity, particularly when exposure occurred during critical developmental periods. A number of potential pathways were identified as vulnerable to disruption including, but not limited to, *1*) adipocyte commitment, differentiation, and storage; *2*) basal metabolic rate and metabolic "set points"; and *3*) regulation of food intake (**FIGURE 7**). In 2015, the Parma Consensus Statement proposed a broader metabolism-disrupting chemical (MDC) hypothesis, suggesting that, in addition to obesity, chemical exposures may drive metabolic changes, such as insulin resistance and β-cell death, that ultimately contribute to metabolic diseases (400).

A primary mechanism of MDC action is through endocrine disruption and indeed, many MDCs are well-documented endocrine disruptors. By definition, endocrine disruptors alter homeostasis or action of endogenous hormone systems. Even transient exposures during critical developmental periods may permanently reprogram the endocrine axes that regulate weight and metabolism, leading to lifelong changes in physiology and disease risk (401). Endocrine disruptors can act on hormone systems in numerous ways, including changing the synthesis, release, transport, metabolism, activity, and elimination of key hormones. Thus far the preponderance of research on endocrine disruptors has focused on disruption of estrogen, androgen, and thyroid activity (402), all of which contribute to the regulation of adipogenesis,



FIGURE 7. Proposed mechanisms by which metabolism-disrupting chemicals may contribute to metabolic diseases. BPA, bisphenol A.

as well as satiety and energy balance (397). For example, production of estradiol, which is important in the regulation of β-cell insulin secretion, may be disrupted by multiple chemicals including bisphenol A (BPA), phthalates, and phytoestrogens (249, 403). Although less well studied, other endocrine pathways involving important metabolic regulators in the gastrointestinal tract (ghrelin, cholecystokinin, glucagon-like peptide-1), pancreas (insulin, glucagon), muscle (insulin), liver (glucagon, insulin, FGF21), adipose tissue (leptin, adiponectin), and brain (neuropeptide Y, proopiomelanocortin) (397) may also be vulnerable to disruption by environmental chemical exposure. Endocrine disruptors can interact with a wide range of nuclear receptors, moreover, including those that are essential for metabolic development and regulation such as aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), and constitutive androstane receptor (CAR), providing additional support for a link between endocrine and metabolic dysregulation (404). Although exposure to MDCs is unlikely to cause metabolic disease or obesity independently, by altering relevant hormonal pathways these chemical exposures may predispose individuals to adipose tissue accumulation, metabolic dysregulation, and weight gain by potentiating the risks of known metabolic risk factors such as caloric excess, circadian dysregulation, or physical activity (405).

4.2. Exposure to MDCs

At present, >85,000 registered chemicals are in production worldwide (406). Although most of these chemicals have not been extensively studied to understand their health impacts, ~1,000 have been identified as endocrine disruptors (407, 408). Of these, it is likely that a large proportion can be classified as MDCs. For many compounds, environmental exposure is widespread in the general population because of their frequent use in consumer products and industrial applications (409–411). Depending on the particular chemical, there may be multiple routes of exposure, including inhalation of polluted air or contaminated dust, absorption through the skin from MDC-containing personal care products (such as lotions, cleansers, sunscreens, and cosmetics), or ingestion of contaminated water and food. As many MDCs can be transported long distances in air or water, they have been found all over the world including in remote locations and populations (412–415). As a result, for many potentially MDCs, such as BPA and phthalates, exposure is near universal, meaning that identifying an unexposed "control" population is impossible. It also means that typically people are concurrently exposed to a mixture of MDCs, which is important when considering potentially additive or synergistic health impacts (416–418). For example, in a study of children participating in the U.S. National Health and Nutrition Examination Survey (NHANES), 81% of chemicals studied (26 of 31) were detectable in >90% of subjects (419). Similarly, a study of pregnant NHANES participants measured 163 synthetic chemicals from 12 different classes, finding that 99–100% of participants had detectable levels of 8 of the 12 chemical classes studied (418). Most of the chemicals



FIGURE 8. Ubiquitous exposure to select metabolism disrupting chemicals among pregnant women in National Health and Nutrition Examination Survey (NHANES). BPA, bisphenol A; DDE, dichlorodiphenyldichloroethylene; DDT, dichlorodiphenyltrichloroethane; MBP, monobutyl phthalate; MEP, monoethyl phthalate; PFAS, perfluoroalkyl substance; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

included in these analyses were suspected MDCs, including perfluoroalkyl substances (PFASs), polybrominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, phthalates, phenols, and polycyclic aromatic hydrocarbons, providing further evidence of widespread exposure in the general population, including pregnant women (**FIGURE 8**). Importantly, these chemicals are also detectable in cord blood and/or amniotic fluid, moreover, indicating widespread fetal exposure (420–423). Even within highly exposed populations, however, individual body burden may vary by an order of magnitude or more, depending on factors such as personal care products used, consumption of processed foods, and use of plastics, providing the variation needed to explore the relationship between these exposures and metabolic outcomes.

With dozens (if not hundreds) of suspected MDCs, it is impossible to comprehensively review their potential to impact metabolic disease. Instead, we focus on a small number of exemplar chemicals that are the subject of ongoing basic science and epidemiological study in the context of metabolic dysregulation, including BPA, phthalates, organochlorine pesticides, and PFASs as summarized in **TABLE 3**. These are among the chemicals identified as potentially strong candidate contributors to the obesity epidemic in a 2012 National Toxicology Program meeting on Environmental Chemicals in Diabetes and Obesity (424). Environmental exposure to these chemicals in the general population is widespread, thus presenting a public health challenge as well as, potentially, an opportunity to intervene through large-scale policy and/or behavioral changes. For each of these chemicals, considerable mechanistic work in animal models has been conducted, yet variation in timing of exposure as well as dose (with older studies often using supranormal doses that far exceed typical human environmental exposures) presents challenges when translating results to humans (401). Inflammation, oxidative stress, and mitochondrial mechanisms are all important candidates for disruption by MDCs, and, importantly, multiple mechanistic pathways may be simultaneously impacted by the same MDC exposure, resulting in a metabolic syndrome-like phenotype rather than targeted effects on individual organ systems (397).

4.2.1. Bisphenol A.

Despite public outcry over its use in the manufacture of baby bottles and reusable plastic water bottles in the 2000s, BPA is still in widespread production, with >15 billion pounds produced annually (425). BPA is most commonly used to make polycarbonate plastics and epoxy resins, and it is widely found in consumer products including DVDs, eyeglasses, food packaging including canned foods, medical equipment, and thermal receipt paper (426). Given that BPA can readily leach from plastic products including epoxy can linings into surrounding media, the potential for inadvertent contamination of food and drink is high and accounts for the vast majority of human exposure (427). Thus although BPA is rapidly metabolized in the body (half-life: 4–5 h), exposure is virtually continuous, and in NHANES BPA was detected in the urine of 92.6% of participants (428). Best known for its estrogenicity (429), BPA's interference in additional pathways, including glucocorticoid, thyroid, and PPARγ systems, may also contribute to metabolic disruption (430). Of all of the purported MDCs, BPA has been most extensively studied, with a large body of in vitro, experimental animal, and epidemiological work examining developmental exposure in relation to glucose tolerance, insulin resistance, β-cell function, and hepatic steatosis as well as weight gain and body size (397, 401).

Table 3. ***Chemical classes with suspected metabolism disrupting impacts during development***

Chemical	Half-Life in Human Body	Major Sources	Summary of Epidemiological Evidence	Potential Mechanisms
Bisphenol A (BPA)	Several hours	Food, thermal receipts, medical/dental devices, DVDs and CDs, electronics, epoxy resins, polycarbonate plastics	Mixed evidence linking prenatal BPA to higher child BMI and adiposity; possible effect modification by sex	Enhanced adipogenesis and lipid storage; impaired glucose utilization; promotion of oxidative stress and inflammation
Phthalates	Several hours	Food, personal care products, polyvinyl chloride (PVC), electronics, scented products	Mixed evidence linking prenatal phthalates to child growth patterns, BMI, and adiposity; possible effect modification by sex	Adipogenesis induction, changes in β-cell structure/number; hepatic steatosis; decreased glycogen storage; transactivation of PPARγ and PPARα pathways; oxidative stress
Organochlorine pesticides (e.g., DDT)	60 days up to 10–15 yr, depending on compound	Pesticides, food	Prenatal concentrations of DDT metabolites associated with increased body size in childhood and adulthood	Reduced insulin secretion; glucose intolerance; dyslipidemia
Perfluoroalkyl substances (PFASs)	Several years	Food, water-, and stain-repellent products, fire-fighting foams	Associations between prenatal exposure and higher cholesterol, BMI, adiposity (particularly in girls)	Dysregulation of lipid homeostasis; impaired glucose tolerance; hepatic stenosis; disrupted hepatocyte development; changes to gut microbiome

BMI, body mass index; DDT, dichlorodiphenyltrichloroethane; PPAR, peroxisome proliferator-activated receptor.

As with the majority of work on MDCs, epidemiological evidence is limited and tends to focus on crude outcome measures such as BMI and obesity in childhood. To date, two studies have linked higher prenatal BPA levels to higher BMI or greater adiposity. In a New York City cohort ($n = 375$), prenatal BPA concentrations were positively associated with FM at age 7 yr in girls but not boys (431). Similarly, in a Spanish study maternal BPA concentrations (in the 1st and 3rd trimesters) were positively associated with children's BMI and waist circumference *z* scores at age 4 yr, although no sex differences were noted (432). By contrast, three other studies have demonstrated inverse associations. In a study of Mexican American children ($n = 311$), there was an inverse relationship between maternal BPA levels during pregnancy and daughters' BMI and adiposity at age 9 yr but no associations observed in sons (433). In a European cohort ($n = 500$), first-trimester BPA concentrations were inversely associated with BMI *z* scores and adiposity in girls in early childhood, whereas the opposite relationship was observed in boys (434). However, in a Cincinnati, Ohio cohort ($n = 297$), higher BPA concentrations in the second and third trimesters were associated with nonsignificantly lower BMI in early childhood (435). Notably, two additional studies (one in boys only) indicated no discernible relationship between prenatal levels and children's body size at birth (436) or adiposity in middle childhood (437). Differences in the timing of prenatal urine sample collection and the type and timing of obesity-related outcomes measured may contribute to the seemingly inconsistent findings across studies, and the observations of sex-specific effects are consistent with the larger literature on the impacts of endocrine-disrupting chemicals.

Several human studies have also examined relevant metabolic biomarkers. In a German cohort, third-trimester BPA levels were associated with reduced promoter methylation and expression of mesoderm-specific transcript (MEST), a member of the α/β hydrolase fold superfamily believed to regulate early adipose tissue development and adipocyte size. Notably, cord blood *MEST* promoter methylation was observed to be a mediator of the relationship between maternal BPA concentrations during pregnancy and child BMI *z* scores (through age 6 yr), and additional work in animal models and in vitro further suggests an important role for *MEST* (438). Maternal first-trimester BPA concentrations have also been linked to reduced cord blood IGF-2 and PPARγ methylation in female infants (439). In a cross-sectional study in adults, urinary BPA was associated with higher β-cell activity, hyperinsulinemia, and insulin resistance, particularly in men, but there is a current

paucity of analogous work on developmental exposures (440). Although much less studied, a host of related newer compounds frequently used as BPA substitutes in consumer products may be of interest given their close chemical similarities. In some studies, structural analogs such as bisphenol S (BPS) and bisphenol F (BPF) may share BPA's adipogenicity, causing lipid accumulation and expression of adipogenic markers in vitro (441, 442). As these compounds are increasingly used as BPA replacements, understanding their potential metabolic effects will be important.

In vitro studies offer the strongest evidence of potential mechanisms leading to BPA-induced metabolic disruption, and many have reported changes in adipogenesis following BPA administration, particularly in estrogen receptor (ER), glucocorticoid receptor (GR), insulin receptor, PPARγ, MAPK, and protein kinase B (Akt) pathways (441, 443–447). In human adipocyte stem cells exposed to 100 pM–10 μM/day of BPA, ER-mediated adipogenesis occurred and was blocked when an ER antagonist was added (446). Differentiation of 3T3-L1 preadipocytes is also stimulated by low, environmentally relevant doses (0.01–10 nM) of BPA, with resulting increases in expression of PPARγ and CCAAT-enhancer-binding protein (C/EBPα) (443, 448, 449). BPA-exposed 3T3-L1 preadipocytes also showed enhanced lipid storage, impaired glucose utilization, and greater expression of the inflammatory cytokines IL-6 and IFN-γ, suggesting metabolic dysfunction and inflammation (448, 450). Levels of fatty acid binding protein 2 (aP2), the terminal marker of adipogenesis, may be upregulated as well, through direct action on the Ap2 promoter (443). At maturity, BPA-exposed adipocytes show increases in lipid accumulation, reductions in insulin-stimulated glucose utilization, and increased mRNA expression of leptin, IL-6, and IFN-γ (448). Reductions in insulin-stimulated glucose uptake following BPA administration have also been observed in 3T3-F442A cell lines (451). BPA acts on the pancreas as well. Studies in mouse and human islet cell lines indicate that low-dose BPA enhances β-cell insulin production through ERα and ERβ pathways (452, 453). Oxidative stress pathways may be important to consider as well. For example, in INS-1 (pancreatic β) cells, BPA promotes oxidative stress, induces reactive oxygen species (ROS), and disrupts mitochondrial structure and gene expression, resulting in glutathione depletion and DNA damage (113, 454). Thus, the molecular mechanisms linking BPA exposure to metabolic dysfunction may be implicated in contributing to the increased prevalence of metabolic diseases in industrialized nations, independent of or in concert with maternal diet and health.

The in vitro work is complemented by a large experimental rodent literature on BPA as a metabolic disruptor, much of it focused on body size outcomes, but results of these studies are often conflicting. For example, whereas some studies have observed that developmental exposure to BPA is positively associated with offspring body weight (455–458), others have noted inverse (459, 460) or no (461, 462) associations. What appear to be disparate findings may actually represent methodological differences in terms of the animal models used; doses, routes, and timing of BPA administration; postnatal diets; and offspring sex and age at outcome assessment rather than a lack of reproducibility (463, 464). Noting great heterogeneity, a recent meta-analysis of >60 experimental rodent studies recently concluded that developmental BPA exposure was positively associated with FM, triglyceride levels, and free fatty acid levels but negatively associated with overall body weight (464). Relationships differed by sex, moreover, with developmental BPA exposure linked to increased triglycerides and free fatty acids in males but inversely associated with body weight and leptin in females.

As supported by in vitro evidence, BPA may impact body size and metabolic markers in rodents by acting on adipose, pancreatic, and/or hepatic tissue. In male (but not female) mice, for example, BPA exposure in utero caused hypomethylation of the promoter for the body weight-linked *fggy* carbohydrate kinase gene in gonadal white adipose tissue, resulting in increased transcription as well as increased whole body weight and gonadal fat weight (465). In the pancreas, after maternal BPA exposure juvenile female mice exhibited insulitis in the pancreatic islets, suggesting possible accelerated β-cell attrition through immune activation (466). Effects on the liver have been examined at length as well. At both high (200 mg) and low (20 mg) doses, in a rat model BPA reduced hepatic glucose oxidation and glycogen content, possibly via impaired insulin signal transduction (467). Hypermethylation of the hepatic glucokinase promoter has been observed along with the reduction in hepatic glycogen levels (468). Effects on the liver may be exacerbated by the postnatal environment. Prenatal BPA exposure paired with a high-fat diet induced a nonalcoholic steatohepatitis-like phenotype in male rodents including increased lipid levels in hepatocytes and liver inflammation; effects of BPA-exposed animals on low-fat diets were much more subtle and included moderate steatosis as well as changes in insulin signaling (469, 470). It is also possible that BPA treatment may indirectly impact fetal development through effects on maternal metabolic function during pregnancy. One study demonstrated long-lasting changes in maternal insulin secretion and sensitivity, increased β-cell apoptosis and reduced β-cell mass, and reduced expression of the cell cycle inhibitors p16 and p53 (471). Overall, developmental BPA exposure appears to alter the liver methylome, which may contribute to insulin

resistance in adulthood through changes in nuclear receptor expression or mitochondrial dysfunction (472).

4.2.2. Phthalates.

Like BPA, phthalates are a class of chemicals widely used in plastics manufacture and are widely found in consumer goods such as food, personal care products, and vinyl products (e.g., flooring, upholstery) (473). Phthalates can leach from their constituent products, with human exposure occurring through inhalation or ingestion or dermally. Although they are readily metabolized in the human body and have a short half-life (several hours), because of ongoing, repeated environmental exposure most major phthalate metabolites are detectable in the urine of 90–100% of individuals sampled (474–477). Phthalates are also widely detected in placenta, cord blood, and amniotic fluid samples, indicating fetal exposure (478–480).

Of the many phthalates in mass production, di-(2-ethylhexyl)phthalate (DEHP) and its metabolite mono-(2-ethylhexyl)phthalate (MEHP) have attracted the most attention in the context of metabolic dysregulation and obesity. In juvenile animals, even a single dose of DEHP promotes adipogenic gene expression, including reduced *UCP1* expression indicating upregulation of white adipocyte differentiation (481). More prolonged in utero DEHP exposure in rodents is linked to a suite of metabolic changes including visceral fat accumulation and increases in circulating leptin, insulin, lipid, and glucose concentrations (187, 481, 482) These effects may be stronger in male offspring and compounded by a high-fat postnatal diet (483). In a recent meta-analysis of 31 rodent studies, developmental DEHP exposure was associated with significantly increased fat (pad) weight and nonsignificantly decreased body weight (464). Although fewer studies have examined metabolic end points after phthalate exposure, evidence suggests potentially sex-specific effects on the developing liver, pancreas, and muscle tissue. In female animals, gestational DEHP exposure led to hyperglycemia when insulin levels were reduced, along with disruptions in β-cell ultrastructure, lower β-cell mass, and lower islet insulin content (112, 484). In males, on the other hand, developmental DEHP exposure has been linked to increased insulin concentrations but normal glucose tolerance, and these sex-specific findings have been noted in some human work on phthalates and diabetes risk (484, 485). Developmental DEHP exposure can also lead to hepatic steatosis and decreased glycogen storage, which could plausibly occur through nuclear receptor changes for peroxisome proliferator-activated receptor (PPAR)α, chimeric antigen receptor (CAR), or pregnane X receptor (PXR) (397, 486–488). Moreover, such effects may be tissue specific, as the JAK/STAT pathway is upregulated in adipose tissue but downregulated in the liver after DEHP exposure in rats (489). Finally, changes in glycolytic intermediates in liver and muscle, suggestive of altered lactate and glucose handling, are evident after chronic DEHP exposure in adult rodents; however, analogous developmental work has not been conducted thus far (490).

A number of in vitro studies have documented transactivation in nuclear PPARγ and PPARα pathways by DEHP and/or MEHP (187, 491–494). Along with Runx2, PPARγ has been proposed as the "master regulator" of fat cell differentiation and is a requisite for normal adipocyte development. In fact, PPARγ-null mice lack adipose tissue, and in humans heterozygous loss-of-function mutations lead to lipodystrophy and insulin resistance (495–497). PPARγ plays a key role in regulating the expression of adiponectin, leptin, TNF, and resistin, ultimately having a profound impact on glucose homeostasis (496). In humans, maternal first-trimester urinary DEHP metabolite concentrations are inversely associated with methylation of PPARα as well as PPARα gene expression in cord blood (439). This work is complementary to rodent studies showing that maternal vitamin A supplementation reduced the expression of PPARα in offspring (97), emphasizing the confluence of dietary and environmental maternal exposures on offspring health.

As well, oxidative stress has also been examined in relation to phthalate exposure, such that in INS-1 cells DEHP administration resulted in oxidative stress as well as p53 and ATM activation, all of which may have been the result of dysregulation of lysosomal-mitochondrial pathways (498, 499). Human studies have also noted associations between urinary DEHP metabolite concentrations and oxidative stress biomarkers including 15-F2t isoprostane, 8-isoprostane, and 8-hydroxydeoxyguanosine (500, 501). The results of untargeted metabolomic analyses indicate dysregulation of multiple pathways, with MEHP exposure resulting in increased expression of genes involved in glyceroneogenesis, cytosolic phosphoenolpyruvate carboxykinase expression, and fatty acid release, suggesting fatty acid reesterification in human subcutaneous adipocytes (502). Finally, although the impact of metabolism-disrupting chemicals on muscle tissue has been understudied, work in L6 myotubes indicates that DEHP exposure downregulates GLUT4 (possibly through inhibitory chromatin modifications at the GLUT4 promoter), resulting in impaired glucose utilization (503, 504), and suggests a need for more attention to the role of muscle in this context.

Given the ubiquity of phthalate exposure in human populations and the compelling animal literature, there

has been a great deal of interest in their impact on humans. In addition to several cross-sectional studies indicating that certain phthalate metabolites (including the DEHP metabolites as well as monobutyl phthalate and monoethyl phthalate) are positively associated with BMI and waist circumference in adults and children (505–508), several prospective pregnancy cohorts have now examined developmental phthalate exposures in relation to measures of childhood body size and adiposity. In a Spanish cohort ($n = 391$), maternal concentrations of the high-molecular-weight phthalate metabolites (averaged across the 1st and 3rd trimesters) were associated with slower growth from 0 to 6 mo and lower BMI *z* scores in boys but more rapid growth from 0 to 6 mo and higher BMI *z* scores in girls up to 7 yr of age (509). In a New York City cohort ($n = 330$), concentrations of non-DEHP metabolites in the third trimester were associated with lower BMI and FM, as well as smaller waist circumferences in boys, but not girls, at ages 5–7 yr (510). In Mexican Americans ($n = 345$), maternal diethyl phthalate (DEP), dibutyl phthalate (DBP), and DEHP metabolite concentrations (measured twice during pregnancy) were associated with increased odds of overweight/obesity in children at age 12 yr (511). No associations between late-pregnancy phthalate metabolite concentrations and childhood FM were observed in either sex in a second New York City cohort (512) or in a Cincinnati, Ohio cohort (513); however, sample sizes were notably smaller, $n = 180$ and $n = 219$, respectively.

4.2.3. Persistent organic pollutants.

In contrast to the short-lived BPA and phthalates, persistent organic pollutants (POPs) are contaminants that persist in the environment and bioaccumulate in living organisms because of their resistance to chemical, biological, and photolytic breakdown. Cross-sectional analyses using NHANES data suggest that serum concentrations of a number of POPs are associated with increased risks of type 2 diabetes, metabolic syndrome, and insulin resistance, although the possibility that these disorders alter metabolism and storage of POPs resulting in higher levels (i.e., reverse causation) cannot be ruled out (514–516). Perhaps the most notorious POP is dichlorodiphenyltrichloroethane (DDT), an organochlorine pesticide that was banned in 1975 in many countries but still persists in the environment and is used for malaria control in some regions of the world. Evidence of DDT's metabolism-disrupting effects is strong. In vitro, DDT reduces insulin secretion following stimulation with glucose or tolbutamide, suggesting diabetogenic effects (517). Similarly in rodents, a wide range of adverse outcomes (including glucose intolerance, hyperinsulinemia, dyslipidemia, and reduced energy expenditure) were observed in females after prenatal exposure to DDT followed by a high-fat diet (518). The obesogenic effects of DDT appear to be transgenerational, moreover, with obesity observed in rodents of the F_3 generation (which received no direct exposure) (519). Multiple epidemiological studies have consistently linked concentrations of the DDT metabolite dichlorodiphenyldichloroethylene (DDE) to body size across childhood (520–524), and in an older United States cohort prenatal DDE concentrations were associated with daughters' BMI in adulthood (525).

Given the long-standing bans on the use of DDT and other organochlorine pesticides in most parts of the world, other POPs in current production, such as perfluoroalkyl substances (PFASs), have emerged as potentially being of more urgent concern. In addition to numerous documented water supply contaminations in the United States (526, 527), leading sources of exposure to PFASs, including perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), include food, stain- and water-repellent household products (clothing, upholstery, cleaning products, polishes) and fire-fighting foams (528). PFASs have been linked to changes in estrogen, androgen, and thyroid activity and have been implicated in lipid dysregulation (529–531). In adolescents and adults, including pregnant women, PFOS and PFOA exposure is consistently associated with elevated cholesterol levels, increased fasting glucose levels, and β-cell function (532–536), indicating altered lipid homeostasis. This epidemiological evidence is supported by experimental literature indicating that high-dose exposure to PFOS and PFOA alters triglyceride and cholesterol levels in rodents (537). Evidence of their developmental effects is growing as well. In a rodent model, maternal PFOS exposure was associated with reduced body weight in offspring as well as with a prediabetic phenotype including elevated fasting insulin and leptin, impaired glucose tolerance, and hepatic steatosis (538, 539). The hepatic effects of PFOA and PFOS may occur through downregulation of hepatocyte nuclear factor 4α (HNF4α), a critical regulator of hepatocyte development (540). Notably, HNF4α mutations result in a form of diabetes (maturity-onset diabetes of the young type 1), suggesting that PFASs (and other MDCs) acting on HNF4α may impact hepatocyte and β-cell function (541).

As well, exposure to these chemicals appears to alter lipid metabolism as demonstrated in a cohort study in Boston in which maternal PFOS, PFOA, and perfluorodecanoic acid (PFDeA) concentrations were associated with higher cholesterol levels in girls in middle childhood, including both higher LDL and HDL concentrations (531), as well as reduced insulin resistance in girls in middle childhood (542). In the same cohort, maternal PFOA concentrations were also positively associated

with BMI, dual X-ray absorptiometry (DXA) total FM, and skinfold thickness in girls but not boys (543). No associations were observed in male offspring or in relation to leptin or adiponectin levels. In a meta-analysis of 10 studies, prenatal PFOA concentrations were associated with increased risk of childhood overweight, higher childhood BMI, and an increased risk of childhood adiposity (544).

Above in this review, a brief discussion of the role of the microbiome on growth was presented, and the role of the microbiome in relationship to nutrient availability and the influence on health and disease risk is clear. Again, the intersection between human diets and environmental exposures is relevant in terms of metabolic diseases, as recent evidence suggests that PFOS exposure can alter the gut microbiome, perturbing gut metabolism in relation to arginine, proline, lysine, methane, and butanoate levels, and suggesting an additional route by which PFASs and other environmental chemical exposures may act as metabolic disruptors (545, 546). Therefore, future studies of environmental toxins and human health should be complemented with studies of the microbiome and other indicators of gastrointestinal health.

4.3. Considerations, Challenges, and Future Directions for Research on Environmental Exposures and DOHaD

The landscape of research on environmental exposures is constantly shifting as new chemicals emerge, production levels change, and policies are implemented. Moreover, there are a number of challenges and considerations that must be addressed to advance our understanding of how environmental chemical exposures may contribute to metabolic dysregulation and obesity. These include new advances in our understanding of how MDCs may impact physiology as well as methodological concerns that must be considered when designing future research.

4.3.1. Nonmonotonic effects.

MDCs provide compelling evidence that the toxicological tenet “the dose makes the poison” is not always true. Like hormones, MDCs can be physiologically active at extremely low levels. Endocrine activity depends not only on hormone concentrations but on other factors including receptor densities and isoforms, binding proteins, and transporters; characterizing the dose or exposure is not necessarily sufficient to predict the physiological response. Defining “thresholds” above which harm may occur is often impossible, and dose-response relationships are frequently nonmonotonic (401, 408). In a meta-analysis of the experimental animal literature on BPA, for example, associations between BPA exposure and relevant outcomes (body weight, triglycerides, and FFA) were stronger in studies with exposures below the reference dose compared with higher doses (464). Similar findings have been reported for phthalates, where low (0.05 mg/kg body wt/day), but not high (0.25–0.5 mg/kg body wt/day), doses of MEHP were associated with increased weight, FM, and altered lipid and glucose profiles in offspring (493). These unexpected relationships are important to keep in mind given that much of the experimental work on MDC exposure (particularly the early studies) dosed animals with MDCs at supranormal levels (547–549).

4.3.2. Epigenetic mechanisms.

As noted in earlier sections of this review, epigenetic modifications are clearly central to potential mechanisms in a number of metabolic diseases related to poor growth or placental development. Likewise, developmental sensitivity to MDCs may occur through epigenetic signaling mechanisms (e.g., DNA methylation, histone marks, noncoding RNA) (397). The classic example of this phenomenon comes from work by Dolinoy et al. (550), who demonstrated that when pregnant mice were fed genistein, the major phytoestrogen in soy, in heterozygous offspring there was increased methylation of six c-g sites upstream of the Agouti coat color gene. This epigenetic change, which persisted through adulthood, resulted in a change in coat color toward pseudoagouti as well as reduced susceptibility to obesity in adulthood (550). More recent work has begun to explore how MDCs may alter epigenetic signaling patterns over multiple generations, resulting in transgenerational transmission of metabolic risk.

Across multiple studies and laboratory groups, prenatal exposures to MDCs in the pregnant F_0 generation have been linked to obesity through at least the F_3 generation. Importantly, in this work, F_0 and F_1 animals are directly exposed to MDCs, the F_2 generation is exposed as germ cells, but the F_3 generation receives no direct chemical exposure (397). In a series of elegant studies, when pregnant mice were given environmentally relevant doses of tributyltin, an endocrine-disrupting biocide, effects on metabolism were evident into the F_4 generation, particularly in male offspring. Males showed a signature thrifty phenotype, gaining weight rapidly on high-fat diets and retaining that weight even when subsequently switched to a low-fat diet. Changes in chromatin structure, DNA methylation, and gene expression were noted in the F_4 generation as well (551). Parallel work on exposure to an MDC mixture containing BPA and phthalates (DEHP and DBP) demonstrated similar increases in

obesity in the F_3 generation concomitant with reproductive disorders in both sexes (552). F_0 BPA exposure, similarly, results in glucose intolerance and insulin resistance two generations downstream and is accompanied by decreased hepatic glucokinase expression and hypermethylation of the relevant gene promoter (553). The majority of this literature has focused on changes in DNA methylation occurring after MDC exposure; however, there is a clear need for more research on other potential mechanisms (401). MDCs may effectively "reprogram" germ line cells and/or alter the activity of somatic cells that support their survival and differentiation (405). Epigenetic mechanisms also provide a plausible way by which paternal MDC exposures may be transmitted to offspring via sperm epimutations, thereby increasing obesity risk in offspring (554).

4.3.3. Timing of exposure.

In terms of precise timing of exposure and fetal outcomes, there may be differential fetal susceptibility to metabolic disruption depending on gestational age at exposure. At present, little is known about critical periods of gestation during which chemical exposures may "program" obesity, and most of the human literature has relied upon chemical exposures measured opportunistically. This presents a particularly acute issue in the case of chemicals like BPA and phthalates that have very short half-lives in the body (hours or days), resulting in considerable potential for exposure misclassification. For these chemicals, human observational studies really represent a "snapshot" rather than a comprehensive characterization of exposure during gestation. For persistent chemicals like PFASs, this is less of an issue, as a single measurement provides a reasonable estimate of exposure across the whole pregnancy.

The issue of the timing of exposure is compounded when we consider a "two-hit" model in which the effects of a prenatal exposure are unmasked or magnified when a second exposure during a subsequent critical period occurs. As an example, in female mice exposed to BPA in utero, dysregulation of triglyceride levels and glucose/insulin homeostasis is heightened in animals that experienced a second, peripubertal BPA exposure (463). Other studies have examined second hits in the form of high-fat diets (555, 556), suggesting that one way to look at MDCs is as altering developmental set points, which thereby increases sensitivity to subsequent metabolic dysregulation. Consistent with this model, some exposures like DDE appear to restrict growth in utero, akin to the classical thrifty phenotype, and it may be the subsequent rapid-catch up growth on a high-fat diet that drives metabolic dysregulation (522).

4.3.4. Sexually dimorphic effects.

As evidenced by the literature discussed, the effects of MDCs on obesity and metabolic function frequently differ by sex. This is not surprising given that in many cases the underlying hormone systems, as well as patterns of fat deposition and adipocyte endocrine function, are sexually dimorphic. Chemicals like BPA also have sex-specific effects on the developing brain and act on sexually dimorphic areas such as the hypothalamus, which may have important implications for feeding behavior and/or metabolic processes (557).

4.3.5. Outcome measurements.

Arguably the most relevant end points to assess metabolic dysregulation include diabetes diagnosis, insulin tolerance and resistance, β-cell function, and liver disease, all of which are most appropriately measured in adult populations. By necessity because the field is young and lacking sensitive biomarkers that are appropriate for study in children, the human literature on in utero MDC exposure in relation to early-life metabolic outcomes has focused on relatively crude measures of body size (such as BMI) or body composition. Moving forward, it will be important to adopt a life course perspective with longitudinal follow-up and assessment of relevant outcomes in prospective pregnancy cohorts later in life as well. This approach is needed, furthermore, to address "multiple hit" models in which the impact of prenatal exposures on metabolic function is only unmasked when paired with relevant postnatal exposures. Unfortunately, for the vast majority of environmental chemical exposures, laboratory analysis of banked biospecimens is the only way to accurately characterize early-life exposures. This stands in contrast to some other developmental exposures of interest (e.g., fetal growth, maternal smoking, and neighborhood stress) that may be captured through medical records, questionnaires, or administrative data sets. One notable exception is the innovative approach of measuring late gestational and early childhood exposures in deciduous teeth, and clearly additional methods to retrospectively quantify prenatal environmental chemical exposures are needed (558).

4.3.6. Confounding factors.

Identifying in utero exposures that impact metabolic function in humans presents a considerable challenge given the potential for confounding by factors including nonchemical stressors, infections, socioeconomic status, genetics, physical activity, and the microbiome. Diet may be a particularly important confounder given its

important role in metabolic function and the fact that it is also a leading source of exposure to certain chemicals (like DEHP, BPA, and PFASs). Teasing apart prenatal and postnatal (and even preconception) exposures may be difficult as well, particularly for exposures that persist in the environment over long periods of time. There is also the very salient issue that although we tend to study chemical exposures individually, in reality, humans are exposed to a complex cocktail of environmental stressors that may have additive, multiplicative, or antagonistic impacts on physiology. Although there is great interest in better understanding how environmental chemicals interact with each other in mixtures and with other potentially modifying factors, improvement in biostatistical and modeling methods is needed to better estimate the impacts of ecologically relevant mixtures of exposures.

In summary, increasing evidence demonstrates that ubiquitous chemicals in the environment such as BPA, phthalates, and POPs can alter fetal physiological development to promote adiposity and metabolic disease in later life. Given the continuous development and production of new synthetic compounds, changing patterns of production among current-use chemicals, and the limited regulation of most synthetic chemicals, continued work on the health impacts of developmental exposure is essential.

5. SUMMARY AND CONCLUSIONS

There is now a substantial body of evidence supporting what was originally referred to as the "Barker hypothesis," and this review updates us on the main drivers predicting a poor in utero environment and long-term metabolic disease, such as exposomes including external stresses, poor maternal diet, and environmental contaminants, which have both direct and indirect effects on the developing fetus. What comes into greater focus in this review is the role of the placenta as both a thermostat of internal insults to the fetus and a direct regulator of fetal growth—with or without compromise. Moreover, this review illustrates both the challenges and opportunities posed by the postnatal environment. Collectively, the animal studies would suggest that regardless of the origin of fetal growth restriction, there is no question that the extent of growth in postpartum life will exacerbate the dysmetabolism present. The discrepancies in the clinical studies arise from variations in the methods used to identify and measure fetal growth restriction versus postnatal metabolic measurements. With the onset of metabolomics and early imaging of both the placenta and fetus, the DOHaD field will be strengthened to better predict fetal growth restriction and ameliorate the incidence of noncommunicable diseases as we enter the next decade. In addition, advances that better manage IUGR infants in postpartum life will undoubtedly further reduce the severity of dysmetabolism in a world population that continues to be exposed to malnutrition, inactivity, and pollution.

CORRESPONDENCE

D. J. Hoffman (dhoffman@sebs.rutgers.edu).

GRANTS

This work was supported by funding from the Robert Wood Johnson Foundation Grant 75084 (D. J. Hoffman); the National Institutes of Health Grants HD-068370 and HD-065007 (T.L. Powell), and P30 ES-005022 (E. S. Barrett); and the Canadian Institutes of Health Research Catalyst Grant CRU 1126 (D. B. Hardy).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

D.J.H., T.L.P., and D.B.H. prepared figures; D.J.H., T.L.P., E.S.B., and D.B.H. drafted manuscript; D.J.H., T.L.P., E.S.B., and D.B.H. approved final version of manuscript.

REFERENCES

1. Centers for Disease Control and Prevention. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999–2000 through 2015–2016. **Natl Health Stat Rep** 122: 1–16, 2018.

2. Takemoto Y, Ota E, Yoneoka D, Mori R, Takeda S. Japanese secular trends in birthweight and the prevalence of low birthweight infants during the last three decades: a population-based study. **Sci Rep** 6: 31396, 2016. doi:10.1038/srep31396.

3. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. **Lancet** 1: 1077–1081, 1986. doi:10.1016/s0140-6736(86)91340-1.

4. Lecomte V, Maloney CA, Wang KW, Morris MJ. Effects of paternal obesity on growth and adiposity of male rat offspring. **Am J Physiol Endocrinol Metab** 312: E117–E125, 2017. doi:10.1152/ajpendo.00262.2016.

5. Sanchez-Garrido MA, Ruiz-Pino F, Velasco I, Barroso A, Fernandois D, Heras V, Manfredi-Lozano M, Vazquez MJ, Castellano JM, Roa J, Pinilla L, Tena-Sempere M. Intergenerational influence of paternal obesity on metabolic and reproductive health parameters of the

offspring: male-preferential impact and involvement of Kiss1-mediated pathways. **Endocrinology** 159: 1005–1018, 2018. doi:10.1210/en.2017-00705.

6. Voerman E, Santos S, Patro Golab B, Amiano P, Ballester F, Barros H, et al**.** Maternal body mass index, gestational weight gain, and the risk of overweight and obesity across childhood: an individual participant data meta-analysis. **PLoS Med** 16: e1002744, 2019. doi:10.1371/journal.pmed.1002744.

7. Cropley JE, Eaton SA, Aiken A, Young PE, Giannoulatou E, Ho JW, Buckland ME, Keam SP, Hutvagner G, Humphreys DT, Langley KG, Henstridge DC, Martin DI, Febbraio MA, Suter CM**.** Male-lineage transmission of an acquired metabolic phenotype induced by grand-paternal obesity. **Mol Metab** 5: 699–708, 2016. doi:10.1016/j.molmet.2016.06.008.

8. Finer S, Iqbal MS, Lowe R, Ogunkolade BW, Pervin S, Mathews C, Smart M, Alam DS, Hitman GA**.** Is famine exposure during developmental life in rural Bangladesh associated with a metabolic and epigenetic signature in young adulthood? A historical cohort study. **BMJ Open** 6: e011768, 2016. doi:10.1136/bmjopen-2016-011768.

9. Berti C, Agostoni C, Davanzo R, Hyppönen E, Isolauri E, Meltzer HM, Steegers-Theunissen RP, Cetin I**.** Early-life nutritional exposures and lifelong health: immediate and long-lasting impacts of probiotics, vitamin D, and breastfeeding. **Nutr Rev** 75: 83–97, 2017. doi:10.1093/nutrit/nuw056.

10. Taylor RM, Fealy SM, Bisquera A, Smith R, Collins CE, Evans TJ, Hure AJ**.** Effects of nutritional interventions during pregnancy on infant and child cognitive outcomes: a systematic review and meta-analysis. **Nutrients** 9: 1265, 2017. doi:10.3390/nu9111265.

11. Ballon M, Botton J, Forhan A, de Lauzon-Guillain B, Melchior M, El Khoury F, Nakamura A, Charles MA, Lioret S, Heude B**.** Which modifiable prenatal factors mediate the relation between socioeconomic position and a child's weight and length at birth? **Matern Child Nutr** 15: e12878, 2019. doi:10.1111/mcn.12878.

12. Ma L, Lu Q, Ouyang J, Huang J, Huang S, Jiao C, Zhang Z, Mao L**.** How are maternal dietary patterns and maternal/fetal cytokines associated with birth weight? A path analysis. **Br J Nutr** 121: 1178–1187, 2019. doi:10.1017/S0007114519000382.

13. Alves-Santos NH, Cocate PG, Benaim C, Farias DR, Emmett PM, Kac G**.** Prepregnancy dietary patterns and their association with perinatal outcomes: a prospective cohort study. **J Acad Nutr Diet** 119: 1439–1451, 2019. doi:10.1016/j.jand.2019.02.016.

14. Shapiro AL, Kaar JL, Crume TL, Starling AP, Siega-Riz AM, Ringham BM, Glueck DH, Norris JM, Barbour LA, Friedman JE, Dabelea D**.** Maternal diet quality in pregnancy and neonatal adiposity: the Healthy Start Study. **Int J Obes (Lond)** 40: 1056–1062, 2016. doi:10.1038/ijo.2016.79.

15. Shapiro AL, Ringham BM, Glueck DH, Norris JM, Barbour LA, Friedman JE, Dabelea D**.** Infant adiposity is independently associated with a maternal high fat diet but not related to niacin intake: the Healthy Start Study. **Matern Child Health J** 21: 1662–1668, 2017. doi:10.1007/s10995-016-2258-8.

16. Stewart CP, Christian P, LeClerq SC, West KP, Khatry SK**.** Antenatal supplementation with folic acid + iron + zinc improves linear growth and reduces peripheral adiposity in school-age children in rural Nepal. **Am J Clin Nutr** 90: 132–140, 2009. doi:10.3945/ajcn.2008.27368.

17. Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW, Oken E**.** Prenatal fatty acid status and child adiposity at age 3 y: results from a US pregnancy cohort. **Am J Clin Nutr** 93: 780–788, 2011. doi:10.3945/ajcn.110.005801.

18. Toro-Ramos T, Sichieri R, Hoffman DJ**.** Maternal fat mass at mid-pregnancy and birth weight in Brazilian women. **Ann Hum Biol** 43: 212–218, 2016. doi:10.3109/03014460.2015.1032348.

19. Sauder KA, Starling AP, Shapiro AL, Kaar JL, Ringham BM, Glueck DH, Dabelea D**.** Exploring the association between maternal prenatal multivitamin use and early infant growth: the Healthy Start Study. **Pediatr Obes** 11: 434–441, 2016. doi:10.1111/ijpo.12084.

20. Ganpule A, Yajnik CS, Fall CH, Rao S, Fisher DJ, Kanade A, Cooper C, Naik S, Joshi N, Lubree H, Deshpande V, Joglekar C**.** Bone mass in Indian children—relationships to maternal nutritional status and diet during pregnancy: the Pune Maternal Nutrition Study. **J Clin Endocrinol Metab** 91: 2994–3001, 2006. doi:10.1210/jc.2005-2431.

21. Heppe DH, Medina-Gomez C, Hofman A, Franco OH, Rivadeneira F, Jaddoe VW**.** Maternal first-trimester diet and childhood bone mass: the Generation R Study. **Am J Clin Nutr** 98: 224–232, 2013. doi:10.3945/ajcn.112.051052.

22. Händel MN, Moon RJ, Titcombe P, Abrahamsen B, Heitmann BL, Calder PC, Dennison EM, Robinson SM, Godfrey KM, Inskip HM, Cooper C, Harvey NC**.** Maternal serum retinol and β-carotene concentrations and neonatal bone mineralization: results from the Southampton Women's Survey cohort. **Am J Clin Nutr** 104: 1183–1188, 2016. doi:10.3945/ajcn.116.130146.

23. Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, Rodford J, Slater-Jefferies JL, Garratt E, Crozier SR, Emerald BS, Gale CR, Inskip HM, Cooper C, Hanson MA**.** Epigenetic gene promoter methylation at birth is associated with child's later adiposity. **Diabetes** 60: 1528–1534, 2011. doi:10.2337/db10-0979.

24. Baum D, Beck RQ, Hammer LD, Brasel JA, Greenwood MR**.** Adipose tissue thymidine kinase activity in man. **Pediatr Res** 20: 118–121, 1986. doi:10.1203/00006450-198602000-00004.

25. World Health Organization. **Noncommunicable Diseases Country Profiles 2018**. Geneva: WHO, 2018.

26. Menting MD, Mintjens S, van de Beek C, Frick CJ, Ozanne SE, Limpens J, Roseboom TJ, Hooijmans CR, van Deutekom AW, Painter RC**.** Maternal obesity in pregnancy impacts offspring cardiometabolic health: systematic review and meta-analysis of animal studies. **Obes Rev** 20: 675–685, 2019. doi:10.1111/obr.12817.

27. Dhana K, Haines J, Liu G, Zhang C, Wang X, Field AE, Chavarro JE, Sun Q**.** Association between maternal adherence to healthy lifestyle practices and risk of obesity in offspring: results from two prospective cohort studies of mother-child pairs in the United States. **BMJ** 362: k2486, 2018. doi:10.1136/bmj.k2486.

28. Martens DS, Plusquin M, Gyselaers W, De Vivo I, Nawrot TS**.** Maternal pre-pregnancy body mass index and newborn telomere length. **BMC Med** 14: 148, 2016. doi:10.1186/s12916-016-0689-0.

29. Alfaradhi MZ, Fernandez-Twinn DS, Martin-Gronert MS, Musial B, Fowden A, Ozanne SE**.** Oxidative stress and altered lipid homeostasis in the programming of offspring fatty liver by maternal obesity. **Am J Physiol Regul Integr Comp Physiol** 307: R26–R34, 2014. doi:10.1152/ajpregu.00049.2014.

30. Lomas-Soria C, Reyes-Castro LA, Rodríguez-González GL, Ibáñez CA, Bautista CJ, Cox LA, Nathanielsz PW, Zambrano E**.** Maternal obesity has sex-dependent effects on insulin, glucose and lipid metabolism and the liver transcriptome in young adult rat offspring. **J Physiol** 596: 4611–4628, 2018. doi:10.1113/JP276372.

31. Puppala S, Li C, Glenn JP, Saxena R, Gawrieh S, Quinn A, Palarczyk J, Dick EJ, Nathanielsz PW, Cox LA. Primate fetal hepatic responses to maternal obesity: epigenetic signalling pathways and lipid accumulation. **J Physiol** 596: 5823–5837, 2018. doi:10.1113/JP275422.

32. Rollins NC, Bhandari N, Hajeebhoy N, Horton S, Lutter CK, Martines JC, Piwoz EG, Richter LM, Victora CG; Lancet Breastfeeding Series Group. Why invest, and what it will take to improve breastfeeding practices? **Lancet** 387: 491–504, 2016. doi:10.1016/S0140-6736(15)01044-2.

33. Victora CG, Bahl R, Barros AJ, França GV, Horton S, Krasevec J, Murch S, Sankar MJ, Walker N, Rollins NC; Lancet Breastfeeding Series Group. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. **Lancet** 387: 475–490, 2016. doi:10.1016/S0140-6736(15)01024-7.

34. Sanchez-Villamil J, Navarro-Garcia F. Role of virulence factors on host inflammatory response induced by diarrheagenic *Escherichia coli* pathotypes. **Future Microbiol** 10: 1009–1033, 2015. doi:10.2217/fmb.15.17.

35. UNICEF. IYCF database: Infant and Young Child Feeding. 2018 (Online). https://data.unicef.org/topic/nutrition/infant-and-young-child-feeding/#status.

36. Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Lanata CF, Mølbak K, Rasmussen ZA, Sack RB, Valentiner-Branth P, Checkley W; Childhood Malnutrition and Infection Network. Diarrhea in early childhood: short-term association with weight and long-term association with length. **Am J Epidemiol** 178: 1129–1138, 2013. doi:10.1093/aje/kwt094.

37. Hoffman DJ, Campos-Ponce M, Taddei CR, Doak CM. Microbiome, growth retardation and metabolism: are they related? **Ann Hum Biol** 44: 201–207, 2017. doi:10.1080/03014460.2016.1267261.

38. Smith-Brown P, Morrison M, Krause L, Davies PS. Male-specific association between fat-free mass index and fecal microbiota in 2- to 3-year-old Australian children. **J Pediatr Gastroenterol Nutr** 66: 147–151, 2018. doi:10.1097/MPG.0000000000001780.

39. Stanislawski MA, Dabelea D, Wagner BD, Iszatt N, Dahl C, Sontag MK, Knight R, Lozupone CA, Eggesbø M. Gut microbiota in the first 2 years of life and the association with body mass index at age 12 in a Norwegian birth cohort. **mBio** 9: e01751-18, 2018. doi:10.1128/mBio.01751-18.

40. Vonaesch P, Morien E, Andrianonimiadana L, Sanke H, Mbecko JR, Huus KE, Naharimanananirina T, Gondje BP, Nigatoloum SN, Vondo SS, Kaleb Kandou JE, Randremanana R, Rakotondrainipiana M, Mazel F, Djorie SG, Gody JC, Finlay BB, Rubbo PA, Wegener Parfrey L, Collard JM, Sansonetti PJ; Afribiota Investigators. Stunted childhood growth is associated with decompartmentalization of the gastrointestinal tract and overgrowth of oropharyngeal taxa. **Proc Natl Acad Sci USA** 115: E8489–E8498, 2018. doi:10.1073/pnas.1806573115.

41. Guerrant RL, DeBoer MD, Moore SR, Scharf RJ, Lima AA. The impoverished gut—a triple burden of diarrhoea, stunting and chronic disease. **Nat Rev Gastroenterol Hepatol** 10: 220–229, 2013. doi:10.1038/nrgastro.2012.239.

42. Abu Shehab M, Iosef C, Wildgruber R, Sardana G, Gupta MB. Phosphorylation of IGFBP-1 at discrete sites elicits variable effects on IGF-I receptor autophosphorylation. **Endocrinology** 154: 1130–1143, 2013. doi:10.1210/en.2012-1962.

43. Abu Shehab M, Damerill I, Shen T, Rosario FJ, Nijland M, Nathanielsz PW, Kamat A, Jansson T, Gupta MB. Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction. **Endocrinology** 155: 1327–1339, 2014. doi:10.1210/en.2013-1759.

44. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. **Gut Microbes** 3: 289–306, 2012. doi:10.4161/gmic.19897.

45. Sodowich BI, Zweitzig DR, Riccardello NM, O'Hara SM. Feasibility study demonstrating that enzymatic template generation and amplification can be employed as a novel method for molecular antimicrobial susceptibility testing. **BMC Microbiol** 13: 191, 2013. doi:10.1186/1471-2180-13-191.

46. Metges CC. Contribution of microbial amino acids to amino acid homeostasis of the host. **J Nutr** 130: 1857S–1864S, 2000. doi:10.1093/jn/130.7.1857S.

47. Hill MJ. Intestinal flora and endogenous vitamin synthesis. **Eur J Cancer Prev** 6: S43–S45, 1997. doi:10.1097/00008469-199703001-00009.

48. Rossi M, Amaretti A, Raimondi S. Folate production by probiotic bacteria. **Nutrients** 3: 118–134, 2011. doi:10.3390/nu3010118.

49. Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, Benezra A, DeStefano J, Meier MF, Muegge BD, Barratt MJ, VanArendonk LG, Zhang Q, Province MA, Petri WA, Ahmed T, Gordon JI. Persistent gut microbiota immaturity in malnourished Bangladeshi children. **Nature** 510: 417–421, 2014. doi:10.1038/nature13421.

50. Blanton LV, Charbonneau MR, Salih T, Barratt MJ, Venkatesh S, Ilkaveya O, Subramanian S, Manary MJ, Trehan I, Jorgensen JM, Fan YM, Henrissat B, Leyn SA, Rodionov DA, Osterman AL, Maleta KM, Newgard CB, Ashorn P, Dewey KG, Gordon JI. Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. **Science** 351: aad3311, 2016. doi:10.1126/science.aad3311.

51. Gehrig JL, Venkatesh S, Chang HW, Hibberd MC, Kung VL, Cheng J, et al. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children. **Science** 365: eaau4732, 2019. doi:10.1126/science.aau4732.

52. Li C, Lumey LH. Exposure to the Chinese famine of 1959-61 in early life and long-term health conditions: a systematic review and meta-analysis. **Int J Epidemiol** 46: 1157–1170, 2017. doi:10.1093/ije/dyx013.

53. Roseboom TJ. Epidemiological evidence for the developmental origins of health and disease: effects of prenatal undernutrition in humans. **J Endocrinol** 242: T135–T144, 2019. doi:10.1530/JOE-18-0683.

54. Ravelli AC, van der Meulen JH, Michels RP, Osmond C, Barker DJ, Hales CN, Bleker OP. Glucose tolerance in adults after prenatal exposure to famine. **Lancet** 351: 173–177, 1998. doi:10.1016/s0140-6736(97)07244-9.

55. Stein AD, Zybert PA, van der Pal-de Bruin K, Lumey LH. Exposure to famine during gestation, size at birth, and blood pressure at age 59 y: evidence from the Dutch Famine. **Eur J Epidemiol** 21: 759–765, 2006. doi:10.1007/s10654-006-9065-2.

56. Lucas A, Fewtrell MS, Cole TJ. Fetal origins of adult disease-the hypothesis revisited. **BMJ** 319: 245–249, 1999. doi:10.1136/bmj.319.7204.245.

57. Stein AD, Zybert PA, van de Bor M, Lumey LH. Intrauterine famine exposure and body proportions at birth: the Dutch Hunger Winter. **Int J Epidemiol** 33: 831–836, 2004. doi:10.1093/ije/dyh083.

58. Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. **N Engl J Med** 295: 349–353, 1976. doi:10.1056/NEJM197608122950701.

59. Wang J, Li Y, Han X, Liu B, Hu H, Wang F, Li X, Yang K, Yuan J, Yao P, Miao X, Wei S, Wang Y, Liang Y, Zhang X, Guo H, Yang H, Hu FB, Wu T, He M. Exposure to the Chinese famine in childhood increases type 2 diabetes risk in adults. **J Nutr** 146: 2289–2295, 2016. doi:10.3945/jn.116.234575.

60. Huang C, Li Z, Wang M, Martorell R. Early life exposure to the 1959-1961 Chinese famine has long-term health consequences. **J Nutr** 140: 1874–1878, 2010. doi:10.3945/jn.110.121293.

61. Yang Z, Zhao W, Zhang X, Mu R, Zhai Y, Kong L, Chen C. Impact of famine during pregnancy and infancy on health in adulthood. **Obes Rev** 9: 95–99, 2008. doi:10.1111/j.1467-789X.2007.00447.x.

62. Li Y, He Y, Qi L, Jaddoe VW, Feskens EJ, Yang X, Ma G, Hu FB. Exposure to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood. **Diabetes** 59: 2400–2406, 2010. doi:10.2337/db10-0385.

63. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64. **BMJ** 303: 1019–1022, 1991. doi:10.1136/bmj.303.6809.1019.

64. Fall CH, Vijayakumar M, Barker DJ, Osmond C, Duggleby S. Weight in infancy and prevalence of coronary heart disease in adult life. **BMJ** 310: 17–19, 1995. doi:10.1136/bmj.310.6971.17.

65. Osmond C, Barker DJ, Winter PD, Fall CH, Simmonds SJ. Early growth and death from cardiovascular disease in women. **BMJ** 307: 1519–1524, 1993. doi:10.1136/bmj.307.6918.1519.

66. Kannisto V, Christensen K, Vaupel JW. No increased mortality in later life for cohorts born during famine. **Am J Epidemiol** 145: 987–994, 1997. doi:10.1093/oxfordjournals.aje.a009067.

67. Musa MG, Kagura J, Pisa PT, Norris SA. Relationship between early growth and CVD risk factors in adolescents. **J Dev Orig Health Dis** 7: 132–143, 2016. doi:10.1017/S2040174415007953.

68. Perng W, Hajj H, Belfort MB, Rifas-Shiman SL, Kramer MS, Gillman MW, Oken E. Birth size, early life weight gain, and midchildhood cardiometabolic health. **J Pediatr** 173: 122–130.e1, 2016. doi:10.1016/j.jpeds.2016.02.053.

69. Victora CG, Barros FC, Lima RC, Behague DP, Gon Alves H, Horta BL, Gigante DP, Vaughan JP. The Pelotas birth cohort study, Rio Grande do Sul, Brazil, 1982-2001. **Cad Saude Publica** 19: 1241–1256, 2003. doi:10.1590/s0102-311x2003000500003.

70. Chirwa ED, Griffiths P, Maleta K, Ashorn P, Pettifor JM, Norris SA. Postnatal growth velocity and overweight in early adolescents: a comparison of rural and urban African boys and girls. **Am J Hum Biol** 26: 643–651, 2014. doi:10.1002/ajhb.22575.

71. Charalampopoulos D, McLoughlin A, Elks CE, Ong KK. Age at menarche and risks of all-cause and cardiovascular death: a systematic review and meta-analysis. **Am J Epidemiol** 180: 29–40, 2014. doi:10.1093/aje/kwu113.

72. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. **Lancet Oncol** 13: 1141–1151, 2012. doi:10.1016/S1470-2045(12)70425-4.

73. Leunissen RW, Stijnen T, Hokken-Koelega AC. Influence of birth size on body composition in early adulthood: the programming factors for growth and metabolism (PROGRAM)-study. **Clin Endocrinol (Oxf)** 70: 245–251, 2009. doi:10.1111/j.1365-2265.2008.03320.x.

74. Barrios PL, Garcia-Feregrino R, Rivera JA, Barraza-Villarreal A, Hernández-Cadena L, Romieu I, Gonzalez-Casanova I, Ramakrishnan U, Hoffman DJ. Height trajectory during early childhood is inversely associated with fat mass in later childhood in Mexican boys. **J Nutr** 149: 2011–2019, 2019. doi:10.1093/jn/nxz157.

75. Crowther NJ, Cameron N, Trusler J, Toman M, Norris SA, Gray IP. Influence of catch-up growth on glucose tolerance and beta-cell function in 7-year-old children: results from the birth to twenty study. **Pediatrics** 121: e1715–e1722, 2008. doi:10.1542/peds.2007-3147.

76. Lane G, Farag M, White J, Nisbet C, Vatanparast H. Chronic health disparities among refugee and immigrant children in Canada. **Appl Physiol Nutr Metab** 43: 1043–1058, 2018. doi:10.1139/apnm-2017-0407.

77. Sandell AM, Baker RD, Maccarone J, Baker SS. Health status and anthropometric changes in resettled refugee children. **J Pediatr Gastroenterol Nutr** 65: 569–573, 2017. doi:10.1097/MPG.0000000000001671.

78. Alasagheirin MH, Clark MK. Skeletal growth, body composition, and metabolic risk among North Sudanese immigrant children. **Public Health Nurs** 35: 91–99, 2018. doi:10.1111/phn.12386.

79. Dawson-Hahn E, Pak-Gorstein S, Matheson J, Zhou C, Yun K, Scott K, Payton C, Stein E, Holland A, Grow HM, Mendoza JA. Growth trajectories of refugee and nonrefugee children in the United States. **Pediatrics** 138: e20160953, 2016. doi:10.1542/peds.2016-0953.

80. Eriksson J, Forsén T, Tuomilehto J, Osmond C, Barker D. Size at birth, childhood growth and obesity in adult life. **Int J Obes Relat Metab Disord** 25: 735–740, 2001. doi:10.1038/sj.ijo.0801602.

81. Newby PK, Dickman PW, Adami HO, Wolk A. Early anthropometric measures and reproductive factors as predictors of body mass index and obesity among older women. **Int J Obes (Lond)** 29: 1084–1092, 2005. doi:10.1038/sj.ijo.0802996.

82. Salgin B, Norris SA, Prentice P, Pettifor JM, Richter LM, Ong KK, Dunger DB. Even transient rapid infancy weight gain is associated with higher BMI in young adults and earlier menarche. **Int J Obes (Lond)** 39: 939–944, 2015. doi:10.1038/ijo.2015.25.

83. Popkin BM, Richards MK, Montiero CA. Stunting is associated with overweight in children of four nations that are undergoing the nutrition transition. **J Nutr** 126: 3009–3016, 1996. doi:10.1093/jn/126.12.3009.

84. Bénéfice E, Garnier D, Simondon KB, Malina RM. Relationship between stunting in infancy and growth and fat distribution during adolescence in Senegalese girls. **Eur J Clin Nutr** 55: 50–58, 2001. doi:10.1038/sj.ejcn.1601121.

85. Schroeder DG, Martorell R. Fatness and body mass index from birth to young adulthood in a rural Guatemalan population. **Am J Clin Nutr** 70: 137S–144S, 1999. doi:10.1093/ajcn/70.1.137s.

86. Hoffman DJ, Martins PA, Roberts SB, Sawaya AL. Body fat distribution in stunted compared with normal-height children from the shantytowns of São Paulo, Brazil. **Nutrition** 23: 640–646, 2007. doi:10.1016/j.nut.2007.06.006.

87. Cameron N, Wright MM, Griffiths PL, Norris SA, Pettifor JM. Stunting at 2 years in relation to body composition at 9 years in African urban children. **Obes Res** 13: 131–136, 2005. doi:10.1038/oby.2005.17.

88. Tanner S, Leonard WR, Reyes-García V; TAPS Bolivia Study Team. The consequences of linear growth stunting: influence on body composition among youth in the Bolivian Amazon. **Am J Phys Anthropol** 153: 92–102, 2014. doi:10.1002/ajpa.22413.

89. Gigante DP, Nazmi A, Lima RC, Barros FC, Victora CG. Epidemiology of early and late growth in height, leg and trunk length: findings from a birth cohort of Brazilian males. **Eur J Clin Nutr** 63: 375–381, 2009. doi:10.1038/sj.ejcn.1602949.

90. Shen L, Li C, Wang Z, Zhang R, Shen Y, Miles T, Wei J, Zou Z. Early-life exposure to severe famine is associated with higher methylation level in the IGF2 gene and higher total cholesterol in late adulthood: the Genomic Research of the Chinese Famine (GRECF) study. **Clin Epigenetics** 11: 88, 2019. doi:10.1186/s13148-019-0676-3.

91. Tobi EW, Goeman JJ, Monajemi R, Gu H, Putter H, Zhang Y, Slieker RC, Stok AP, Thijssen PE, Müller F, van Zwet EW, Bock C, Meissner A, Lumey LH, Eline Slagboom P, Heijmans BT. DNA methylation signatures link prenatal famine exposure to growth and metabolism. **Nat Commun** 5: 5592, 2014. doi:10.1038/ncomms6592.

92. Hoffman DJ, Sawaya AL, Verreschi I, Tucker KL, Roberts SB. Why are nutritionally stunted children at increased risk of obesity? Studies of metabolic rate and fat oxidation in shantytown children from São Paulo, Brazil. **Am J Clin Nutr** 72: 702–707, 2000. doi:10.1093/ajcn/72.3.702.

93. Kensara OA, Wooton SA, Phillips DI, Patel M, Hoffman DJ, Jackson AA, Elia M; Hertfordshire Study Group. Substrate-energy metabolism and metabolic risk factors for cardiovascular disease in relation to fetal growth and adult body composition. **Am J Physiol Endocrinol Metab** 291: E365–E371, 2006. doi:10.1152/ajpendo.00599.2005.

94. Lee SK, Nam SY, Hoffman DJ. Growth retardation at early life and metabolic adaptation among North Korean children. **J Dev Orig Health Dis** 6: 291–298, 2015. doi:10.1017/S204017441500118X.

95. Leonard WR, Sorensen MV, Mosher MJ, Spitsyn V, Comuzzie AG. Reduced fat oxidation and obesity risks among the Buryat of Southern Siberia. **Am J Hum Biol** 21: 664–670, 2009. doi:10.1002/ajhb.20903.

96. Krueger R, Derno M, Goers S, Metzler-Zebeli BU, Nuernberg G, Martens K, Pfuhl R, Nebendahl C, Zeyner A, Hammon HM, Metges CC. Higher body fatness in intrauterine growth retarded juvenile pigs is associated with lower fat and higher carbohydrate oxidation during ad libitum and restricted feeding. **Eur J Nutr** 53: 583–597, 2014. doi:10.1007/s00394-013-0567-x.

97. Granados N, Amengual J, Ribot J, Musinovic H, Ceresi E, von Lintig J, Palou A, Bonet ML. Vitamin A supplementation in early life affects later response to an obesogenic diet in rats. **Int J Obes (Lond)** 37: 1169–1176, 2013. doi:10.1038/ijo.2012.190.

98. Liu J, He J, Yang Y, Yu J, Mao X, Yu B, Chen D. Effects of intrauterine growth retardation and postnatal high-fat diet on hepatic inflammatory response in pigs. **Arch Anim Nutr** 68: 111–125, 2014. doi:10.1080/1745039X.2014.897532.

99. Ballester M, Amills M, González-Rodríguez O, Cardoso TF, Pascual M, González-Prendes R, Panella-Riera N, Díaz I, Tibau J, Quintanilla R. Role of AMPK signalling pathway during compensatory growth in pigs. **BMC Genomics** 19: 682, 2018. doi:10.1186/s12864-018-5071-5.

100. Dominguez-Salas P, Moore SE, Baker MS, Bergen AW, Cox SE, Dyer RA, Fulford AJ, Guan Y, Laritsky E, Silver MJ, Swan GE, Zeisel SH, Innis SM, Waterland RA, Prentice AM, Hennig BJ. Maternal nutrition at conception modulates DNA methylation of human metastable epialleles. **Nat Commun** 5: 3746, 2014. doi:10.1038/ncomms4746.

101. Wren RE, Blume H, Mazariegos M, Solomons N, Alvarez JO, Goran MI. Body composition, resting metabolic rate, and energy requirements of short- and normal-stature, low-income Guatemalan children. **Am J Clin Nutr** 66: 406–412, 1997. doi:10.1093/ajcn/66.2.406.

102. Hoffman DJ, Sawaya AL, Coward WA, Wright A, Martins PA, de Nascimento C, Tucker KL, Roberts SB. Energy expenditure of stunted and nonstunted boys and girls living in the shantytowns of São Paulo, Brazil. **Am J Clin Nutr** 72: 1025–1031, 2000. doi:10.1093/ajcn/72.4.1025.

103. Grillol LP, Siqueira AF, Silva AC, Martins PA, Verreschi IT, Sawaya AL. Lower resting metabolic rate and higher velocity of weight gain in a prospective study of stunted vs nonstunted girls living in the shantytowns of São Paulo, Brazil. **Eur J Clin Nutr** 59: 835–842, 2005. doi:10.1038/sj.ejcn.1602150.

104. Nishimoto Y, Ida S, Etani Y, Miyatani S. Resting energy expenditure in short-stature children. **Endocr J** 59: 265–271, 2012. doi:10.1507/endocrj.ej11-0138.

105. Said-Mohamed R, Bernard JY, Ndzana AC, Pasquet P. Is overweight in stunted preschool children in Cameroon related to reductions in fat oxidation, resting energy expenditure and physical activity? **PLoS ONE** 7: e39007, 2012. doi:10.1371/journal.pone.0039007.

106. Allison DB, Paultre F, Goran MI, Poehlman ET, Heymsfield SB. Statistical considerations regarding the use of ratios to adjust data. **Int J Obes Relat Metab Disord** 19: 644–652, 1995.

107. Li Y, Li F, Chen S, Duan Y, Guo Q, Wang W, Wen C, Yin Y. Protein-restricted diet regulates lipid and energy metabolism in skeletal muscle of growing pigs. **J Agric Food Chem** 64: 9412–9420, 2016. doi:10.1021/acs.jafc.6b03959.

108. Brown LD, Rozance PJ, Bruce JL, Friedman JE, Hay WW, Wesolowski SR. Limited capacity for glucose oxidation in fetal sheep with intrauterine growth restriction. **Am J Physiol Regul Integr Comp Physiol** 309: R920–R928, 2015. doi:10.1152/ajpregu.00197.2015.

109. Liu B, Page AJ, Hutchison AT, Wittert GA, Heilbronn LK. Intermittent fasting increases energy expenditure and promotes adipose tissue browning in mice. **Nutrition** 66: 38–43, 2019. doi:10.1016/j.nut.2019.03.015.

110. Calonne J, Isacco L, Miles-Chan J, Arsenijevic D, Montani JP, Guillet C, Boirie Y, Dulloo AG. Reduced skeletal muscle protein turnover and thyroid hormone metabolism in adaptive thermogenesis that facilitates body fat recovery during weight regain. **Front Endocrinol (Lausanne)** 10: 119, 2019. doi:10.3389/fendo.2019.00119.

111. Popper K. **The Logic of Scientific Discovery** (2nd ed.). New York: Routledge Press, 2002.

112. Rajesh P, Balasubramanian K. Gestational exposure to di(2-ethylhexyl) phthalate (DEHP) impairs pancreatic β-cell function in F1 rat offspring. **Toxicol Lett** 232: 46–57, 2015. doi:10.1016/j.toxlet.2014.09.025.

113. Xin F, Jiang L, Liu X, Geng C, Wang W, Zhong L, Yang G, Chen M. Bisphenol A induces oxidative stress-associated DNA damage in INS-1 cells. **Mutat Res Genet Toxicol Environ Mutagen** 769: 29–33, 2014. doi:10.1016/j.mrgentox.2014.04.019.

114. Jansson T, Powell TL. Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. **Clin Sci (Lond)** 113: 1–13, 2007. doi:10.1042/CS20060339.

115. Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. **Philos Trans R Soc Lond B Biol Sci** 370: 20140066, 2015. doi:10.1098/rstb.2014.0066.

116. Huppertz B. The anatomy of the normal placenta. **J Clin Pathol** 61: 1296–1302, 2008. doi:10.1136/jcp.2008.055277.

117. Brett KE, Ferraro ZM, Yockell-Lelievre J, Gruslin A, Adamo KB. Maternal-fetal nutrient transport in pregnancy pathologies: the role of the placenta. **Int J Mol Sci** 15: 16153–16185, 2014. doi:10.3390/ijms150916153.

118. Sibley CP. Understanding placental nutrient transfer—why bother? New biomarkers of fetal growth. **J Physiol** 587: 3431–3440, 2009. doi:10.1113/jphysiol.2009.172403.

119. Jansson T, Powell TL. IFPA 2005 Award in Placentology Lecture. Human placental transport in altered fetal growth: does the placenta function as a nutrient sensor?— a review. **Placenta** 27, Suppl A: S91–S7, 2006. doi:10.1016/j.placenta.2005.11.010.

120. Jansson T, Myatt L, Powell TL. The role of trophoblast nutrient and ion transporters in the development of pregnancy complications and adult disease. **Curr Vasc Pharmacol** 7: 521–533, 2009. doi:10.2174/157016109789043982.

121. Perazzolo S, Lewis RM, Sengers BG. Modelling nutrient transfer based on 3D imaging of the human placental microstructure. **Annu Int Conf IEEE Eng Med Biol Soc** 2016: 5953–5956, 2016. doi:10.1109/EMBC.2016.7592084.

122. Plitman Mayo R, Olsthoorn J, Charnock-Jones DS, Burton GJ, Oyen ML. Computational modeling of the structure-function relationship in human placental terminal villi. **J Biomech** 49: 3780–3787, 2016. doi:10.1016/j.jbiomech.2016.10.001.

123. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. **Placenta** 27: 939–958, 2006. doi:10.1016/j.placenta.2005.12.006.

124. James JL, Chamley LW, Clark AR. Feeding your baby in utero: how the uteroplacental circulation impacts pregnancy. **Physiology (Bethesda)** 32: 234–245, 2017. doi:10.1152/physiol.00033.2016.

125. Meah VL, Cockcroft JR, Backx K, Shave R, Stöhr EJ. Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses. **Heart** 102: 518–526, 2016. doi:10.1136/heartjnl-2015-308476.

126. de Haas S, Ghossein-Doha C, van Kuijk SM, van Drongelen J, Spaanderman ME. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. **Ultrasound Obstet Gynecol** 49: 177–187, 2017. doi:10.1002/uog.17360.

127. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. **N Engl J Med** 355: 992–1005, 2006. doi:10.1056/NEJMoa055352.

128. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. **J Clin Endocrinol Metab** 90: 4895–4903, 2005. doi:10.1210/jc.2004-1955.

129. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. **Biol Reprod** 69: 1–7, 2003. doi:10.1095/biolreprod.102.014977.

130. Li Y, Lorca RA, Su EJ. Molecular and cellular underpinnings of normal and abnormal human placental blood flows. **J Mol Endocrinol** 60: R9–R22, 2018. doi:10.1530/JME-17-0139.

131. Reilly FD, Russell PT. Neurohistochemical evidence supporting an absence of adrenergic and cholinergic innervation in the human placenta and umbilical cord. **Anat Rec** 188: 277–286, 1977. doi:10.1002/ar.1091880302.

132. Luria O, Bar J, Barnea O, Golan A, Kovo M. Reactivity of blood vessels in response to prostaglandin E2 in placentas from pregnancies complicated by fetal growth restriction. **Prenat Diagn** 32: 417–422, 2012. doi:10.1002/pd.3827.

133. McQeen J, Kingdom JC, Connell JM, Whittle MJ. Fetal endothelin levels and placental vascular endothelin receptors in intrauterine growth retardation. **Obstet Gynecol** 82: 992–998, 1993.

134. Kingdom J, Huppertz B, Seaward G, Kaufmann P. Development of the placental villous tree and its consequences for fetal growth. **Eur J Obstet Gynecol Reprod Biol** 92: 35–43, 2000. doi:10.1016/s0301-2115(00)00423-1.

135. Dymara-Konopka W, Laskowska M, Błażewicz A. Angiogenic imbalance as a contributor of preeclampsia. **Curr Pharm Biotechnol** 19: 797–815, 2018. doi:10.2174/1389201019666180925115559.

136. Uquillas KR, Grubbs BH, Prosper AE, Chmait RH, Grant EG, Walker DK. Doppler US in the evaluation of fetal growth and perinatal health. **Radiographics** 37: 1831–1838, 2017. doi:10.1148/rg.2017170020.

137. McCowan LM, Thompson JM, Taylor RS, Baker PN, North RA, Poston L, Roberts CT, Simpson NA, Walker JJ, Myers J, Kenny LC; SCOPE Consortium. Prediction of small for gestational age infants in healthy nulliparous women using clinical and ultrasound risk factors combined with early pregnancy biomarkers. **PLoS ONE** 12: e0169311, 2017. doi:10.1371/journal.pone.0169311.

138. Camm EJ, Botting KJ, Sferruzzi-Perri , AN. Near to one's heart: the intimate relationship between the placenta and fetal heart. **Front Physiol** 9: 629, 2018. doi:10.3389/fphys.2018.00629.

139. Mestan KK, Check J, Minturn L, Yallapragada S, Farrow KN, Liu X, Su E, Porta N, Gotteiner N, Ernst LM. Placental pathologic changes of maternal vascular underperfusion in bronchopulmonary dysplasia and pulmonary hypertension. **Placenta** 35: 570–574, 2014. doi:10.1016/j.placenta.2014.05.003.

140. Rozance PJ, Hay WW. Pancreatic islet hepatocyte growth factor and vascular endothelial growth factor A signaling in growth restricted fetuses. **Mol Cell Endocrinol** 435: 78–84, 2016. doi:10.1016/j.mce.2016.01.025.

141. Mestan KK, Gotteiner N, Porta N, Grobman W, Su EJ, Ernst LM. Cord blood biomarkers of placental maternal vascular underperfusion predict bronchopulmonary dysplasia-associated pulmonary hypertension. **J Pediatr** 185: 33–41, 2017. doi:10.1016/j.jpeds.2017.01.015.

142. Rozance PJ, Anderson M, Martinez M, Fahy A, Macko AR, Kailey J, Seedorf GJ, Abman SH, Hay WW, Limesand SW. Placental insufficiency decreases pancreatic vascularity and disrupts hepatocyte growth factor signaling in the pancreatic islet endothelial cell in fetal sheep. **Diabetes** 64: 555–564, 2015. doi:10.2337/db14-0462.

143. Sutherland MR, Ng KW, Drenckhahn JD, Wlodek ME, Black MJ. Impact of intrauterine growth restriction on the capillarization of the early postnatal rat heart. **Anat Rec (Hoboken)** 302: 1580–1586, 2019. doi:10.1002/ar.24037.

144. Taglauer E, Abman SH, Keller RL. Recent advances in antenatal factors predisposing to bronchopulmonary dysplasia. **Semin Perinatol** 42: 413–424, 2018. doi:10.1053/j.semperi.2018.09.002.

145. Jansson T, Wennergren M, Illsley NP. Glucose transporter protein expression in human placenta throughout gestation and in

intrauterine growth retardation. **J Clin Endocrinol Metab** 77: 1554–1562, 1993. doi:10.1210/jcem.77.6.8263141.

146. Stanirowski PJ, Szukiewicz D, Pyzlak M, Abdalla N, Sawicki W, Cendrowski K**.** Impact of pre-gestational and gestational diabetes mellitus on the expression of glucose transporters GLUT-1, GLUT-4 and GLUT-9 in human term placenta. **Endocrine** 55: 799–808, 2017. doi:10.1007/s12020-016-1202-4.

147. Michelsen TM, Holme AM, Holm MB, Roland MC, Haugen G, Powell TL, Jansson T, Henriksen T**.** Uteroplacental glucose uptake and fetal glucose consumption: a quantitative study in human pregnancies. **J Clin Endocrinol Metab** 104: 873–882, 2019. doi:10.1210/jc.2018-01154.

148. Jansson T, Ylvén K, Wennergren M, Powell TL**.** Glucose transport and system A activity in syncytiotrophoblast microvillous and basal plasma membranes in intrauterine growth restriction. **Placenta** 23: 392–399, 2002. doi:10.1053/plac.2002.0826.

149. Acosta O, Ramirez VI, Lager S, Gaccioli F, Dudley DJ, Powell TL, Jansson T**.** Increased glucose and placental GLUT-1 in large infants of obese nondiabetic mothers. **Am J Obstet Gynecol** 212: 227.e1–227.e7, 2015. doi:10.1016/j.ajog.2014.08.009.

150. Stanirowski PJ, Szukiewicz D, Pyzlak M, Abdalla N, Sawicki W, Cendrowski K**.** Analysis of correlations between the placental expression of glucose transporters GLUT-1, GLUT-4 and GLUT-9 and selected maternal and fetal parameters in pregnancies complicated by diabetes mellitus. **J Matern Fetal Neonatal Med** 32: 650–659, 2019. doi:10.1080/14767058.2017.1387897.

151. James-Allan LB, Arbet J, Teal SB, Powell TL, Jansson T**.** Insulin stimulates GLUT4 trafficking to the syncytiotrophoblast basal plasma membrane in the human placenta. **J Clin Endocrinol Metab** 104: 4225–4238, 2019. doi:10.1210/jc.2018-02778.

152. Boehmer BH, Limesand SW, Rozance PJ**.** The impact of IUGR on pancreatic islet development and β-cell function. **J Endocrinol** 235: R63–R76, 2017. doi:10.1530/JOE-17-0076.

153. Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, Lowe LP, Trimble ER, Coustan DR, Hadden DR, Persson B, Hod M, Oats JJ; HAPO Study Cooperative Research Group**.** The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. **Diabetes Care** 35: 780–786, 2012. doi:10.2337/dc11-1790.

154. Strid H, Powell TL**.** ATP-dependent Ca^{2+} transport is up-regulated during third trimester in human syncytiotrophoblast basal membranes. **Pediatr Res** 48: 58–63, 2000. doi:10.1203/00006450-200007000-00012.

155. Strid H, Bucht E, Jansson T, Wennergren M, Powell TL**.** ATP dependent Ca^{2+} transport across basal membrane of human syncytiotrophoblast in pregnancies complicated by intrauterine growth restriction or diabetes. **Placenta** 24: 445–452, 2003. doi:10.1053/plac.2002.0941.

156. Mahendran D, Donnai P, Glazier JD, D'Souza SW, Boyd RD, Sibley CP**.** Amino acid (system A) transporter activity in microvillous membrane vesicles from the placentas of appropriate and small for gestational age babies. **Pediatr Res** 34: 661–665, 1993. doi:10.1203/00006450-199311000-00019.

157. Cleal JK, Glazier JD, Ntani G, Crozier SR, Day PE, Harvey NC, Robinson SM, Cooper C, Godfrey KM, Hanson MA, Lewis RM**.** Facilitated transporters mediate net efflux of amino acids to the fetus across the basal membrane of the placental syncytiotrophoblast. **J Physiol** 589: 987–997, 2011. doi:10.1113/jphysiol.2010.198549.

158. Gaccioli F, Aye IL, Roos S, Lager S, Ramirez VI, Kanai Y, Powell TL, Jansson T**.** Expression and functional characterisation of System L amino acid transporters in the human term placenta. **Reprod Biol Endocrinol** 13: 57, 2015. doi:10.1186/s12958-015-0054-8.

159. Casanello P, Sobrevia L**.** Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems y+/hCAT-1 and y+/hCAT-2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. **Circ Res** 91: 127–134, 2002. doi:10.1161/01.res.0000027813.55750.e7.

160. Chen YY, Rosario FJ, Shehab MA, Powell TL, Gupta MB, Jansson T**.** Increased ubiquitination and reduced plasma membrane trafficking of placental amino acid transporter SNAT-2 in human IUGR. **Clin Sci** 129: 1131–1141, 2015. doi:10.1042/CS20150511.

161. Huang X, Anderle P, Hostettler L, Baumann MU, Surbek DV, Ontsouka EC, Albrecht C**.** Identification of placental nutrient transporters associated with intrauterine growth restriction and pre-eclampsia. **BMC Genomics** 19: 173, 2018. doi:10.1186/s12864-018-4518-z.

162. Jansson T, Scholtbach V, Powell TL**.** Placental transport of leucine and lysine is reduced in intrauterine growth restriction. **Pediatr Res** 44: 532–537, 1998. doi:10.1203/00006450-199810000-00011.

163. Mandò C, Tabano S, Pileri P, Colapietro P, Marino MA, Avagliano L, Doi P, Bulfamante G, Miozzo M, Cetin I**.** SNAT2 expression and regulation in human growth-restricted placentas. **Pediatr Res** 74: 104–110, 2013. doi:10.1038/pr.2013.83.

164. Norberg S, Powell TL, Jansson T**.** Intrauterine growth restriction is associated with a reduced activity of placental taurine transporters. **Pediatr Res** 44: 233–238, 1998. doi:10.1203/00006450-199808000-00016.

165. Paolini CL, Marconi AM, Ronzoni S, Di Noio M, Fennessey PV, Pardi G, Battaglia FC**.** Placental transport of leucine, phenylalanine, glycine, and proline in intrauterine growth-restricted pregnancies. **J Clin Endocrinol Metab** 86: 5427–5432, 2001. doi:10.1210/jcem.86.11.8036.

166. Shibata E, Hubel CA, Powers RW, von Versen-Hoeynck F, Gammill H, Rajakumar A, Roberts JM**.** Placental system A amino acid transport is reduced in pregnancies with small for gestational age (SGA) infants but not in preeclampsia with SGA infants. **Placenta** 29: 879–882, 2008. doi:10.1016/j.placenta.2008.07.001.

167. Sibley C, Glazier J, D'Souza S**.** Placental transporter activity and expression in relation to fetal growth. **Exp Physiol** 82: 389–402, 1997. doi:10.1113/expphysiol.1997.sp004034.

168. Araújo JR, Correia-Branco A, Ramalho C, Gonçalves P, Pinho MJ, Keating E, Martel F**.** L-methionine placental uptake: characterization and modulation in gestational diabetes mellitus. **Reprod Sci** 20: 1492–1507, 2013. doi:10.1177/1933719113488442.

169. Araújo JR, Keating E, Martel F**.** Impact of gestational diabetes mellitus in the maternal-to-fetal transport of nutrients. **Curr Diab Rep** 15: 569, 2015. doi:10.1007/s11892-014-0569-y.

170. Gallo LA, Barrett HL, Dekker Nitert M**.** Review: placental transport and metabolism of energy substrates in maternal obesity and diabetes. **Placenta** 54: 59–67, 2017. doi:10.1016/j.placenta.2016.12.006.

171. Gauster M, Desoye G, Tötsch M, Hiden U**.** The placenta and gestational diabetes mellitus. **Curr Diab Rep** 12: 16–23, 2012. doi:10.1007/s11892-011-0244-5.

172. Jansson N, Rosario FJ, Gaccioli F, Lager S, Jones HN, Roos S, Jansson T, Powell TL**.** Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large

babies. **J Clin Endocrinol Metab** 98: 105–113, 2013. doi:10.1210/jc.2012-2667.

173. Jansson T, Ekstrand Y, Björn C, Wennergren M, Powell TL**.** Alterations in the activity of placental amino acid transporters in pregnancies complicated by diabetes. **Diabetes** 51: 2214–2219, 2002. doi:10.2337/diabetes.51.7.2214.

174. Kuruvilla AG, D'Souza SW, Glazier JD, Mahendran D, Maresh MJ, Sibley CP**.** Altered activity of the system A amino acid transporter in microvillous membrane vesicles from placentas of macrosomic babies born to diabetic women. **J Clin Invest** 94: 689–695, 1994. doi:10.1172/JCI117386.

175. Nandakumaran M, Al-Shammari M, Al-Saleh E**.** Maternal-fetal transport kinetics of L-leucine in vitro in gestational diabetic pregnancies. **Diabetes Metab** 30: 367–374, 2004. doi:10.1016/s1262-3636(07)70130-1.

176. Shang M, Wen Z**.** Increased placental IGF-1/mTOR activity in macrosomia born to women with gestational diabetes. **Diabetes Res Clin Pract** 146: 211–219, 2018. doi:10.1016/j.diabres.2018.10.017.

177. Herrera E, Ortega-Senovilla H**.** Lipid metabolism during pregnancy and its implications for fetal growth. **Curr Pharm Biotechnol** 15: 24–31, 2014. doi:10.2174/1389201015666140330192345.

178. Herrera E, Amusquivar E, López-Soldado I, Ortega H**.** Maternal lipid metabolism and placental lipid transfer. **Horm Res** 65, Suppl 3: 59–64, 2006. doi:10.1159/000091507.

179. Wadsack C, Hammer A, Levak-Frank S, Desoye G, Kozarsky KF, Hirschmugl B, Sattler W, Malle E**.** Selective cholesteryl ester uptake from high density lipoprotein by human first trimester and term villous trophoblast cells. **Placenta** 24: 131–143, 2003. doi:10.1053/plac.2002.0912.

180. Waterman IJ, Emmison N, Dutta-Roy AK**.** Characterisation of triacylglycerol hydrolase activities in human placenta. **Biochim Biophys Acta** 1394: 169–176, 1998. doi:10.1016/s0005-2760(98)00105-2.

181. Lager S, Ramirez VI, Gaccioli F, Jang B, Jansson T, Powell TL**.** Protein expression of fatty acid transporter 2 is polarized to the trophoblast basal plasma membrane and increased in placentas from overweight/obese women. **Placenta** 40: 60–66, 2016. doi:10.1016/j.placenta.2016.02.010.

182. Magnusson AL, Waterman IJ, Wennergren M, Jansson T, Powell TL**.** Triglyceride hydrolase activities and expression of fatty acid binding proteins in the human placenta in pregnancies complicated by intrauterine growth restriction and diabetes. **J Clin Endocrinol Metab** 89: 4607–4614, 2004. doi:10.1210/jc.2003-032234.

183. Chassen SS, Ferchaud-Roucher V, Gupta MB, Jansson T, Powell TL**.** Alterations in placental long chain polyunsaturated fatty acid metabolism in human intrauterine growth restriction. **Clin Sci (Lond)** 132: 595–607, 2018. doi:10.1042/CS20171340.

184. Prieto-Sánchez MT, Ruiz-Palacios M, Blanco-Carnero JE, Pagan A, Hellmuth C, Uhl O, Peissner W, Ruiz-Alcaraz AJ, Parrilla JJ, Koletzko B, Larqué E**.** Placental MFSD2a transporter is related to decreased DHA in cord blood of women with treated gestational diabetes. **Clin Nutr** 36: 513–521, 2017. doi:10.1016/j.clnu.2016.01.014.

185. Ferchaud-Roucher V, Kramer A, Silva E, Pantham P, Weintraub ST, Jansson T, Powell TL**.** A potential role for lysophosphatidylcholine in the delivery of long chain polyunsaturated fatty acids to the fetal circulation. **Biochim Biophys Acta Mol Cell Biol Lipids** 1864: 394–402, 2019. doi:10.1016/j.bbalip.2018.12.007.

186. Cosmi E, Visentin S, Fanelli T, Mautone AJ, Zanardo V**.** Aortic intima media thickness in fetuses and children with intrauterine growth restriction. **Obstet Gynecol** 114: 1109–1114, 2009. doi:10.1097/AOG.0b013e3181bb23d3.

187. Schmidt JS, Schaedlich K, Fiandanese N, Pocar P, Fischer B**.** Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/N mice. **Environ Health Perspect** 120: 1123–1129, 2012. doi:10.1289/ehp.1104016.

188. Schneider JL, Cuervo AM**.** Liver autophagy: much more than just taking out the trash. **Nat Rev Gastroenterol Hepatol** 11: 187–200, 2014. doi:10.1038/nrgastro.2013.211.

189. Costa MA**.** The endocrine function of human placenta: an overview. **Reprod Biomed Online** 32: 14–43, 2016. doi:10.1016/j.rbmo.2015.10.005.

190. Napso T, Yong HE, Lopez-Tello J, Sferruzzi-Perri AN**.** The role of placental hormones in mediating maternal adaptations to support pregnancy and lactation. **Front Physiol** 9: 1091, 2018. doi:10.3389/fphys.2018.01091.

191. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo AO**.** The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders. **Am J Obstet Gynecol** 201: 412.e1–412.e6, 2009. doi:10.1016/j.ajog.2009.07.016.

192. Newbern D, Freemark M**.** Placental hormones and the control of maternal metabolism and fetal growth. **Curr Opin Endocrinol Diabetes Obes** 18: 409–416, 2011. doi:10.1097/MED.0b013e32834c800d.

193. Simpson S, Smith L, Bowe J**.** Placental peptides regulating islet adaptation to pregnancy: clinical potential in gestational diabetes mellitus. **Curr Opin Pharmacol** 43: 59–65, 2018. doi:10.1016/j.coph.2018.08.004.

194. Handwerger S**.** Clinical counterpoint: the physiology of placental lactogen in human pregnancy. **Endocr Rev** 12: 329–336, 1991. doi:10.1210/edrv-12-4-329.

195. Markestad T, Bergsjø P, Aakvaag A, Lie RT, Jacobsen G, Hoffman HJ, Bakketeig LS**.** Prediction of fetal growth based on maternal serum concentrations of human chorionic gonadotropin, human placental lactogen and estriol. **Acta Obstet Gynecol Scand Suppl** 165: 50–55, 1997.

196. Pedersen NG, Juul A, Christiansen M, Wøjdemann KR, Tabor A**.** Maternal serum placental growth hormone, but not human placental lactogen or insulin growth factor-1, is positively associated with fetal growth in the first half of pregnancy. **Ultrasound Obstet Gynecol** 36: 534–541, 2010. doi:10.1002/uog.7727.

197. Vaughan OR, Rosario FJ, Powell TL, Jansson T**.** Regulation of placental amino acid transport and fetal growth. **Prog Mol Biol Transl Sci** 145: 217–251, 2017. doi:10.1016/bs.pmbts.2016.12.008.

198. Damaj MI, Trouvin JH, Lambrey B, Jacquot C**.** Determination of a new 2-amino-2-oxazoline (COR 3224) in plasma and brain tissue of the rat by high-performance liquid chromatography with electrochemical detection. **J Chromatogr** 563: 476–479, 1991. doi:10.1016/0378-4347(91)80059-I.

199. Männik J, Vaas P, Rull K, Teesalu P, Rebane T, Laan M**.** Differential expression profile of growth hormone/chorionic somatomammotropin genes in placenta of small- and large-for-gestational-age newborns. **J Clin Endocrinol Metab** 95: 2433–2442, 2010. doi:10.1210/jc.2010-0023.

200. Liao S, Vickers MH, Taylor RS, Fraser M, McCowan LM, Baker PN, Perry JK**.** Maternal serum placental growth hormone, insulin-like growth factors and their binding proteins at 20 weeks' gestation in

pregnancies complicated by gestational diabetes mellitus. **Hormones (Athens)** 16: 282–290, 2017. doi:10.1007/BF03401522.

201. Liao S, Vickers MH, Taylor RS, Jones B, Fraser M, McCowan LM, Baker PN, Perry JK**.** Human placental growth hormone is increased in maternal serum at 20 weeks of gestation in pregnancies with large-for-gestational-age babies. **Growth Factors** 34: 203–209, 2016. doi:10.1080/08977194.2016.1273223.

202. Timasheva Y, Putku M, Kivi R, Kozõich V, Männik J, Laan M**.** Developmental programming of growth: genetic variant in GH2 gene encoding placental growth hormone contributes to adult height determination. **Placenta** 34: 995–1001, 2013. doi:10.1016/j.placenta.2013.08.012.

203. Sferruzzi-Perri AN, Sandovici I, Constancia M, Fowden AL**.** Placental phenotype and the insulin-like growth factors: resource allocation to fetal growth. **J Physiol** 595: 5057–5093, 2017. doi:10.1113/JP273330.

204. Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D**.** Human placental growth hormone—a review. **Placenta** 23, Suppl A: S87–S94, 2002. doi:10.1053/plac.2002.0811.

205. Sferruzzi-Perri AN, Owens JA, Pringle KG, Roberts CT**.** The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth. **J Physiol** 589: 7–20, 2011. doi:10.1113/jphysiol.2010.198622.

206. Sferruzzi-Perri AN, Camm EJ**.** The programming power of the placenta. **Front Physiol** 7: 33, 2016. doi:10.3389/fphys.2016.00033.

207. Demetriou C, Abu-Amero S, Thomas AC, Ishida M, Aggarwal R, Al-Olabi L, Leon LJ, Stafford JL, Syngelaki A, Peebles D, Nicolaides KH, Regan L, Stanier P, Moore GE**.** Paternally expressed, imprinted insulin-like growth factor-2 in chorionic villi correlates significantly with birth weight. **PLoS ONE** 9: e85454, 2014. doi:10.1371/journal.pone.0085454.

208. Leger J, Noel M, Limal JM, Czernichow P**.** Growth factors and intrauterine growth retardation. II. Serum growth hormone, insulin-like growth factor (IGF) I, and IGF-binding protein 3 levels in children with intrauterine growth retardation compared with normal control subjects: prospective study from birth to two years of age. Study Group of IUGR. **Pediatr Res** 40: 101–107, 1996. doi:10.1203/00006450-199607000-00018.

209. Gupta MB, Abu Shehab M, Nygard K, Biggar K, Singal SS, Santoro N, Powell TL, Jansson T**.** IUGR is associated with marked hyperphosphorylation of decidual and maternal plasma IGFBP-1. **J Clin Endocrinol Metab** 104: 408–422, 2019. doi:10.1210/jc.2018-00820.

210. Lappas M**.** Insulin-like growth factor-binding protein 1 and 7 concentrations are lower in obese pregnant women, women with gestational diabetes and their fetuses. **J Perinatol** 35: 32–38, 2015. doi:10.1038/jp.2014.144.

211. Chatuphonprasert W, Jarukamjorn K, Ellinger I**.** Physiology and pathophysiology of steroid biosynthesis, transport and metabolism in the human placenta. **Front Pharmacol** 9: 1027, 2018. doi:10.3389/fphar.2018.01027.

212. Pepe GJ, Maniu A, Aberdeen G, Lynch TJ, Kim SO, Nadler J, Albrecht ED**.** Insulin resistance elicited in postpubertal primate offspring deprived of estrogen in utero. **Endocrine** 54: 788–797, 2016. doi:10.1007/s12020-016-1145-9.

213. Wang HH, Zhou CL, Lv M, Yang Q, Li JX, Hou M, Lin J, Liu XM, Wu YT, Sheng JZ, Huang HF**.** Prenatal high estradiol exposure induces sex-specific and dietarily reversible insulin resistance through decreased hypothalamic INSR. **Endocrinology** 159: 465–476, 2018. doi:10.1210/en.2017-03017.

214. Adam S, Elfeky O, Kinhal V, Dutta S, Lai A, Jayabalan N, Nuzhat Z, Palma C, Rice GE, Salomon C**.** Review: fetal-maternal communication via extracellular vesicles - Implications for complications of pregnancies. **Placenta** 54: 83–88, 2017. doi:10.1016/j.placenta.2016.12.001.

215. Salomon C, Rice GE**.** Role of exosomes in placental homeostasis and pregnancy disorders. **Prog Mol Biol Transl Sci** 145: 163–179, 2017. doi:10.1016/bs.pmbts.2016.12.006.

216. Nair S, Jayabalan N, Guanzon D, Palma C, Scholz-Romero K, Elfeky O, Zuñiga F, Ormazabal V, Diaz E, Rice GE, Duncombe G, Jansson T, McIntyre HD, Lappas M, Salomon C**.** Human placental exosomes in gestational diabetes mellitus carry a specific set of miRNAs associated with skeletal muscle insulin sensitivity. **Clin Sci (Lond)** 132: 2451–2467, 2018. doi:10.1042/CS20180487.

217. Pillay P, Maharaj N, Moodley J, Mackraj I**.** Placental exosomes and pre-eclampsia: maternal circulating levels in normal pregnancies and, early and late onset pre-eclamptic pregnancies. **Placenta** 46: 18–25, 2016. doi:10.1016/j.placenta.2016.08.078.

218. Miranda J, Paules C, Nair S, Lai A, Palma C, Scholz-Romero K, Rice GE, Gratacos E, Crispi F, Salomon C**.** Placental exosomes profile in maternal and fetal circulation in intrauterine growth restriction—liquid biopsies to monitoring fetal growth. **Placenta** 64: 34–43, 2018. doi:10.1016/j.placenta.2018.02.006.

219. Jansson N, Nilsfelt A, Gellerstedt M, Wennergren M, Rossander-Hulthén L, Powell TL, Jansson T**.** Maternal hormones linking maternal body mass index and dietary intake to birth weight. **Am J Clin Nutr** 87: 1743–1749, 2008. doi:10.1093/ajcn/87.6.1743.

220. Fahlbusch FB, Hartner A, Menendez-Castro C, Nögel SC, Marek I, Beckmann MW, Schleussner E, Ruebner M, Huebner H, Dörr HG, Schild RL, Dötsch J, Rascher W**.** The placental mTOR-pathway: correlation with early growth trajectories following intrauterine growth restriction? **J Dev Orig Health Dis** 6: 317–326, 2015. doi:10.1017/S2040174415001154.

221. Kavitha JV, Rosario FJ, Nijland MJ, McDonald TJ, Wu G, Kanai Y, Powell TL, Nathanielsz PW, Jansson T**.** Down-regulation of placental mTOR, insulin/IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon. **FASEB J** 28: 1294–1305, 2014. doi:10.1096/fj.13-242271.

222. Roos S, Jansson N, Palmberg I, Säljö K, Powell TL, Jansson T**.** Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. **J Physiol** 582: 449–459, 2007. doi:10.1113/jphysiol.2007.129676.

223. Roos S, Kanai Y, Prasad PD, Powell TL, Jansson T**.** Regulation of placental amino acid transporter activity by mammalian target of rapamycin. **Am J Physiol Cell Physiol** 296: C142–C150, 2009. doi:10.1152/ajpcell.00330.2008.

224. Roos S, Lagerlöf O, Wennergren M, Powell TL, Jansson T**.** Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR signaling. **Am J Physiol Cell Physiol** 297: C723–C731, 2009. doi:10.1152/ajpcell.00191.2009.

225. Huang K, Fingar DC**.** Growing knowledge of the mTOR signaling network. **Semin Cell Dev Biol** 36: 79–90, 2014. doi:10.1016/j.semcdb.2014.09.011.

226. Ben-Sahra I, Manning BD**.** mTORC1 signaling and the metabolic control of cell growth. **Curr Opin Cell Biol** 45: 72–82, 2017. doi:10.1016/j.ceb.2017.02.012.

227. Rosario FJ, Kanai Y, Powell TL, Jansson T**.** Mammalian target of rapamycin signalling modulates amino acid uptake by regulating

transporter cell surface abundance in primary human trophoblast cells. **J Physiol** 591: 609–625, 2013. doi:10.1113/jphysiol.2012.238014.

228. Rosario FJ, Dimasuay KG, Kanai Y, Powell TL, Jansson T. Regulation of amino acid transporter trafficking by mTORC1 in primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2. **Clin Sci (Lond)** 130: 499–512, 2016. doi:10.1042/CS20150554.

229. Lager S, Gaccioli F, Ramirez VI, Jones HN, Jansson T, Powell TL. Oleic acid stimulates system A amino acid transport in primary human trophoblast cells mediated by toll-like receptor 4. **J Lipid Res** 54: 725–733, 2013. doi:10.1194/jlr.M033050.

230. Lager S, Jansson T, Powell TL. Differential regulation of placental amino acid transport by saturated and unsaturated fatty acids. **Am J Physiol Cell Physiol** 307: C738–C744, 2014. doi:10.1152/ajpcell.00196.2014.

231. Wang J, Moore D, Subramanian A, Cheng KK, Toulis KA, Qiu X, Saravanan P, Price MJ, Nirantharakumar K. Gestational dyslipidaemia and adverse birthweight outcomes: a systematic review and meta-analysis. **Obes Rev** 19: 1256–1268, 2018. doi:10.1111/obr.12693.

232. Chen YY, Gupta MB, Gratton R, Powell TL, Jansson T. Down-regulation of placental folate transporters in intrauterine growth restriction. **J Nutr Biochem** 59: 136–141, 2018. doi:10.1016/j.jnutbio.2018.06.003.

233. Tamura T, Picciano MF. Folate and human reproduction. **Am J Clin Nutr** 83: 993–1016, 2006. doi:10.1093/ajcn/83.5.993.

234. Silva E, Rosario FJ, Powell TL, Jansson T. Mechanistic target of rapamycin is a novel molecular mechanism linking folate availability and cell function. **J Nutr** 147: 1237–1242, 2017. doi:10.3945/jn.117.248823.

235. Rosario FJ, Nathanielsz PW, Powell TL, Jansson T. Maternal folate deficiency causes inhibition of mTOR signaling, down-regulation of placental amino acid transporters and fetal growth restriction in mice. **Sci Rep** 7: 3982, 2017. doi:10.1038/s41598-017-03888-2.

236. Rosario FJ, Gupta MB, Myatt L, Powell TL, Glenn JP, Cox L, Jansson T. Mechanistic target of rapamycin complex 1 promotes the expression of genes encoding electron transport chain proteins and stimulates oxidative phosphorylation in primary human trophoblast cells by regulating mitochondrial biogenesis. **Sci Rep** 9: 246, 2019. doi:10.1038/s41598-018-36265-8.

237. Kimball R, Wayment M, Merrill D, Wahlquist T, Reynolds PR, Arroyo JA. Hypoxia reduces placental mTOR activation in a hypoxia-induced model of intrauterine growth restriction (IUGR). **Physiol Rep** 3: e12651, 2015. doi:10.14814/phy2.12651.

238. Hung TH, Hsieh TT, Wu CP, Li MJ, Yeh YL, Chen SF. Mammalian target of rapamycin signaling is a mechanistic link between increased endoplasmic reticulum stress and autophagy in the placentas of pregnancies complicated by growth restriction. **Placenta** 60: 9–20, 2017. doi:10.1016/j.placenta.2017.10.001.

239. Yung HW, Hemberger M, Watson ED, Senner CE, Jones CP, Kaufman RJ, Charnock-Jones DS, Burton GJ. Endoplasmic reticulum stress disrupts placental morphogenesis: implications for human intrauterine growth restriction. **J Pathol** 228: 554–564, 2012. doi:10.1002/path.4068.

240. Arroyo JA, Brown LD, Galan HL. Placental mammalian target of rapamycin and related signaling pathways in an ovine model of intrauterine growth restriction. **Am J Obstet Gynecol** 201: 616.e1–616.e7, 2009. doi:10.1016/j.ajog.2009.07.031.

241. Rosario FJ, Jansson N, Kanai Y, Prasad PD, Powell TL, Jansson T. Maternal protein restriction in the rat inhibits placental insulin, mTOR, and STAT3 signaling and down-regulates placental amino acid transporters. **Endocrinology** 152: 1119–1129, 2011. doi:10.1210/en.2010-1153.

242. Aye IL, Rosario FJ, Powell TL, Jansson T. Adiponectin supplementation in pregnant mice prevents the adverse effects of maternal obesity on placental function and fetal growth. **Proc Natl Acad Sci USA** 112: 12858–12863, 2015. doi:10.1073/pnas.1515484112.

243. Capobianco E, Fornes D, Linenberg I, Powell TL, Jansson T, Jawerbaum A. A novel rat model of gestational diabetes induced by intrauterine programming is associated with alterations in placental signaling and fetal overgrowth. **Mol Cell Endocrinol** 422: 221–232, 2016. doi:10.1016/j.mce.2015.12.020.

244. Martino J, Sebert S, Segura MT, García-Valdés L, Florido J, Padilla MC, Marcos A, Rueda R, McArdle HJ, Budge H, Symonds ME, Campoy C. Maternal body weight and gestational diabetes differentially influence placental and pregnancy outcomes. **J Clin Endocrinol Metab** 101: 59–68, 2016. doi:10.1210/jc.2015-2590.

245. Sati L, Soygur B, Celik-Ozenci C. Expression of mammalian target of rapamycin and downstream targets in normal and gestational diabetic human term placenta. **Reprod Sci** 23: 324–332, 2016. doi:10.1177/1933719115602765.

246. Santangeli L, Sattar N, Huda SS. Impact of maternal obesity on perinatal and childhood outcomes. **Best Pract Res Clin Obstet Gynaecol** 29: 438–448, 2015. doi:10.1016/j.bpobgyn.2014.10.009.

247. Gupta MB, Jansson T. Novel roles of mTOR signaling in regulating fetal growth. **Biol Reprod** 100: 872–884, 2019. doi:10.1093/biolre/ioy249.

248. Roberts A, Nava S, Bocconi L, Salmona S, Nicolini U. Liver function tests and glucose and lipid metabolism in growth-restricted fetuses. **Obstet Gynecol** 94: 290–294, 1999. doi:10.1016/s0029-7844(99)00235-5.

249. Ropero AB, Fuentes E, Rovira JM, Ripoll C, Soria B, Nadal A. Non-genomic actions of 17beta-oestradiol in mouse pancreatic beta-cells are mediated by a cGMP-dependent protein kinase. **J Physiol** 521: 397–407, 1999. doi:10.1111/j.1469-7793.1999.00397.x.

250. Bedinger DH, Adams SH. Metabolic, anabolic, and mitogenic insulin responses: a tissue-specific perspective for insulin receptor activators. **Mol Cell Endocrinol** 415: 143–156, 2015. doi:10.1016/j.mce.2015.08.013.

251. Castillo-Castrejon M, Powell TL. Placental nutrient transport in gestational diabetic pregnancies. **Front Endocrinol (Lausanne)** 8: 306, 2017. doi:10.3389/fendo.2017.00306.

252. Ruiz-Palacios M, Ruiz-Alcaraz AJ, Sanchez-Campillo M, Larqué E. Role of insulin in placental transport of nutrients in gestational diabetes mellitus. **Ann Nutr Metab** 70: 16–25, 2017. doi:10.1159/000455904.

253. Setia S, Sridhar MG. Changes in GH/IGF-1 axis in intrauterine growth retardation: consequences of fetal programming? **Horm Metab Res** 41: 791–798, 2009. doi:10.1055/s-0029-1231026.

254. Fowden AL, Valenzuela OA, Vaughan OR, Jellyman JK, Forhead AJ. Glucocorticoid programming of intrauterine development. **Domest Anim Endocrinol** 56, Suppl: S121–S132, 2016. doi:10.1016/j.domaniend.2016.02.014.

255. Fowden AL, Forhead AJ, Sferruzzi-Perri AN, Burton GJ, Vaughan OR. Review: endocrine regulation of placental phenotype. **Placenta** 36, Suppl 1: S50–S59, 2015. doi:10.1016/j.placenta.2014.11.018.

256. Braun T, Li S, Moss TJ, Newnham JP, Challis JR, Gluckman PD, Sloboda DM. Maternal betamethasone administration reduces binucleate cell number and placental lactogen in sheep. **J Endocrinol** 194: 337–347, 2007. doi:10.1677/JOE-07-0123.

257. Vaughan OR, Sferruzzi-Perri AN, Coan PM, Fowden AL. Environmental regulation of placental phenotype: implications for fetal growth. **Reprod Fertil Dev** 24: 80–96, 2011. doi:10.1071/RD11909.

258. Jones HN, Ashworth CJ, Page KR, McArdle HJ. Cortisol stimulates system A amino acid transport and SNAT2 expression in a human placental cell line (BeWo). **Am J Physiol Endocrinol Metab** 291: E596–E603, 2006. doi:10.1152/ajpendo.00359.2005.

259. Langdown ML, Sugden MC. Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. **Mol Cell Endocrinol** 185: 109–117, 2001. doi:10.1016/S0303-7207(01)00629-3.

260. Vaughan OR, Fisher HM, Dionelis KN, Jeffreys EC, Higgins JS, Musial B, Sferruzzi-Perri AN, Fowden AL. Corticosterone alters materno-fetal glucose partitioning and insulin signalling in pregnant mice. **J Physiol** 593: 1307–1321, 2015. doi:10.1113/jphysiol.2014.287177.

261. Ozmen A, Unek G, Kipmen-Korgun D, Cetinkaya B, Avcil Z, Korgun ET. Glucocorticoid exposure altered angiogenic factor expression via Akt/mTOR pathway in rat placenta. **Ann Anat** 198: 34–40, 2015. doi:10.1016/j.aanat.2014.10.007.

262. Lee JY, Yun HJ, Kim CY, Cho YW, Lee Y, Kim MH. Prenatal exposure to dexamethasone in the mouse induces sex-specific differences in placental gene expression. **Dev Growth Differ** 59: 515–525, 2017. doi:10.1111/dgd.12376.

263. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. **World J Diabetes** 7: 483–514, 2016. doi:10.4239/wjd.v7.i19.483.

264. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. **Int J Mol Sci** 18: 1321, 2017. doi:10.3390/ijms18061321.

265. Shirahase H, Usui H, Manabe K, Kurahashi K, Fujiwara M. An endothelium-dependent contraction induced by A-23187, a Ca^{++} ionophore in canine basilar artery. **J Pharmacol Exp Ther** 247: 701–705, 1988.

266. Aye IL, Powell TL, Jansson T. Review: Adiponectin—the missing link between maternal adiposity, placental transport and fetal growth? **Placenta** 34, Suppl: S40–S45, 2013. doi:10.1016/j.placenta.2012.11.024.

267. Lekva T, Roland MC, Michelsen AE, Friis CM, Aukrust P, Bollerslev J, Henriksen T, Ueland T. Large reduction in adiponectin during pregnancy is associated with large-for-gestational-age newborns. **J Clin Endocrinol Metab** 102: 2552–2559, 2017. doi:10.1210/jc.2017-00289.

268. Paulsen ME, Rosario FJ, Wesolowski SR, Powell TL, Jansson T. Normalizing adiponectin levels in obese pregnant mice prevents adverse metabolic outcomes in offspring. **FASEB J** 33: 2899–2909, 2019. doi:10.1096/fj.201801015R.

269. Vaughan O, Rosario F, Powell TL, Jansson T. Normalisation of circulating adiponectin levels in obese pregnant mice prevents cardiac dysfunction in adult offspring. **Int J Obes (Lond)** 44: 488–499, 2020.

270. Kerr B, Leiva A, Farías M, Contreras-Duarte S, Toledo F, Stolzenbach F, Silva L, Sobrevia L. Foetoplacental epigenetic changes associated with maternal metabolic dysfunction. **Placenta** 69: 146–152, 2018. doi:10.1016/j.placenta.2018.04.006.

271. Novakovic B, Saffery R. The importance of the intrauterine environment in shaping the human neonatal epigenome. **Epigenomics** 5: 1–4, 2013. doi:10.2217/epi.12.77.

272. Kohan-Ghadr HR, Kadam L, Jain C, Armant DR, Drewlo S. Potential role of epigenetic mechanisms in regulation of trophoblast differentiation, migration, and invasion in the human placenta. **Cell Adh Migr** 10: 126–135, 2016. doi:10.1080/19336918.2015.1098800.

273. Coan PM, Burton GJ, Ferguson-Smith AC. Imprinted genes in the placenta—a review. **Placenta** 26, Suppl A: S10–S20, 2005. doi:10.1016/j.placenta.2004.12.009.

274. Cassidy FC, Charalambous M. Genomic imprinting, growth and maternal-fetal interactions. **J Exp Biol** 221: jeb164517, 2018. doi:10.1242/jeb.164517.

275. Constância M, Kelsey G, Reik W. Resourceful imprinting. **Nature** 432: 53–57, 2004. doi:10.1038/432053a.

276. Haig D, Westoby M. An earlier formulation of the genetic conflict hypothesis of genomic imprinting. **Nat Genet** 38: 271, 2006. doi:10.1038/ng0306-271.

277. Monk D. Genomic imprinting in the human placenta. **Am J Obstet Gynecol** 213: S152–S162, 2015. doi:10.1016/j.ajog.2015.06.032.

278. Moore GE, Ishida M, Demetriou C, Al-Olabi L, Leon LJ, Thomas AC, Abu-Amero S, Frost JM, Stafford JL, Chaoqun Y, Duncan AJ, Baigel R, Brimioulle M, Iglesias-Platas I, Apostolidou S, Aggarwal R, Whittaker JC, Syngelaki A, Nicolaides KH, Regan L, Monk D, Stanier P. The role and interaction of imprinted genes in human fetal growth. **Philos Trans R Soc Lond B Biol Sci** 370: 20140074, 2015. doi:10.1098/rstb.2014.0074.

279. Gicquel C, Rossignol S, Cabrol S, Houang M, Steunou V, Barbu V, Danton F, Thibaud N, Le Merrer M, Burglen L, Bertrand AM, Netchine I, Le Bouc Y. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. **Nat Genet** 37: 1003–1007, 2005. doi:10.1038/ng1629.

280. Ishida M. New developments in Silver-Russell syndrome and implications for clinical practice. **Epigenomics** 8: 563–580, 2016. doi:10.2217/epi-2015-0010.

281. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. **Am J Med Genet C Semin Med Genet** 137C: 12–23, 2005. doi:10.1002/ajmg.c.30058.

282. Januar V, Desoye G, Novakovic B, Cvitic S, Saffery R. Epigenetic regulation of human placental function and pregnancy outcome: considerations for causal inference. **Am J Obstet Gynecol** 213: S182–S196, 2015. doi:10.1016/j.ajog.2015.07.011.

283. Koukoura O, Sifakis S, Spandidos DA. DNA methylation in the human placenta and fetal growth (review). **Mol Med Rep** 5: 883–889, 2012. doi:10.3892/mmr.2012.763.

284. Banister CE, Koestler DC, Maccani MA, Padbury JF, Houseman EA, Marsit CJ. Infant growth restriction is associated with distinct patterns of DNA methylation in human placentas. **Epigenetics** 6: 920–927, 2011. doi:10.4161/epi.6.7.16079.

285. Hillman SL, Finer S, Smart MC, Mathews C, Lowe R, Rakyan VK, Hitman GA, Williams DJ. Novel DNA methylation profiles associated with key gene regulation and transcription pathways in blood and placenta of growth-restricted neonates. **Epigenetics** 10: 50–61, 2015. doi:10.4161/15592294.2014.989741.

286. Chen PY, Chu A, Liao WW, Rubbi L, Janzen C, Hsu FM, Thamotharan S, Ganguly A, Lam L, Montoya D, Pellegrini M, Devaskar SU. prenatal growth patterns and birthweight are associated with differential DNA methylation and gene expression of cardiometabolic risk genes in human placentas: a discovery-based approach. **Reprod Sci** 25: 523–539, 2018. doi:10.1177/1933719117716779.

287. Brunst KJ, Tignor N, Just A, Liu Z, Lin X, Hacker MR, Bosquet Enlow M, Wright RO, Wang P, Baccarelli AA, Wright RJ. Cumulative lifetime maternal stress and epigenome-wide placental DNA methylation in the PRISM cohort. **Epigenetics** 13: 665–681, 2018. doi:10.1080/15592294.2018.1497387.

288. Lendvai Á, Deutsch MJ, Plösch T, Ensenauer R. The peroxisome proliferator-activated receptors under epigenetic control in placental metabolism and fetal development. **Am J Physiol Endocrinol Metab** 310: E797–E810, 2016. doi:10.1152/ajpendo.00372.2015.

289. Fujiki R, Hashiba W, Sekine H, Yokoyama A, Chikanishi T, Ito S, Imai Y, Kim J, He HH, Igarashi K, Kanno J, Ohtake F, Kitagawa H, Roeder RG, Brown M, Kato S. GlcNAcylation of histone H2B facilitates its monoubiquitination. **Nature** 480: 557–560, 2011. doi:10.1038/nature10656.

290. Howerton CL, Bale TL. Targeted placental deletion of OGT recapitulates the prenatal stress phenotype including hypothalamic mitochondrial dysfunction. **Proc Natl Acad Sci USA** 111: 9639–9644, 2014. doi:10.1073/pnas.1401203111.

291. Barker DJ. The fetal and infant origins of adult disease. **BMJ** 301: 1111, 1990. doi:10.1136/bmj.301.6761.1111.

292. Crume TL, Scherzinger A, Stamm E, McDuffie R, Bischoff KJ, Hamman RF, Dabelea D. The long-term impact of intrauterine growth restriction in a diverse U.S. cohort of children: the EPOCH study. **Obesity (Silver Spring)** 22: 608–615, 2014. doi:10.1002/oby.20565.

293. Kasuga M. Insulin resistance and pancreatic beta cell failure. **J Clin Invest** 116: 1756–1760, 2006. doi:10.1172/JCI29189.

294. Camacho LE, Chen X, Hay WW, Limesand SW. Enhanced insulin secretion and insulin sensitivity in young lambs with placental insufficiency-induced intrauterine growth restriction. **Am J Physiol Regul Integr Comp Physiol** 313: R101–R109, 2017. doi:10.1152/ajpregu.00068.2017.

295. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA. Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight. **Diabetes** 51: 1271–1280, 2002. doi:10.2337/diabetes.51.4.1271.

296. Mathai S, Cutfield WS, Derraik JG, Dalziel SR, Harding JE, Robinson E, Biggs J, Jefferies C, Hofman PL. Insulin sensitivity and β-cell function in adults born preterm and their children. **Diabetes** 61: 2479–2483, 2012. doi:10.2337/db11-1672.

297. Mericq V, Ong KK, Bazaes R, Peña V, Avila A, Salazar T, Soto N, Iñiguez G, Dunger DB. Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. **Diabetologia** 48: 2609–2614, 2005. doi:10.1007/s00125-005-0036-z.

298. Rozance PJ, Hay WW. New approaches to management of neonatal hypoglycemia. **Matern Health Neonatol Perinatol** 2: 3, 2016. doi:10.1186/s40748-016-0031-z.

299. Jensen CB, Storgaard H, Madsbad S, Richter EA, Vaag AA. Altered skeletal muscle fiber composition and size precede whole-body insulin resistance in young men with low birth weight. **J Clin Endocrinol Metab** 92: 1530–1534, 2007. doi:10.1210/jc.2006-2360.

300. Fabricius-Bjerre S, Jensen RB, Færch K, Larsen T, Mølgaard C, Michaelsen KF, Vaag A, Greisen G. Impact of birth weight and early infant weight gain on insulin resistance and associated cardiovascular risk factors in adolescence. **PLoS ONE** 6: e20595, 2011. doi:10.1371/journal.pone.0020595.

301. Forsén T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D. The fetal and childhood growth of persons who develop type 2 diabetes. **Ann Intern Med** 133: 176–182, 2000. doi:10.7326/0003-4819-133-3-200008010-00008.

302. Kajantie E, Strang-Karlsson S, Hovi P, Wehkalampi K, Lahti J, Kaseva N, Järvenpää AL, Räikkönen K, Eriksson JG, Andersson S. Insulin sensitivity and secretory response in adults born preterm: the Helsinki Study of Very Low Birth Weight Adults. **J Clin Endocrinol Metab** 100: 244–250, 2015. doi:10.1210/jc.2014-3184.

303. Cook JT, Levy JC, Page RC, Shaw JA, Hattersley AT, Turner RC. Association of low birth weight with beta cell function in the adult first degree relatives of non-insulin dependent diabetic subjects. **BMJ** 306: 302–306, 1993. doi:10.1136/bmj.306.6873.302.

304. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. **BJOG** 120: 681–694, 2013. doi:10.1111/1471-0528.12172.

305. Dessì A, Atzori L, Noto A, Visser GH, Gazzolo D, Zanardo V, Barberini L, Puddu M, Ottonello G, Atzei A, De Magistris A, Lussu M, Murgia F, Fanos V. Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. **J Matern Fetal Neonatal Med** 24: 35–39, 2011. doi:10.3109/14767058.2011.605868.

306. Dessì A, Fanos V. Myoinositol: a new marker of intrauterine growth restriction? **J Obstet Gynaecol** 33: 776–780, 2013. doi:10.3109/01443615.2013.831046.

307. Story L, Damodaram MS, Supramaniam V, Allsop JM, Mcguinness A, Patel A, Wylezinska M, Kumar S, Rutherford MA. Myo-inositol metabolism in appropriately grown and growth-restricted fetuses: a proton magnetic resonance spectroscopy study. **Eur J Obstet Gynecol Reprod Biol** 170: 77–81, 2013. doi:10.1016/j.ejogrb.2013.05.006.

308. Ross MG, Beall MH. Prediction of preterm birth: nonsonographic cervical methods. **Semin Perinatol** 33: 312–316, 2009. doi:10.1053/j.semperi.2009.06.004.

309. Schwitzgebel VM, Somm E, Klee P. Modeling intrauterine growth retardation in rodents: Impact on pancreas development and glucose homeostasis. **Mol Cell Endocrinol** 304: 78–83, 2009. doi:10.1016/j.mce.2009.02.019.

310. Henriksen T, Clausen T. The fetal origins hypothesis: placental insufficiency and inheritance versus maternal malnutrition in well-nourished populations. **Acta Obstet Gynecol Scand** 81: 112–114, 2002. doi:10.1034/j.1600-0412.2002.810204.x.

311. Jaquet D, Gaboriau A, Czernichow P, Levy-Marchal C. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. **J Clin Endocrinol Metab** 85: 1401–1406, 2000. doi:10.1210/jcem.85.4.6544.

312. Murotsuki J, Challis JR, Han VK, Fraher LJ, Gagnon R. Chronic fetal placental embolization and hypoxemia cause hypertension and myocardial hypertrophy in fetal sheep. **Am J Physiol Regul Integr Comp Physiol** 272: R201–R207, 1997. doi:10.1152/ajpregu.1997.272.1.R201.

313. Ogata ES, Bussey ME, Finley S. Altered gas exchange, limited glucose and branched chain amino acids, and hypoinsulinism retard

fetal growth in the rat. **Metabolism** 35: 970–977, 1986. doi:10.1016/0026-0495(86)90064-8.

314. Simmons RA, Gounis AS, Bangalore SA, Ogata ES**.** Intrauterine growth retardation: fetal glucose transport is diminished in lung but spared in brain. **Pediatr Res** 31: 59–63, 1992. doi:10.1203/00006450-199201000-00011.

315. Wigglesworth JS**.** Experimental growth retardation in the foetal rat. **J Pathol Bacteriol** 88: 1–13, 1964. doi:10.1002/path.1700880102.

316. Wigglesworth JS**.** Fetal growth retardation. Animal model: uterine vessel ligation in the pregnant rat. **Am J Pathol** 77: 347–350, 1974.

317. Eixarch E, Hernandez-Andrade E, Crispi F, Illa M, Torre I, Figueras F, Gratacos E**.** Impact on fetal mortality and cardiovascular Doppler of selective ligature of uteroplacental vessels compared with undernutrition in a rabbit model of intrauterine growth restriction. **Placenta** 32: 304–309, 2011. doi:10.1016/j.placenta.2011.01.014.

318. Lane RH, Kelley DE, Gruetzmacher EM, Devaskar SU**.** Uteroplacental insufficiency alters hepatic fatty acid-metabolizing enzymes in juvenile and adult rats. **Am J Physiol Regul Integr Comp Physiol** 280: R183–R190, 2001. doi:10.1152/ajpregu.2001.280.1.R183.

319. Raab EL, Vuguin PM, Stoffers DA, Simmons RA**.** Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. **Am J Physiol Regul Integr Comp Physiol** 297: R1785–R1794, 2009. doi:10.1152/ajpregu.00519.2009.

320. Simmons RA, Templeton LJ, Gertz SJ**.** Intrauterine growth retardation leads to the development of type 2 diabetes in the rat. **Diabetes** 50: 2279–2286, 2001. doi:10.2337/diabetes.50.10.2279.

321. Goodspeed D, Seferovic MD, Holland W, Mcknight RA, Summers SA, Branch DW, Lane RH, Aagaard KM**.** Essential nutrient supplementation prevents heritable metabolic disease in multigenerational intrauterine growth-restricted rats. **FASEB J** 29: 807–819, 2015. doi:10.1096/fj.14-259614.

322. Tran M, Gallo LA, Jefferies AJ, Moritz KM, Wlodek ME**.** Transgenerational metabolic outcomes associated with uteroplacental insufficiency. **J Endocrinol** 217: 105–118, 2013. doi:10.1530/JOE-12-0560.

323. Park JH, Stoffers DA, Nicholls RD, Simmons RA**.** Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. **J Clin Invest** 118: 2316–2324, 2008. doi:10.1172/JCI33655.

324. Ham JN, Crutchlow MF, Desai BM, Simmons RA, Stoffers DA**.** Exendin-4 normalizes islet vascularity in intrauterine growth restricted rats: potential role of VEGF. **Pediatr Res** 66: 42–46, 2009. doi:10.1203/PDR.0b013e3181a282a5.

325. Stoffers DA, Desai BM, DeLeon DD, Simmons RA**.** Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. **Diabetes** 52: 734–740, 2003. doi:10.2337/diabetes.52.3.734.

326. Delghingaro-Augusto V, Madad L, Chandra A, Simeonovic CJ, Dahlstrom JE, Nolan CJ**.** Islet inflammation, hemosiderosis, and fibrosis in intrauterine growth-restricted and high fat-fed Sprague-Dawley rats. **Am J Pathol** 184: 1446–1457, 2014. doi:10.1016/j.ajpath.2014.01.024.

327. Selak MA, Storey BT, Peterside I, Simmons , RA**.** Impaired oxidative phosphorylation in skeletal muscle of intrauterine growth-retarded rats. **Am J Physiol Endocrinol Metab** 285: E130–E137, 2003. doi:10.1152/ajpendo.00322.2002.

328. Wadley GD, Siebel AL, Cooney GJ, McConell GK, Wlodek ME, Owens JA**.** Uteroplacental insufficiency and reducing litter size alters skeletal muscle mitochondrial biogenesis in a sex-specific manner in the adult rat. **Am J Physiol Endocrinol Metab** 294: E861–E869, 2008. doi:10.1152/ajpendo.00037.2008.

329. Stojanovska V, Sharma N, Dijkstra DJ, Scherjon SA, Jäger A, Schorle H, Plösch T**.** Placental insufficiency contributes to fatty acid metabolism alterations in aged female mouse offspring. **Am J Physiol Regul Integr Comp Physiol** 315: R1107–R1114, 2018. doi:10.1152/ajpregu.00420.2017.

330. Baserga M, Hale MA, McKnight RA, Yu X, Callaway CW, Lane RH**.** Uteroplacental insufficiency alters hepatic expression, phosphorylation, and activity of the glucocorticoid receptor in fetal IUGR rats. **Am J Physiol Regul Integr Comp Physiol** 289: R1348–R1353, 2005. doi:10.1152/ajpregu.00211.2005.

331. Lane RH, Crawford SE, Flozak AS, Simmons RA**.** Localization and quantification of glucose transporters in liver of growth-retarded fetal and neonatal rats. **Am J Physiol Endocrinol Metab** 276: E135–E142, 1999. doi:10.1152/ajpendo.1999.276.1.E135.

332. Lane RH, MacLennan NK, Hsu JL, Janke SM, Pham TD**.** Increased hepatic peroxisome proliferator-activated receptor-gamma coactivator-1 gene expression in a rat model of intrauterine growth retardation and subsequent insulin resistance. **Endocrinology** 143: 2486–2490, 2002. doi:10.1210/endo.143.7.8898.

333. Fu Q, Yu X, Callaway CW, Lane RH, McKnight RA**.** Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. **FASEB J** 23: 2438–2449, 2009. doi:10.1096/fj.08-124768.

334. Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH**.** Growth in utero and serum cholesterol concentrations in adult life. **BMJ** 307: 1524–1527, 1993. doi:10.1136/bmj.307.6918.1524.

335. Singhal A, Cole TJ, Fewtrell M, Lucas A**.** Breastmilk feeding and lipoprotein profile in adolescents born preterm: follow-up of a prospective randomised study. **Lancet** 363: 1571–1578, 2004. doi:10.1016/S0140-6736(04)16198-9.

336. Pecks U, Rath W, Bauerschlag DO, Maass N, Orlikowsky T, Mohaupt MG, Escher G**.** Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses. **J Perinat Med** 45: 829–835, 2017. doi:10.1515/jpm-2016-0270.

337. Tenhola S, Martikainen A, Rahiala E, Herrgård E, Halonen P, Voutilainen R**.** Serum lipid concentrations and growth characteristics in 12-year-old children born small for gestational age. **Pediatr Res** 48: 623–628, 2000. doi:10.1203/00006450-200011000-00012.

338. Huxley R, Owen CG, Whincup PH, Cook DG, Colman S, Collins R**.** Birth weight and subsequent cholesterol levels: exploration of the "fetal origins" hypothesis. **JAMA** 292: 2755–2764, 2004. doi:10.1001/jama.292.22.2755.

339. Jaddoe VW, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R**.** First trimester fetal growth restriction and cardiovascular risk factors in school age children: population based cohort study. **BMJ** 348: g14, 2014. doi:10.1136/bmj.g14.

340. Rytter D, Bech BH, Frydenberg M, Henriksen TB, Olsen SF**.** Fetal growth and cardio-metabolic risk factors in the 20-year-old offspring. **Acta Obstet Gynecol Scand** 93: 1150–1159, 2014. doi:10.1111/aogs.12463.

341. Skilton MR, Viikari JS, Juonala M, Laitinen T, Lehtimäki T, Taittonen L, Kähönen M, Celermajer DS, Raitakari OT**.** Fetal growth and preterm birth influence cardiovascular risk factors and arterial health in young adults: the Cardiovascular Risk in Young Finns Study.

Arterioscler Thromb Vasc Biol 31: 2975–2981, 2011. doi:10.1161/ATVBAHA.111.234757.

342. Sayers S, Singh G, Mott S, McDonnell J, Hoy W**.** Relationships between birthweight and biomarkers of chronic disease in childhood: Aboriginal Birth Cohort Study 1987-2001. **Paediatr Perinat Epidemiol** 23: 548–556, 2009. doi:10.1111/j.1365-3016.2009.01071.x.

343. Baldin AD, Siviero-Miachon AA, Fabbri T, de Lemos-Marini SH, Spinola-Castro AM, Baptista MT, D'Souza-Li LF, Morcillo AM, Maciel-Guerra AT, Guerra-Junior G**.** Turner syndrome and metabolic derangements: another example of fetal programming. **Early Hum Dev** 88: 99–102, 2012. doi:10.1016/j.earlhumdev.2011.07.014.

344. Kuo AH, Li C, Mattern V, Huber HF, Comuzzie A, Cox L, Schwab M, Nathanielsz PW, Clarke GD**.** Sex-dimorphic acceleration of pericardial, subcutaneous, and plasma lipid increase in offspring of poorly nourished baboons. **Int J Obes (Lond)** 42: 1092–1096, 2018. doi:10.1038/s41366-018-0008-2.

345. Zinkhan EK, Yu B, McKnight R**.** Uteroplacental insufficiency impairs cholesterol elimination in adult female growth-restricted rat offspring fed a high-fat diet. **Reprod Sci** 26: 1173–1180, 2019. doi:10.1177/1933719118811649.

346. Sohi G, Marchand K, Revesz A, Arany E, Hardy DB**.** Maternal protein restriction elevates cholesterol in adult rat offspring due to repressive changes in histone modifications at the cholesterol 7alpha-hydroxylase promoter. **Mol Endocrinol** 25: 785–798, 2011. doi:10.1210/me.2010-0395.

347. Sarr O, Thompson JA, Zhao L, Lee TY, Regnault TR**.** Low birth weight male guinea pig offspring display increased visceral adiposity in early adulthood. **PLoS ONE** 9: e98433, 2014. doi:10.1371/journal.pone.0098433.

348. Rinella ME**.** Nonalcoholic fatty liver disease: a systematic review. **JAMA** 313: 2263–2273, 2015. doi:10.1001/jama.2015.5370.

349. Henderson NC, Iredale JP**.** Liver fibrosis: cellular mechanisms of progression and resolution. **Clin Sci (Lond)** 112: 265–280, 2007. doi:10.1042/CS20060242.

350. Mehal WZ, Iredale J, Friedman SL**.** Scraping fibrosis: expressway to the core of fibrosis. **Nat Med** 17: 552–553, 2011. doi:10.1038/nm0511-552.

351. Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, et al.; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Low and high birth weights are risk factors for nonalcoholic fatty liver disease in children. **J Pediatr** 187: 141–146.e1, 2017. doi:10.1016/j.jpeds.2017.03.007.

352. Nobili V, Alisi A, Panera N, Agostoni C**.** Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. **Pediatr Endocrinol Rev** 6: 241–247, 2008.

353. Faienza MF, Brunetti G, Ventura A, D'Aniello M, Pepe T, Giordano P, Monteduro M, Cavallo , L**.** Nonalcoholic fatty liver disease in prepubertal children born small for gestational age: influence of rapid weight catch-up growth. **Horm Res Paediatr** 79: 103–109, 2013. doi:10.1159/000347217.

354. Sarr O, Blake A, Thompson JA, Zhao L, Rabicki K, Walsh JC, Welch I, Regnault TR**.** The differential effects of low birth weight and Western diet consumption upon early life hepatic fibrosis development in guinea pig. **J Physiol** 594: 1753–1772, 2016. doi:10.1113/JP271777.

355. Ernst LM, Salafia CM, Carter AM, Pezzullo JC**.** Hepatic histology in intrauterine growth retardation following uterine artery ligation in the guinea pig. **Pediatr Pathol** 13: 763–772, 1993. doi:10.3109/15513819309048263.

356. Teller IC, Hoyer-Kuhn H, Brönneke H, Nosthoff-Horstmann P, Oosting A, Lippach G, Wohlfarth M, Rauh M, van der Beek EM, Dötsch J, Nüsken KD**.** Complex lipid globules in early-life nutrition improve long-term metabolic phenotype in intra-uterine growth-restricted rats. **Br J Nutr** 120: 763–776, 2018. doi:10.1017/S0007114518001988.

357. Vuguin P, Raab E, Liu B, Barzilai N, Simmons R**.** Hepatic insulin resistance precedes the development of diabetes in a model of intrauterine growth retardation. **Diabetes** 53: 2617–2622, 2004. doi:10.2337/diabetes.53.10.2617.

358. Rueda-Clausen CF, Dolinsky VW, Morton JS, Proctor SD, Dyck JR, Davidge ST**.** Hypoxia-induced intrauterine growth restriction increases the susceptibility of rats to high-fat diet-induced metabolic syndrome. **Diabetes** 60: 507–516, 2011. doi:10.2337/db10-1239.

359. Yee JK, Han G, Vega J, Lee W-NP, Ross MG, Desai M**.** Fatty acid de novo synthesis in adult intrauterine growth-restricted offspring, and adult male response to a high fat diet. **Lipids** 51: 1339–1351, 2016. doi:10.1007/s11745-016-4199-9.

360. Riddle ES, Campbell MS, Lang BY, Bierer R, Wang Y, Bagley HN, Joss-Moore LA**.** Intrauterine growth restriction increases TNF α and activates the unfolded protein response in male rat pups. **J Obes** 2014: 829862, 2014. doi:10.1155/2014/829862.

361. Muramatsu-Kato K, Itoh H, Kohmura-Kobayashi Y, Ferdous UJ, Tamura N, Yaguchi C, Uchida T, Suzuki K, Hashimoto K, Suganami T, Ogawa Y, Kanayama N**.** Undernourishment in utero primes hepatic steatosis in adult mice offspring on an obesogenic diet; involvement of endoplasmic reticulum stress. **Sci Rep** 5: 16867, 2015. doi:10.1038/srep16867.

362. Sohi G, Revesz A, Hardy DB**.** Nutritional mismatch in postnatal life of low birth weight rat offspring leads to increased phosphorylation of hepatic eukaryotic initiation factor 2 α in adulthood. **Metabolism** 62: 1367–1374, 2013. doi:10.1016/j.metabol.2013.05.002.

363. Long B, Yin C, Fan Q, Yan G, Wang Z, Li X, Chen C, Yang X, Liu L, Zheng Z, Shi M, Yan X**.** Global liver proteome analysis using iTRAQ reveals AMPK-mTOR-autophagy signaling is altered by intrauterine growth restriction in newborn piglets. **J Proteome Res** 15: 1262–1273, 2016. doi:10.1021/acs.jproteome.6b00001.

364. Shen L, Liu Z, Gong J, Zhang L, Wang L, Magdalou J, Chen L, Wang H**.** Prenatal ethanol exposure programs an increased susceptibility of non-alcoholic fatty liver disease in female adult offspring rats. **Toxicol Appl Pharmacol** 274: 263–273, 2014. doi:10.1016/j.taap.2013.11.009.

365. Wang L, Shen L, Ping J, Zhang L, Liu Z, Wu Y, Liu Y, Huang H, Chen L, Wang H**.** Intrauterine metabolic programming alteration increased susceptibility to non-alcoholic adult fatty liver disease in prenatal caffeine-exposed rat offspring. **Toxicol Lett** 224: 311–318, 2014. doi:10.1016/j.toxlet.2013.11.006.

366. Knorr S, Bytoft B, Lohse Z, Boisen AB, Clausen TD, Jensen RB, Damm P, Beck-Nielsen H, Holst JJ, Hartmann B, Møller HJ, Højlund K, Gravholt CH, Jensen DM**.** Fatty liver among adolescent offspring of women with type 1 diabetes (the EPICOM Study). **Diabetes Care** 42: 1560–1568, 2019. doi:10.2337/dc19-0571.

367. Thompson MD, Derse A, Ferey JL, Reid M, Xie Y, Christ M, Chatterjee D, Nguyen C, Harasymowicz N, Guilak F, Moley KH, Davidson NO**.** Transgenerational impact of maternal obesogenic diet on offspring bile acid homeostasis and nonalcoholic fatty liver

disease. **Am J Physiol Endocrinol Metab** 316: E674–E686, 2019. doi:10.1152/ajpendo.00474.2018.

368. Kramer MS, Joseph KS. Enigma of fetal/infant-origins hypothesis. **Lancet** 348: 1254–1255, 1996. doi:10.1016/s0140-6736(05)65750-9.

369. Leon DA, Lithell HO, Vagero D, Koupilova I, Mohsen R, Berglund L, Lithell UB, McKeigue PM. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915-29. **BMJ** 317: 241–245, 1998.

370. Rich-Edwards JW, Gillman MW. Commentary: a hypothesis challenged. **BMJ** 315: 1348–1349, 1997. doi:10.1136/bmj.315.7119.1348.

371. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz GA, Willett WC, Hennekens CH. Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. **BMJ** 315: 396–400, 1997. doi:10.1136/bmj.315.7105.396.

372. Curhan GC, Chertow GM, Willett WC, Spiegelman D, Colditz GA, Manson JE, Speizer FE, Stampfer MJ. Birth weight and adult hypertension and obesity in women. **Circulation** 94: 1310–1315, 1996. doi:10.1161/01.CIR.94.6.1310.

373. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Ascherio AL, Stampfer MJ. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. **Circulation** 94: 3246–3250, 1996. doi:10.1161/01.CIR.94.12.3246.

374. Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. **J Hypertens** 14: 935–941, 1996.

375. Lawlor DA, Ebrahim S, Davey Smith G. Is there a sex difference in the association between birth weight and systolic blood pressure in later life? Findings from a meta-regression analysis. **Am J Epidemiol** 156: 1100–1104, 2002. doi:10.1093/aje/kwf154.

376. Whincup PH, Bredow M, Payne F, Sadler S, Golding J; ALSPAC Study. Size at birth and blood pressure at 3 years of age. The Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC). **Am J Epidemiol** 149: 730–739, 1999. doi:10.1093/oxfordjournals.aje.a009882.

377. Radunovic N, Kuczynski E, Rosen T, Dukanac J, Petkovic S, Lockwood CJ. Plasma apolipoprotein A-I and B concentrations in growth-retarded fetuses: a link between low birth weight and adult atherosclerosis. **J Clin Endocrinol Metab** 85: 85–88, 2000. doi:10.1210/jcem.85.1.6243.

378. Crispi F, Hernandez-Andrade E, Pelsers MM, Plasencia W, Benavides-Serralde JA, Eixarch E, Le Noble F, Ahmed A, Glatz JF, Nicolaides KH, Gratacos E. Cardiac dysfunction and cell damage across clinical stages of severity in growth-restricted fetuses. **Am J Obstet Gynecol** 199: 254.e1–254.e8, 2008. doi:10.1016/j.ajog.2008.06.056.

379. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. **BMJ** 330: 625, 2005. doi:10.1136/bmj.330.7492.625.

380. Crispi F, Figueras F, Cruz-Lemini M, Bartrons J, Bijnens B, Gratacos E. Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity. **Am J Obstet Gynecol** 207: 121.e1–121.e9, 2012. doi:10.1016/j.ajog.2012.05.011.

381. Eriksson JG, Forsén T, Tuomilehto J, Winter PD, Osmond C, Barker DJ. Catch-up growth in childhood and death from coronary heart disease: longitudinal study. **BMJ** 318: 427–431, 1999. doi:10.1136/bmj.318.7181.427.

382. Tzschoppe A, von Kries R, Struwe E, Rascher W, Dörr HG, Jüngert J, Rauh M, Beckmann M, Schild R, Goecke TW, Dötsch J. Intrauterine growth restriction (IUGR) induces signs of subclinical atherosclerosis in 6-year-old infants despite absence of excessive growth. **Klin Padiatr** 229: 209–215, 2017. doi:10.1055/s-0043-104528.

383. Koklu E, Kurtoglu S, Akcakus M, Koklu S, Buyukkayhan D, Gumus H, Yikilmaz A. Increased aortic intima-media thickness is related to lipid profile in newborns with intrauterine growth restriction. **Horm Res** 65: 269–275, 2006. doi:10.1159/000092536.

384. Skilton MR, Evans N, Griffiths KA, Harmer JA, Celermajer DS. Aortic wall thickness in newborns with intrauterine growth restriction. **Lancet** 365: 1484–1486, 2005. doi:10.1016/S0140-6736(05)66419-7.

385. Skilton MR, Ayer JG, Harmer JA, Webb K, Leeder SR, Marks GB, Celermajer DS. Impaired fetal growth and arterial wall thickening: a randomized trial of omega-3 supplementation. **Pediatrics** 129: e698–e703, 2012. doi:10.1542/peds.2011-2472.

386. Adair LS, Cole TJ. Rapid child growth raises blood pressure in adolescent boys who were thin at birth. **Hypertension** 41: 451–456, 2003. doi:10.1161/01.HYP.0000054212.23528.B2.

387. Leunissen RW, Kerkhof GF, Stijnen T, Hokken-Koelega AC. Effect of birth size and catch-up growth on adult blood pressure and carotid intima-media thickness. **Horm Res Paediatr** 77: 394–401, 2012. doi:10.1159/000338791.

388. Uiterwaal CS, Anthony S, Launer LJ, Witteman JC, Trouwborst AM, Hofman A, Grobbee DE. Birth weight, growth, and blood pressure: an annual follow-up study of children aged 5 through 21 years. **Hypertension** 30: 267–271, 1997. doi:10.1161/01.hyp.30.2.267.

389. Reynolds RM, Allan KM, Raja EA, Bhattacharya S, McNeill G, Hannaford PC, Sarwar N, Lee AJ, Bhattacharya S, Norman JE. Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years. **BMJ** 347: f4539, 2013. doi:10.1136/bmj.f4539.

390. Loche E, Blackmore HL, Carpenter AA, Beeson JH, Pinnock A, Ashmore TJ, Aiken CE, de Almeida-Faria J, Schoonejans JM, Giussani DA, Fernandez-Twinn DS, Ozanne SE. Maternal diet-induced obesity programmes cardiac dysfunction in male mice independently of post-weaning diet. **Cardiovasc Res** 114: 1372–1384, 2018. doi:10.1093/cvr/cvy082.

391. Visentin S, Grumolato F, Nardelli GB, Di Camillo B, Grisan E, Cosmi E. Early origins of adult disease: low birth weight and vascular remodeling. **Atherosclerosis** 237: 391–399, 2014. doi:10.1016/j.atherosclerosis.2014.09.027.

392. Briscoe TA, Rehn AE, Dieni S, Duncan JR, Wlodek ME, Owens JA, Rees SM. Cardiovascular and renal disease in the adolescent guinea pig after chronic placental insufficiency. **Am J Obstet Gynecol** 191: 847–855, 2004. doi:10.1016/j.ajog.2004.01.050.

393. Thompson JA, Sarr O, Piorkowska K, Gros R, Regnault TR. Low birth weight followed by postnatal over-nutrition in the guinea pig exposes a predominant player in the development of vascular dysfunction. **J Physiol** 592: 5429–5443, 2014. doi:10.1113/jphysiol.2014.275016.

394. Thompson JA, Gros R, Richardson BS, Piorkowska K, Regnault TR. Central stiffening in adulthood linked to aberrant aortic remodeling under suboptimal intrauterine conditions. **Am J Physiol Regul Integr Comp Physiol** 301: R1731–R1737, 2011. doi:10.1152/ajpregu.00274.2011.

395. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. **Birth Defects Res C Embryo Today** 105: 140–156, 2015. doi:10.1002/bdrc.21096.

396. Watanabe C, Satoh H. Evolution of our understanding of methylmercury as a health threat. **Environ Health Perspect** 104: 367–379, 1996. doi:10.2307/3432657.

397. Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, Nadal A, Palanza P, Panzica G, Sargis R, Vandenberg LN, Vom Saal F. Metabolism disrupting chemicals and metabolic disorders. **Reprod Toxicol** 68: 3–33, 2017. doi:10.1016/j.reprotox.2016.10.001.

398. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. **J Altern Complement Med** 8: 185–192, 2002. doi:10.1089/107555302317371479.

399. Grün F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. **Endocrinology** 147: S50–S55, 2006. doi:10.1210/en.2005-1129.

400. Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, et al. Parma consensus statement on metabolic disruptors. **Environ Health** 14: 54, 2015. doi:10.1186/s12940-015-0042-7.

401. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. **Endocr Rev** 36: E1–E150, 2015. doi:10.1210/er.2015-1010.

402. Barrett ES, Patisaul HB. Endocrine disrupting chemicals and behavior: re-evaluating the science at a critical turning point. **Horm Behav** 96: A1–A6, 2017. doi:10.1016/j.yhbeh.2017.09.010.

403. Weldingh NM, Jørgensen-Kaur L, Becher R, Holme JA, Bodin J, Nygaard UC, Bølling AK. Bisphenol A is more potent than phthalate metabolites in reducing pancreatic β-cell function. **Biomed Res Int** 2017: 4614379, 2017. doi:10.1155/2017/4614379.

404. Casals-Casas C, Desvergne B. Endocrine disruptors: from endocrine to metabolic disruption. **Annu Rev Physiol** 73: 135–162, 2011. doi:10.1146/annurev-physiol-012110-142200.

405. Heindel JJ, Blumberg B. Environmental obesogens: mechanisms and controversies. **Annu Rev Pharmacol Toxicol** 59: 89–106, 2019. doi:10.1146/annurev-pharmtox-010818-021304.

406. Palanza P, Nagel SC, Parmigiani S, Vom Saal FS. Perinatal exposure to endocrine disruptors: sex, timing and behavioral endpoints. **Curr Opin Behav Sci** 7: 69–75, 2016. doi:10.1016/j.cobeha.2015.11.017.

407. Gore AC, Heindel JJ, Zoeller RT. Endocrine disruption for endocrinologists (and others). **Endocrinology** 147: S1–S3, 2006. doi:10.1210/en.2005-1367.

408. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, Lee DH, Shioda T, Soto AM, Vom Saal FS, Welshons WV, Zoeller RT, Myers JP. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. **Endocr Rev** 33: 378–455, 2012. doi:10.1210/er.2011-1050.

409. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. **Lancet** 368: 2167–2178, 2006. doi:10.1016/S0140-6736(06)69665-7.

410. Li D, Suh S. Health risks of chemicals in consumer products: a review. **Environ Int** 123: 580–587, 2019. doi:10.1016/j.envint.2018.12.033.

411. Wang A, Padula A, Sirota M, Woodruff TJ. Environmental influences on reproductive health: the importance of chemical exposures. **Fertil Steril** 106: 905–929, 2016. doi:10.1016/j.fertnstert.2016.07.1076.

412. Atlas E, Giam CS. Global transport of organic pollutants: ambient concentrations in the remote marine atmosphere. **Science** 211: 163–165, 1981. doi:10.1126/science.211.4478.163.

413. Byrne SC, Miller P, Seguinot-Medina S, Waghiyi V, Buck CL, von Hippel FA, Carpenter DO. Exposure to perfluoroalkyl substances and associations with serum thyroid hormones in a remote population of Alaska Natives. **Environ Res** 166: 537–543, 2018. doi:10.1016/j.envres.2018.06.014.

414. Fu P, Kawamura K. Ubiquity of bisphenol A in the atmosphere. **Environ Pollut** 158: 3138–3143, 2010. doi:10.1016/j.envpol.2010.06.040.

415. Sobolewski M, Weiss B, Martin M, Gurven M, Barrett E. Toxicoanthropology: phthalate exposure in relation to market access in a remote forager-horticulturalist population. **Int J Hyg Environ Health** 220: 799–809, 2017. doi:10.1016/j.ijheh.2017.03.009.

416. Lee S, Hong YC, Park H, Kim Y, Ha M, Ha E. Combined effects of multiple prenatal exposure to pollutants on birth weight: The Mothers and Children's Environmental Health (MOCEH) study. **Environ Res** 181: 108832, 2020. doi:10.1016/j.envres.2019.108832.

417. Rosofsky A, Janulewicz P, Thayer KA, McClean M, Wise LA, Calafat AM, Mikkelsen EM, Taylor KW, Hatch EE. Exposure to multiple chemicals in a cohort of reproductive-aged Danish women. **Environ Res** 154: 73–85, 2017. doi:10.1016/j.envres.2016.12.011.

418. Woodruff TJ, Zota AR, Schwartz JM. Environmental chemicals in pregnant women in the United States: NHANES 2003-2004. **Environ Health Perspect** 119: 878–885, 2011. doi:10.1289/ehp.1002727.

419. Hendryx M, Luo J. Children's environmental chemical exposures in the USA, NHANES 2003-2012. **Environ Sci Pollut Res Int** 25: 5336–5343, 2018. doi:10.1007/s11356-017-0874-5.

420. Aylward LL, Hays SM, Kirman CR, Marchitti SA, Kenneke JF, English C, Mattison DR, Becker RA. Relationships of chemical concentrations in maternal and cord blood: a review of available data. **J Toxicol Environ Health B Crit Rev** 17: 175–203, 2014. doi:10.1080/10937404.2014.884956.

421. Jensen MS, Nørgaard-Pedersen B, Toft G, Hougaard DM, Bonde JP, Cohen A, Thulstrup AM, Ivell R, Anand-Ivell R, Lindh CH, Jönsson BA. Phthalates and perfluorooctanesulfonic acid in human amniotic fluid: temporal trends and timing of amniocentesis in pregnancy. **Environ Health Perspect** 120: 897–903, 2012. doi:10.1289/ehp.1104522.

422. Morello-Frosch R, Cushing LJ, Jesdale BM, Schwartz JM, Guo W, Guo T, Wang M, Harwani S, Petropoulou SS, Duong W, Park JS, Petreas M, Gajek R, Alvaran J, She J, Dobraca D, Das R, Woodruff TJ. Environmental chemicals in an urban population of pregnant women and their newborns from San Francisco. **Environ Sci Technol** 50: 12464–12472, 2016. doi:10.1021/acs.est.6b03492.

423. Pinney SE, Mesaros CA, Snyder NW, Busch CM, Xiao R, Aijaz S, Ijaz N, Blair IA, Manson JM. Second trimester amniotic fluid bisphenol A concentration is associated with decreased birth weight in term infants. **Reprod Toxicol** 67: 1–9, 2017. doi:10.1016/j.reprotox.2016.11.007.

424. Thayer KA, Heindel JJ, Bucher JR, Gallo MA. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. **Environ Health Perspect** 120: 779–789, 2012. doi:10.1289/ehp.1104597.

425. Vom Saal FS, Welshons WV. Evidence that bisphenol A (BPA) can be accurately measured without contamination in human serum and

urine, and that BPA causes numerous hazards from multiple routes of exposure. **Mol Cell Endocrinol** 398: 101–113, 2014. doi:10.1016/j.mce.2014.09.028.

426. Michałowicz J**.** Bisphenol A—sources, toxicity and biotransformation. **Environ Toxicol Pharmacol** 37: 738–758, 2014. doi:10.1016/j.etap.2014.02.003.

427. Martínez MA, Rovira J, Prasad Sharma R, Nadal M, Schuhmacher M, Kumar V**.** Comparing dietary and non-dietary source contribution of BPA and DEHP to prenatal exposure: a Catalonia (Spain) case study. **Environ Res** 166: 25–34, 2018. doi:10.1016/j.envres.2018.05.008.

428. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL**.** Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. **Environ Health Perspect** 116: 39–44, 2008. doi:10.1289/ehp.10753.

429. Vogel SA**.** The politics of plastics: the making and unmaking of bisphenol A "safety". **Am J Public Health** 99*Suppl*3: S559–S566, 2009. doi:10.2105/AJPH.2008.159228.

430. Rubin BS**.** Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. **J Steroid Biochem Mol Biol** 127: 27–34, 2011. doi:10.1016/j.jsbmb.2011.05.002.

431. Hoepner LA, Whyatt RM, Widen EM, Hassoun A, Oberfield SE, Mueller NT, Diaz D, Calafat AM, Perera FP, Rundle AG**.** Bisphenol A and adiposity in an inner-city birth cohort. **Environ Health Perspect** 124: 1644–1650, 2016. doi:10.1289/EHP205.

432. Valvi D, Casas M, Mendez MA, Ballesteros-Gómez A, Luque N, Rubio S, Sunyer J, Vrijheid M**.** Prenatal bisphenol a urine concentrations and early rapid growth and overweight risk in the offspring. **Epidemiology** 24: 791–799, 2013. doi:10.1097/EDE.0b013e3182a67822.

433. Harley KG, Aguilar Schall R, Chevrier J, Tyler K, Aguirre H, Bradman A, Holland NT, Lustig RH, Calafat AM, Eskenazi B**.** Prenatal and postnatal bisphenol A exposure and body mass index in childhood in the CHAMACOS cohort. **Environ Health Perspect** 121: 514–520, 2013. doi:10.1289/ehp.1205548.

434. Vafeiadi M, Roumeliotaki T, Myridakis A, Chalkiadaki G, Fthenou E, Dermitzaki E, Karachaliou M, Sarri K, Vassilaki M, Stephanou EG, Kogevinas M, Chatzi L**.** Association of early life exposure to bisphenol A with obesity and cardiometabolic traits in childhood. **Environ Res** 146: 379–387, 2016. doi:10.1016/j.envres.2016.01.017.

435. Braun JM, Lanphear BP, Calafat AM, Deria S, Khoury J, Howe CJ, Venners SA**.** Early-life bisphenol a exposure and child body mass index: a prospective cohort study. **Environ Health Perspect** 122: 1239–1245, 2014. doi:10.1289/ehp.1408258.

436. Philippat C, Botton J, Calafat AM, Ye X, Charles MA, Slama R; EDEN Study Group**.** Prenatal exposure to phenols and growth in boys. **Epidemiology** 25: 625–635, 2014. doi:10.1097/EDE.0000000000000132.

437. Buckley JP, Herring AH, Wolff MS, Calafat AM, Engel SM**.** Prenatal exposure to environmental phenols and childhood fat mass in the Mount Sinai Children's Environmental Health Study. **Environ Int** 91: 350–356, 2016. doi:10.1016/j.envint.2016.03.019.

438. Junge KM, Leppert B, Jahreis S, Wissenbach DK, Feltens R, Grützmann K, Thürmann L, Bauer T, Ishaque N, Schick M, Bewerunge-Hudler M, Röder S, Bauer M, Schulz A, Borte M, Landgraf K, Körner A, Kiess W, von Bergen M, Stangl GI, Trump S, Eils R, Polte T, Lehmann I**.** MEST mediates the impact of prenatal bisphenol A exposure on long-term body weight development. **Clin Epigenetics** 10: 58, 2018. doi:10.1186/s13148-018-0478-z.

439. Montrose L, Padmanabhan V, Goodrich JM, Domino SE, Treadwell MC, Meeker JD, Watkins DJ, Dolinoy DC**.** Maternal levels of endocrine disrupting chemicals in the first trimester of pregnancy are associated with infant cord blood DNA methylation. **Epigenetics** 13: 301–309, 2018. doi:10.1080/15592294.2018.1448680.

440. Beydoun HA, Khanal S, Zonderman AB, Beydoun MA**.** Sex differences in the association of urinary bisphenol-A concentration with selected indices of glucose homeostasis among U.S. adults. **Ann Epidemiol** 24: 90–97, 2014. doi:10.1016/j.annepidem.2013.07.014.

441. Ahmed S, Atlas E**.** Bisphenol S- and bisphenol A-induced adipogenesis of murine preadipocytes occurs through direct peroxisome proliferator-activated receptor gamma activation. **Int J Obes (Lond)** 40: 1566–1573, 2016. doi:10.1038/ijo.2016.95.

442. Skledar DG, Carino A, Trontelj J, Troberg J, Distrutti E, Marchianò S, Tomašič T, Zega A, Finel M, Fiorucci S, Mašič LP**.** Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite. **Chemosphere** 215: 870–880, 2019. doi:10.1016/j.chemosphere.2018.10.129.

443. Atlas E, Pope L, Wade MG, Kawata A, Boudreau A, Boucher JG**.** Bisphenol A increases aP2 expression in 3T3L1 by enhancing the transcriptional activity of nuclear receptors at the promoter. **Adipocyte** 3: 170–179, 2014. doi:10.4161/adip.28436.

444. Batista TM, Alonso-Magdalena P, Vieira E, Amaral ME, Cederroth CR, Nef S, Quesada I, Carneiro EM, Nadal A**.** Short-term treatment with bisphenol-A leads to metabolic abnormalities in adult male mice. **PLoS ONE** 7: e33814, 2012. doi:10.1371/journal.pone.0033814.

445. Kidani T, Kamei S, Miyawaki J, Aizawa J, Sakayama K, Masuno H**.** Bisphenol A downregulates Akt signaling and inhibits adiponectin production and secretion in 3T3-L1 adipocytes. **J Atheroscler Thromn** 17: 834–843, 2010. doi:10.5551/jat.4051.

446. Ohlstein JF, Strong AL, McLachlan JA, Gimble JM, Burow ME, Bunnell BA**.** Bisphenol A enhances adipogenic differentiation of human adipose stromal/stem cells. **J Mol Endocrinol** 53: 345–353, 2014. doi:10.1530/JME-14-0052.

447. Xie X, Song J, Li G**.** MiR-21a-5p suppresses bisphenol A-induced pre-adipocyte differentiation by targeting map2k3 through MKK3/p38/MAPK. **Biochem Biophys Res Commun** 473: 140–146, 2016. doi:10.1016/j.bbrc.2016.03.066.

448. Ariemma F, D'Esposito V, Liguoro D, Oriente F, Cabaro S, Liotti A, Cimmino I, Longo M, Beguinot F, Formisano P, Valentino R**.** Low-dose bisphenol-A impairs adipogenesis and generates dysfunctional 3T3-L1 adipocytes. **PLoS One** 11: e0150762, 2016. doi:10.1371/journal.pone.0150762.

449. Chamorro-García R, Kirchner S, Li X, Janesick A, Casey SC, Chow C, Blumberg B**.** Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism. **Environ Health Perspect** 120: 984–989, 2012. doi:10.1289/ehp.1205063.

450. Valentino R, D'Esposito V, Passaretti F, Liotti A, Cabaro S, Longo M, Perruolo G, Oriente F, Beguinot F, Formisano P**.** Bisphenol-A impairs insulin action and up-regulates inflammatory pathways in human subcutaneous adipocytes and 3T3-L1 cells. **PLoS ONE** 8: e82099, 2013. doi:10.1371/journal.pone.0082099.

451. Sakurai K, Kawazuma M, Adachi T, Harigaya T, Saito Y, Hashimoto N, Mori C**.** Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. **Br J Pharmacol** 141: 209–214, 2004. doi:10.1038/sj.bjp.0705520.

452. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. **Environ Health Perspect** 114: 106–112, 2006. doi:10.1289/ehp.8451.

453. Soriano S, Alonso-Magdalena P, García-Arévalo M, Novials A, Muhammed SJ, Salehi A, Gustafsson J-A, Quesada I, Nadal A. Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen receptor β. **PLoS ONE** 7: e31109, 2012. doi:10.1371/journal.pone.0031109.

454. Song L, Xia W, Zhou Z, Li Y, Lin Y, Wei J, Wei Z, Xu B, Shen J, Li W, Xu S. Low-level phenolic estrogen pollutants impair islet morphology and β-cell function in isolated rat islets. **J Endocrinol** 215: 303–311, 2012. doi:10.1530/JOE-12-0219.

455. Angle BM, Do RP, Ponzi D, Stahlhut RW, Drury BE, Nagel SC, Welshons WV, Besch-Williford CL, Palanza P, Parmigiani S, Vom Saal FS, Taylor JA. Metabolic disruption in male mice due to fetal exposure to low but not high doses of bisphenol A (BPA): evidence for effects on body weight, food intake, adipocytes, leptin, adiponectin, insulin and glucose regulation. **Reprod Toxicol** 42: 256–268, 2013. doi:10.1016/j.reprotox.2013.07.017.

456. Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenbergh JG, Vom Saal FS. Exposure to bisphenol A advances puberty. **Nature** 401: 763–764, 1999. doi:10.1038/44517.

457. Rubin BS, Murray MK, Damassa DA, King JC, Soto AM. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. **Environ Health Perspect** 109: 675–680, 2001. doi:10.1289/ehp.01109675.

458. Somm E, Schwitzgebel VM, Toulotte A, Cederroth CR, Combescure C, Nef S, Aubert ML, Hüppi PS. Perinatal exposure to bisphenol a alters early adipogenesis in the rat. **Environ Health Perspect** 117: 1549–1555, 2009. doi:10.1289/ehp.11342.

459. Anderson OS, Peterson KE, Sanchez BN, Zhang Z, Mancuso P, Dolinoy DC. Perinatal bisphenol A exposure promotes hyperactivity, lean body composition, and hormonal responses across the murine life course. **FASEB J** 27: 1784–1792, 2013. doi:10.1096/fj.12-223545.

460. van Esterik JC, Dollé ME, Lamoree MH, van Leeuwen SP, Hamers T, Legler J, van der Ven LT. Programming of metabolic effects in C57BL/6JxFVB mice by exposure to bisphenol A during gestation and lactation. **Toxicology** 321: 40–52, 2014. doi:10.1016/j.tox.2014.04.001.

461. Alonso-Magdalena P, Vieira E, Soriano S, Menes L, Burks D, Quesada I, Nadal A. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. **Environ Health Perspect** 118: 1243–1250, 2010. doi:10.1289/ehp.1001993.

462. Cao J, Echelberger R, Liu M, Sluzas E, McCaffrey K, Buckley B, Patisaul HB. Soy but not bisphenol A (BPA) or the phytoestrogen genistin alters developmental weight gain and food intake in pregnant rats and their offspring. **Reprod Toxicol** 58: 282–294, 2015. doi:10.1016/j.reprotox.2015.07.077.

463. Rubin BS, Paranjpe M, DaFonte T, Schaeberle C, Soto AM, Obin M, Greenberg AS. Perinatal BPA exposure alters body weight and composition in a dose specific and sex specific manner: the addition of peripubertal exposure exacerbates adverse effects in female mice. **Reprod Toxicol** 68: 130–144, 2017. doi:10.1016/j.reprotox.2016.07.020.

464. Wassenaar PN, Trasande L, Legler J. Systematic review and meta-analysis of early-life exposure to bisphenol A and obesity-related outcomes in rodents. **Environ Health Perspect** 125: 106001, 2017. doi:10.1289/EHP1233.

465. Taylor JA, Shioda K, Mitsunaga S, Yawata S, Angle BM, Nagel SC, Vom Saal FS, Shioda T. Prenatal exposure to bisphenol A disrupts naturally occurring bimodal DNA methylation at proximal promoter of fggy, an obesity-relevant gene encoding a carbohydrate kinase, in gonadal white adipose tissues of CD-1 mice. **Endocrinology** 159: 779–794, 2018. doi:10.1210/en.2017-00711.

466. Bodin J, Bølling AK, Becher R, Kuper F, Løvik M, Nygaard UC. Transmaternal bisphenol A exposure accelerates diabetes type 1 development in NOD mice. **Toxicol Sci** 137: 311–323, 2014. doi:10.1093/toxsci/kft242.

467. Jayashree S, Indumathi D, Akilavalli N, Sathish S, Selvaraj J, Balasubramanian K. Effect of Bisphenol-A on insulin signal transduction and glucose oxidation in liver of adult male albino rat. **Environ Toxicol Pharmacol** 35: 300–310, 2013. doi:10.1016/j.etap.2012.12.016.

468. Ma Y, Xia W, Wang DQ, Wan YJ, Xu B, Chen X, Li YY, Xu SQ. Hepatic DNA methylation modifications in early development of rats resulting from perinatal BPA exposure contribute to insulin resistance in adulthood. **Diabetologia** 56: 2059–2067, 2013. doi:10.1007/s00125-013-2944-7.

469. Strakovsky RS, Wang H, Engeseth NJ, Flaws JA, Helferich WG, Pan YX, Lezmi S. Developmental bisphenol A (BPA) exposure leads to sex-specific modification of hepatic gene expression and epigenome at birth that may exacerbate high-fat diet-induced hepatic steatosis. **Toxicol Appl Pharmacol** 284: 101–112, 2015. doi:10.1016/j.taap.2015.02.021.

470. Wei J, Sun X, Chen Y, Li Y, Song L, Zhou Z, Xu B, Lin Y, Xu S. Perinatal exposure to bisphenol A exacerbates nonalcoholic steatohepatitis-like phenotype in male rat offspring fed on a high-fat diet. **J Endocrinol** 222: 313–325, 2014. doi:10.1530/JOE-14-0356.

471. Alonso-Magdalena P, García-Arévalo M, Quesada I, Nadal Á. Bisphenol-A treatment during pregnancy in mice: a new window of susceptibility for the development of diabetes in mothers later in life. **Endocrinology** 156: 1659–1670, 2015. doi:10.1210/en.2014-1952.

472. Faulk C, Kim JH, Jones TR, McEachin RC, Nahar MS, Dolinoy DC, Sartor MA. Bisphenol A-associated alterations in genome-wide DNA methylation and gene expression patterns reveal sequence-dependent and non-monotonic effects in human fetal liver. **Environ Epigenet** 1: dvv006, 2015. doi:10.1093/eep/dvv006.

473. Wittassek M, Koch HM, Angerer J, Brüning T. Assessing exposure to phthalates—the human biomonitoring approach. **Mol Nutr Food Res** 55: 7–31, 2011. doi:10.1002/mnfr.201000121.

474. Johns LE, Ferguson KK, Cantonwine DE, McElrath TF, Mukherjee B, Meeker JD. Urinary BPA and phthalate metabolite concentrations and plasma vitamin D levels in pregnant women: a repeated measures analysis. **Environ Health Perspect** 125: 087026, 2017. doi:10.1289/EHP1178.

475. Saravanabhavan G, Guay M, Langlois É, Giroux S, Murray J, Haines D. Biomonitoring of phthalate metabolites in the Canadian population through the Canadian Health Measures Survey (2007-2009). **Int J Hyg Environ Health** 216: 652–661, 2013. doi:10.1016/j.ijheh.2012.12.009.

476. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, Brock JW, Needham LL, Calafat AM. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. **Environ Health Perspect** 112: 331–338, 2004. doi:10.1289/ehp.6723.

477. Swan SH, Sathyanarayana S, Barrett ES, Janssen S, Liu F, Nguyen RH, Redmon JB; TIDES Study Team. First trimester phthalate exposure and anogenital distance in newborns. **Hum Reprod** 30: 963–972, 2015. doi:10.1093/humrep/deu363.

478. Araki A, Mitsui T, Goudarzi H, Nakajima T, Miyashita C, Itoh S, Sasaki S, Cho K, Moriya K, Shinohara N, Nonomura K, Kishi R. Prenatal di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: the Hokkaido Study. **Sci Total Environ** 581-582: 297–304, 2017. doi:10.1016/j.scitotenv.2016.12.124.

479. Jensen MS, Anand-Ivell R, Nørgaard-Pedersen B, Jönsson BAG, Bonde JP, Hougaard DM, Cohen A, Lindh CH, Ivell R, Toft G. Amniotic fluid phthalate levels and male fetal gonad function. **Epidemiology** 26: 91–99, 2015. doi:10.1097/EDE.0000000000000198.

480. Strakovsky RS, Schantz SL. Using experimental models to assess effects of bisphenol A (BPA) and phthalates on the placenta: challenges and perspectives. **Toxicol Sci** 166: 250–268, 2018. doi:10.1093/toxsci/kfy224.

481. Hao C, Cheng X, Guo J, Xia H, Ma X. Perinatal exposure to diethylhexyl-phthalate induces obesity in mice. **Front Biosci (Elite Ed)** 5: 725–733, 2013. doi:10.2741/e653.

482. Gu H, Liu Y, Wang W, Ding L, Teng W, Liu L. In utero exposure to di-(2-ethylhexyl) phthalate induces metabolic disorder and increases fat accumulation in visceral depots of C57BL/6J mice offspring. **Exp Ther Med** 12: 3806–3812, 2016. doi:10.3892/etm.2016.3820.

483. Strakovsky RS, Lezmi S, Shkoda I, Flaws JA, Helferich WG, Pan YX. In utero growth restriction and catch-up adipogenesis after developmental di (2-ethylhexyl) phthalate exposure cause glucose intolerance in adult male rats following a high-fat dietary challenge. **J Nutr Biochem** 26: 1208–1220, 2015. doi:10.1016/j.jnutbio.2015.05.012.

484. Lin Y, Wei J, Li Y, Chen J, Zhou Z, Song L, Wei Z, Lv Z, Chen X, Xia W, Xu S. Developmental exposure to di(2-ethylhexyl) phthalate impairs endocrine pancreas and leads to long-term adverse effects on glucose homeostasis in the rat. **Am J Physiol Endocrinol Metab** 301: E527–E538, 2011. doi:10.1152/ajpendo.00233.2011.

485. Huang T, Saxena AR, Isganaitis E, James-Todd T. Gender and racial/ethnic differences in the associations of urinary phthalate metabolites with markers of diabetes risk: National Health and Nutrition Examination Survey 2001-2008. **Environ Health** 13: 6, 2014. doi:10.1186/1476-069X-13-6.

486. Cooper BW, Cho TM, Thompson PM, Wallace AD. Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. **Toxicol Sci** 103: 268–277, 2008. doi:10.1093/toxsci/kfn047.

487. Eveillard A, Mselli-Lakhal L, Mogha A, Lasserre F, Polizzi A, Pascussi JM, Guillou H, Martin PG, Pineau T. Di-(2-ethylhexyl)-phthalate (DEHP) activates the constitutive androstane receptor (CAR): a novel signalling pathway sensitive to phthalates. **Biochem Pharmacol** 77: 1735–1746, 2009. doi:10.1016/j.bcp.2009.02.023.

488. Zhang W, Shen XY, Zhang WW, Chen H, Xu WP, Wei W. The effects of di 2-ethyl hexyl phthalate (DEHP) on cellular lipid accumulation in HepG2 cells and its potential mechanisms in the molecular level. **Toxicol Mech Methods** 27: 245–252, 2017. doi:10.1080/15376516.2016.1273427.

489. Jia Y, Liu T, Zhou L, Zhu J, Wu J, Sun D, Xu J, Wang Q, Chen H, Xu F, Zhang Y, Zhang T, Liu H, Ye L. Effects of di-(2-ethylhexyl) phthalate on lipid metabolism by the JAK/STAT pathway in rats. **Int J Environ Res Public Health** 13: 1085, 2016. doi:10.3390/ijerph13111085.

490. Martinelli MI, Mocchiutti NO, Bernal CA. Dietary di(2-ethylhexyl) phthalate-impaired glucose metabolism in experimental animals. **Hum Exp Toxicol** 25: 531–538, 2006. doi:10.1191/0960327106het651oa.

491. Biemann R, Navarrete Santos A, Navarrete Santos A, Riemann D, Knelangen J, Blüher M, Koch H, Fischer B. Endocrine disrupting chemicals affect the adipogenic differentiation of mesenchymal stem cells in distinct ontogenetic windows. **Biochem Biophys Res Commun** 417: 747–752, 2012. doi:10.1016/j.bbrc.2011.12.028.

492. Engel A, Buhrke T, Imber F, Jessel S, Seidel A, Völkel W, Lampen A. Agonistic and antagonistic effects of phthalates and their urinary metabolites on the steroid hormone receptors ERα, ERβ, and AR. **Toxicol Lett** 277: 54–63, 2017. doi:10.1016/j.toxlet.2017.05.028.

493. Hao C, Cheng X, Xia H, Ma X. The endocrine disruptor mono-(2-ethylhexyl) phthalate promotes adipocyte differentiation and induces obesity in mice. **Biosci Rep** 32: 619–629, 2012. doi:10.1042/BSR20120042.

494. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. **Toxicol Sci** 74: 297–308, 2003. doi:10.1093/toxsci/kfg145.

495. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. **J Clin Endocrinol Metab** 87: 408–411, 2002. doi:10.1210/jcem.87.1.8290.

496. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. **Nat Rev Mol Cell Biol** 9: 367–377, 2008. doi:10.1038/nrm2391.

497. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. **Nat Rev Mol Cell Biol** 7: 885–896, 2006. doi:10.1038/nrm2066.

498. She Y, Jiang L, Zheng L, Zuo H, Chen M, Sun X, Li Q, Geng C, Yang G, Jiang L, Liu X. The role of oxidative stress in DNA damage in pancreatic β cells induced by di-(2-ethylhexyl) phthalate. **Chem Biol Interact** 265: 8–15, 2017. doi:10.1016/j.cbi.2017.01.015.

499. Sun X, Lin Y, Huang Q, Shi J, Qiu L, Kang M, Chen Y, Fang C, Ye T, Dong S. Di(2-ethylhexyl) phthalate-induced apoptosis in rat INS-1 cells is dependent on activation of endoplasmic reticulum stress and suppression of antioxidant protection. **J Cell Mol Med** 19: 581–594, 2015. doi:10.1111/jcmm.12409.

500. Ferguson KK, McElrath TF, Chen YH, Mukherjee B, Meeker JD. Urinary phthalate metabolites and biomarkers of oxidative stress in pregnant women: a repeated measures analysis. **Environ Health Perspect** 123: 210–216, 2015. doi:10.1289/ehp.1307996.

501. van T Erve TJ, Rosen EM, Barrett ES, Nguyen RH, Sathyanarayana S, Milne GL, Calafat AM, Swan SH, Ferguson KK. Phthalates and phthalate alternatives have diverse associations with oxidative stress and inflammation in pregnant women. **Environ Sci Technol** 53: 3258–3267, 2019. doi:10.1021/acs.est.8b05729.

502. Ellero-Simatos S, Claus SP, Benelli C, Forest C, Letourneur F, Cagnard N, Beaune PH, de Waziers I. Combined transcriptomic-^{1}H NMR metabonomic study reveals that monoethylhexyl phthalate stimulates adipogenesis and glyceroneogenesis in human adipocytes. **J Proteome Res** 10: 5493–5502, 2011. doi:10.1021/pr200765v.

503. Rajesh P, Balasubramanian K. Di(2-ethylhexyl)phthalate exposure impairs insulin receptor and glucose transporter 4 gene expression in L6 myotubes. **Hum Exp Toxicol** 33: 685–700, 2014. doi:10.1177/0960327113506238.

504. Rajesh P, Balasubramanian K. Phthalate exposure in utero causes epigenetic changes and impairs insulin signalling. **J Endocrinol** 223: 47–66, 2014. doi:10.1530/JOE-14-0111.

505. Buser MC, Murray HE, Scinicariello F. Age and sex differences in childhood and adulthood obesity association with phthalates: analyses of NHANES 2007-2010. **Int J Hyg Environ Health** 217: 687–694, 2014. doi:10.1016/j.ijheh.2014.02.005.

506. Hatch EE, Nelson JW, Qureshi MM, Weinberg J, Moore LL, Singer M, Webster TF. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999-2002. **Environ Health** 7: 27, 2008. doi:10.1186/1476-069X-7-27.

507. Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. **Environ Health Perspect** 115: 876–882, 2007. doi:10.1289/ehp.9882.

508. Trasande L, Attina TM, Sathyanarayana S, Spanier AJ, Blustein J. Race/ethnicity-specific associations of urinary phthalates with childhood body mass in a nationally representative sample. **Environ Health Perspect** 121: 501–506, 2013. doi:10.1289/ehp.1205526.

509. Valvi D, Casas M, Romaguera D, Monfort N, Ventura R, Martinez D, Sunyer J, Vrijheid M. Prenatal phthalate exposure and childhood growth and blood pressure: evidence from the Spanish INMA-Sabadell Birth Cohort Study. **Environ Health Perspect** 123: 1022–1029, 2015. doi:10.1289/ehp.1408887.

510. Maresca MM, Hoepner LA, Hassoun A, Oberfield SE, Mooney SJ, Calafat AM, Ramirez J, Freyer G, Perera FP, Whyatt RM, Rundle AG. Prenatal exposure to phthalates and childhood body size in an urban cohort. **Environ Health Perspect** 124: 514–520, 2016. doi:10.1289/ehp.1408750.

511. Harley KG, Berger K, Rauch S, Kogut K, Claus Henn B, Calafat AM, Huen K, Eskenazi B, Holland N. Association of prenatal urinary phthalate metabolite concentrations and childhood BMI and obesity. **Pediatr Res** 82: 405–415, 2017. doi:10.1038/pr.2017.112.

512. Buckley JP, Engel SM, Mendez MA, Richardson DB, Daniels JL, Calafat AM, Wolff MS, Herring AH. Prenatal phthalate exposures and childhood fat mass in a New York City cohort. **Environ Health Perspect** 124: 507–513, 2016. doi:10.1289/ehp.1509788.

513. Shoaff J, Papandonatos GD, Calafat AM, Ye X, Chen A, Lanphear BP, Yolton K, Braun JM. Early-life phthalate exposure and adiposity at 8 years of age. **Environ Health Perspect** 125: 097008, 2017. doi:10.1289/EHP1022.

514. Lee DH, Lee IK, Jin SH, Steffes M, Jacobs DR. Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. **Diabetes Care** 30: 622–628, 2007. doi:10.2337/dc06-2190.

515. Lee DH, Lee IK, Porta M, Steffes M, Jacobs DR. Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. **Diabetologia** 50: 1841–1851, 2007. doi:10.1007/s00125-007-0755-4.

516. Lee DH, Steffes MW, Sjödin A, Jones RS, Needham LL, Jacobs DR. Low dose of some persistent organic pollutants predicts type 2 diabetes: a nested case-control study. **Environ Health Perspect** 118: 1235–1242, 2010. doi:10.1289/ehp.0901480.

517. Yau DT, Mennear JH. The inhibitory effect of DDT on insulin secretion in mice. **Toxicol Appl Pharmacol** 39: 81–88, 1977. doi:10.1016/0041-008x(77)90179-x.

518. La Merrill M, Karey E, Moshier E, Lindtner C, La Frano MR, Newman JW, Buettner C. Perinatal exposure of mice to the pesticide DDT impairs energy expenditure and metabolism in adult female offspring. **PLoS ONE** 9: e103337, 2014. doi:10.1371/journal.pone.0103337.

519. Skinner MK, Manikkam M, Tracey R, Guerrero-Bosagna C, Haque M, Nilsson EE. Ancestral dichlorodiphenyltrichloroethane (DDT) exposure promotes epigenetic transgenerational inheritance of obesity. **BMC Med** 11: 228, 2013. doi:10.1186/1741-7015-11-228.

520. Cupul-Uicab LA, Klebanoff MA, Brock JW, Longnecker MP. Prenatal exposure to persistent organochlorines and childhood obesity in the US collaborative perinatal project. **Environ Health Perspect** 121: 1103–1109, 2013. doi:10.1289/ehp.1205901.

521. Iszatt N, Stigum H, Verner MA, White RA, Govarts E, Murinova LP, Schoeters G, Trnovec T, Legler J, Pelé F, Botton J, Chevrier C, Wittsiepe J, Ranft U, Vandentorren S, Kasper-Sonnenberg M, Klümper C, Weisglas-Kuperus N, Polder A, Eggesbø M; OBELIX. Prenatal and postnatal exposure to persistent organic pollutants and infant growth: a pooled analysis of seven European birth cohorts. **Environ Health Perspect** 123: 730–736, 2015. doi:10.1289/ehp.1308005.

522. Mendez MA, Garcia-Esteban R, Guxens M, Vrijheid M, Kogevinas M, Goñi F, Fochs S, Sunyer J. Prenatal organochlorine compound exposure, rapid weight gain, and overweight in infancy. **Environ Health Perspect** 119: 272–278, 2011. doi:10.1289/ehp.1002169.

523. Verhulst SL, Nelen V, Hond ED, Koppen G, Beunckens C, Vael C, Schoeters G, Desager K. Intrauterine exposure to environmental pollutants and body mass index during the first 3 years of life. **Environ Health Perspect** 117: 122–126, 2009. doi:10.1289/ehp.0800003.

524. Warner M, Wesselink A, Harley KG, Bradman A, Kogut K, Eskenazi B. Prenatal exposure to dichlorodiphenyltrichloroethane and obesity at 9 years of age in the CHAMACOS study cohort. **Am J Epidemiol** 179: 1312–1322, 2014. doi:10.1093/aje/kwu046.

525. Karmaus W, Osuch JR, Eneli I, Mudd LM, Zhang J, Mikucki D, Haan P, Davis S. Maternal levels of dichlorodiphenyl-dichloroethylene (DDE) may increase weight and body mass index in adult female offspring. **Occup Environ Med** 66: 143–149, 2009. doi:10.1136/oem.2008.041921.

526. Guelfo JL, Adamson DT. Evaluation of a national data set for insights into sources, composition, and concentrations of per- and polyfluoroalkyl substances (PFASs) in U.S. drinking water. **Environ Pollut** 236: 505–513, 2018. doi:10.1016/j.envpol.2018.01.066.

527. Guelfo JL, Marlow T, Klein DM, Savitz DA, Frickel S, Crimi M, Suuberg EM. Evaluation and management strategies for per- and polyfluoroalkyl substances (PFASs) in drinking water aquifers: perspectives from impacted U.S. northeast communities. **Environ Health Perspect** 126: 065001, 2018. doi:10.1289/EHP2727.

528. Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. **J Expo Sci Environ Epidemiol** 29: 131–147, 2019. doi:10.1038/s41370-018-0094-1.

529. Aimuzi R, Luo K, Chen Q, Wang H, Feng L, Ouyang F, Zhang J. Perfluoroalkyl and polyfluoroalkyl substances and fetal thyroid hormone levels in umbilical cord blood among newborns by prelabor

caesarean delivery. **Environ Int** 130: 104929, 2019. doi:10.1016/j.envint.2019.104929.

530. Chen J, Wang X, Ge X, Wang D, Wang T, Zhang L, Tanguay RL, Simonich M, Huang C, Dong Q**.** Chronic perfluorooctanesulphonic acid (PFOS) exposure produces estrogenic effects in zebrafish. **Environ Pollut** 218: 702–708, 2016. doi:10.1016/j.envpol.2016.07.064.

531. Mora AM, Fleisch AF, Rifas-Shiman SL, Woo Baidal JA, Pardo L, Webster TF, Calafat AM, Ye X, Oken E, Sagiv SK**.** Early life exposure to per- and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. **Environ Int** 111: 1–13, 2018. doi:10.1016/j.envint.2017.11.008.

532. Fisher M, Arbuckle TE, Wade M, Haines DA**.** Do perfluoroalkyl substances affect metabolic function and plasma lipids?—analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. **Environ Res** 121: 95–103, 2013. doi:10.1016/j.envres.2012.11.006.

533. Frisbee SJ, Shankar A, Knox SS, Steenland K, Savitz DA, Fletcher T, Ducatman AM**.** Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. **Arch Pediatr Adolesc Med** 164: 860–869, 2010. doi:10.1001/archpediatrics.2010.163.

534. Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A**.** The association between PFOA, PFOS and serum lipid levels in adolescents. **Chemosphere** 98: 78–83, 2014. doi:10.1016/j.chemosphere.2013.10.005.

535. Liu HS, Wen LL, Chu PL, Lin CY**.** Association among total serum isomers of perfluorinated chemicals, glucose homeostasis, lipid profiles, serum protein and metabolic syndrome in adults: NHANES, 2013-2014. **Environ Pollut** 232: 73–79, 2018. doi:10.1016/j.envpol.2017.09.019.

536. Starling AP, Engel SM, Whitworth KW, Richardson DB, Stuebe AM, Daniels JL, Haug LS, Eggesbø M, Becher G, Sabaredzovic A, Thomsen C, Wilson RE, Travlos GS, Hoppin JA, Baird DD, Longnecker MP**.** Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. **Environ Int** 62: 104–112, 2014. doi:10.1016/j.envint.2013.10.004.

537. Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, Butenhoff JL, Stevenson LA, Lau C**.** Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. **Toxicol Sci** 74: 369–381, 2003. doi:10.1093/toxsci/kfg121.

538. Lv Z, Li G, Li Y, Ying C, Chen J, Chen T, Wei J, Lin Y, Jiang Y, Wang Y, Shu B, Xu B, Xu S**.** Glucose and lipid homeostasis in adult rat is impaired by early-life exposure to perfluorooctane sulfonate. **Environ Toxicol** 28: 532–542, 2013. doi:10.1002/tox.20747.

539. Wan HT, Zhao YG, Leung PY, Wong CK**.** Perinatal exposure to perfluorooctane sulfonate affects glucose metabolism in adult offspring. **PLoS ONE** 9: e87137, 2014. doi:10.1371/journal.pone.0087137.

540. Beggs KM, McGreal SR, McCarthy A, Gunewardena S, Lampe JN, Lau C, Apte U**.** The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. **Toxicol Appl Pharmacol** 304: 18–29, 2016. doi:10.1016/j.taap.2016.05.001.

541. Mimoto MS, Nadal A, Sargis RM**.** Polluted pathways: mechanisms of metabolic disruption by endocrine disrupting chemicals. **Curr Environ Health Rep** 4: 208–222, 2017. doi:10.1007/s40572-017-0137-0.

542. Fleisch AF, Rifas-Shiman SL, Mora AM, Calafat AM, Ye X, Luttmann-Gibson H, Gillman MW, Oken E, Sagiv SK**.** Early-life exposure to perfluoroalkyl substances and childhood metabolic function. **Environ Health Perspect** 125: 481–487, 2017. doi:10.1289/EHP303.

543. Mora AM, Oken E, Rifas-Shiman SL, Webster TF, Gillman MW, Calafat AM, Ye X, Sagiv SK**.** Prenatal exposure to perfluoroalkyl substances and adiposity in early and mid-childhood. **Environ Health Perspect** 125: 467–473, 2017. doi:10.1289/EHP246.

544. Liu P, Yang F, Wang Y, Yuan Z**.** Perfluorooctanoic acid (PFOA) exposure in early life increases risk of childhood adiposity: a meta-analysis of prospective cohort studies. **Int J Environ Res Public Health** 15: 2070, 2018. doi:10.3390/ijerph15102070.

545. Lai KP, Ng AH, Wan HT, Wong AY, Leung CC, Li R, Wong CK**.** Dietary exposure to the environmental chemical, PFOS on the diversity of gut microbiota, associated with the development of metabolic syndrome. **Front Microbiol** 9: 2552, 2018. doi:10.3389/fmicb.2018.02552.

546. Rosenfeld CS**.** Gut dysbiosis in animals due to environmental chemical exposures. **Front Cell Infect Microbiol** 7: 396, 2017. doi:10.3389/fcimb.2017.00396.

547. Hine CH, Kodama JK, Anderson HH, Simonson DW, Wellington JS**.** The toxicology of epoxy resins. **AMA Arch Ind Health** 17: 129–144, 1958.

548. Salgado R, Pereiro N, López-Doval S, Lafuente A**.** Initial study on the possible mechanisms involved in the effects of high doses of perfluorooctane sulfonate (PFOS) on prolactin secretion. **Food Chem Toxicol** 83: 10–16, 2015. doi:10.1016/j.fct.2015.05.013.

549. Shelby MD**.** NTP-CERHR monograph on the potential human reproductive and developmental effects of di (2-ethylhexyl) phthalate (DEHP). **NTP CERHR MON** 2006: v, 2006.

550. Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL**.** Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. **Environ Health Perspect** 114: 567–572, 2006. doi:10.1289/ehp.8700.

551. Chamorro-Garcia R, Diaz-Castillo C, Shoucri BM, Käch H, Leavitt R, Shioda T, Blumberg B**.** Ancestral perinatal obesogen exposure results in a transgenerational thrifty phenotype in mice. **Nat Commun** 8: 2012, 2017. doi:10.1038/s41467-017-01944-z.

552. Manikkam M, Tracey R, Guerrero-Bosagna C, Skinner MK**.** Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. **PLoS One** 8: e55387, 2013. doi:10.1371/journal.pone.0055387.

553. Li G, Chang H, Xia W, Mao Z, Li Y, Xu S**.** F0 maternal BPA exposure induced glucose intolerance of F2 generation through DNA methylation change in Gck. **Toxicol Lett** 228: 192–199, 2014. doi:10.1016/j.toxlet.2014.04.012.

554. Guerrero-Bosagna C, Weeks S, Skinner MK**.** Identification of genomic features in environmentally induced epigenetic transgenerational inherited sperm epimutations. **PLoS ONE** 9: e100194, 2014. doi:10.1371/journal.pone.0100194.

555. Moon MK, Jeong I-K, Jung Oh T, Ahn HY, Kim HH, Park YJ, Jang HC, Park KS**.** Long-term oral exposure to bisphenol A induces glucose intolerance and insulin resistance. **J Endocrinol** 226: 35–42, 2015. doi:10.1530/JOE-14-0714.

556. Wei J, Lin Y, Li Y, Ying C, Chen J, Song L, Zhou Z, Lv Z, Xia W, Chen X, Xu S**.** Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a high-fat

diet. **Endocrinology** 152: 3049–3061, 2011. doi:10.1210/en.2011-0045.

557. Panzica GC, Bo E, Martini MA, Miceli D, Mura E, Viglietti-Panzica C, Gotti S**.** Neuropeptides and enzymes are targets for the action of endocrine disrupting chemicals in the vertebrate brain. **J Toxicol Environ Health B Crit Rev** 14: 449–472, 2011. doi:10.1080/10937404.2011.578562.

558. Andra SS, Austin C, Arora M**.** The tooth exposome in children's health research. **Curr Opin Pediatr** 28: 221–227, 2016. doi:10.1097/MOP.0000000000000327.